



Australian Government

Australian Institute of
Health and Welfare

National Cervical Screening Program Data Dictionary

Version 1.1

National Cervical Screening Program Data Dictionary

Version 1.1

The AIHW is an independent statutory Australian Government agency producing authoritative and accessible information and statistics to inform and support better policy and service delivery decisions, leading to better health and wellbeing for all Australians.

© Australian Institute of Health and Welfare 2022 

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 3.0 (CC BY 3.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build upon this work. However, you must attribute the AIHW as the copyright holder of the work in compliance with our attribution policy available at www.aihw.gov.au/copyright/. The full terms and conditions of this licence are available at <http://creativecommons.org/licenses/by/3.0/au/>.

A complete list of the Institute's publications is available from the Institute's website www.aihw.gov.au.

ISBN 978-1-76054-983-1 (Online)

ISBN 978-1-76054-984-8 (Print)

DOI: 10.25816/117y-3m09

Suggested citation

Australian Institute of Health and Welfare (2022) *National Cervical Screening Program Data Dictionary: Version 1.1*, catalogue number CAN 146, AIHW, Australian Government.

Australian Institute of Health and Welfare

Board Chair

Mrs Louise Markus

Chief Executive Officer

Mr Rob Heferen

Any enquiries about or comments on this publication should be directed to:

Australian Institute of Health and Welfare

GPO Box 570

Canberra ACT 2601

Tel: (02) 6244 1000

Email: info@aihw.gov.au

Published by the Australian Institute of Health and Welfare.

**Please note that there is the potential for minor revisions of data in this report.
Please check the online version at www.aihw.gov.au for any amendments.**

Contents

Terminology.....	viii
1 Introduction	1
2 Summary of updates to the National Cervical Screening Program data dictionary	3
3 Data items	11
Group A: Participant identifier data items	23
A1 Participant identifier.....	24
A2 Previous participant identifier	25
A3 Medicare card number	27
A4 Individual healthcare identifier	28
Group B: Participant data items	29
B1 Family name	30
B2 Given name.....	31
B3 Other given names.....	32
B4 Date of birth	33
B5 Sex.....	34
B6 Gender	38
B7 Indigenous status	42
B8 Main language other than English spoken at home	47
B9 Country of birth.....	50
B10 CALD status	52
Group C: Participant status data items.....	53
C1 Defer flag	54
C2 Reason to defer screening	55
C3 Defer start date	56
C4 Defer end date	57
C5 Opt out flag	58
C6 Reason for opt out	59
C7 Opt out date	60
C8 Opt in date	61
C9 Hysterectomy flag	63
C10 Date of hysterectomy	64
C11 Death flag	65

C12 Date of death	66
C13 DES exposed	67
C14 Immunocompromised	69
Group D: Participant vaccination status data items	71
D1 HPV vaccination clinical completion status	72
D2 HPV vaccination clinical completion date	74
D3 HPV vaccine dose date	75
D4 HPV vaccine dose age	76
D5 HPV vaccine implied dose number	77
D6 HPV vaccine type	78
Group E: Participant demographic data items	79
E1 Residential address	80
E2 Residential suburb/town/locality	81
E3 Residential alternative or other names for suburb/town/locality	82
E4 Residential Australian state/territory	83
E5 Residential Australian postcode	84
E6 Residential geocode – latitude	85
E7 Residential geocode – longitude	86
E8 Residential geocode – quality	87
E9 Residential SA1	88
Group F: Correspondence data items	89
F1 Correspondence type	90
F2 Correspondence date	92
F3 Correspondence method	93
F4 Correspondence failure flag	94
F5 Correspondence failure date	95
F6 Correspondence failure type	96
Group G: Test type data item	97
G1 Type of test	98
Group H: HPV test data items	99
H1 HPV test date	100
H2 HPV test collection method	101
H3 HPV test specimen site	102
H4 Reason for HPV test	103
H5 HPV test result – oncogenic HPV	104

H6 HPV test result – secondary oncogenic HPV	106
H7 HPV test type	108
H8 HPV test sample	110
H9 HPV test batch information – Control kit lot number	111
H10 HPV test batch information – Control kit expiry date.....	112
H11 HPV test batch information – Cellular (LBC) extraction kit lot number	113
H12 HPV test batch information – Cellular (LBC) extraction kit expiry date.....	114
H13 HPV test batch information – Nucleic acid extraction kit lot number	115
H14 HPV test batch information – Nucleic acid extraction kit expiry date.....	116
H15 HPV test batch information – Amplification kit lot number	117
H16 HPV test batch information – Amplification kit expiry date.....	118
H17 HPV test batch information – Detection kit lot number.....	119
H18 HPV test batch information – Detection kit expiry date	120
H19 HPV test batch information – Wash buffer lot number	121
H20 HPV test batch information – Wash buffer expiry date	122
Group I: Cytology test data items.....	123
I1 Cytology test date.....	124
I2 Cytology test specimen type	125
I3 Cytology test specimen site	126
I4 Reason for cytology test	127
I5 Cytology test squamous cytology cell analysis.....	128
I6 Cytology test endocervical (glandular) cytology cell analysis	130
I7 Cytology test other/non-cervical cytology cell analysis.....	132
I8 Cytology test result	134
Group J: Screening episode data items	135
J1 Primary screening episode commencement date.....	136
J2 Primary screening episode completion date.....	137
J3 Primary screening episode result.....	138
J4 Primary screening episode risk of significant cervical abnormality	140
J5 Primary screening episode recommendation	141
J6 Follow-up episode commencement date.....	142
J7 Follow-up episode completion date.....	143
J8 Follow-up episode result	144
J9 Follow-up episode risk of significant cervical abnormality	145
J10 Follow-up episode recommendation	147

Group K: Colposcopy data items	148
K1 Date of colposcopy episode	149
K2 Indication for colposcopy	150
K3 Indication for colposcopy – other indication free text	151
K4 General colposcopic assessment – adequacy.....	152
K5 General colposcopic assessment – transformation zone visibility.....	153
K6 Colposcopic impression – primary diagnosis.....	155
K7 Colposcopic impression – other finding free text	157
K8 Biopsy this episode	158
K9 Pregnant at time of colposcopy	159
K10 Colposcopy data source	160
Group L: Histology test data items	162
L1 Histology test date	163
L2 Histology test specimen site	164
L3 Procedure used for obtaining specimen for histological analysis	165
L4 Squamous histology cell analysis	166
L5 Endocervical (glandular) histology cell analysis	168
L6 Other/non-cervical histology cell analysis	170
L7 Histology test result	171
L8 Histology report text.....	173
L9 Histology stain	174
L10 Histology stain result.....	175
L11 Histology data source	176
Group M: Treatment data items.....	177
M1 Treatment this episode	178
M2 Treatment date	179
M3 Excision performed this episode	180
M4 Modality/method used for excision.....	181
M5 Ablation performed this episode	182
M6 Hysterectomy.....	183
M7 Treatment anaesthetic type	184
M8 Location of service.....	185
M9 Eligible for test of cure flag.....	186
M10 Eligible for test of cure date	187
M11 Test of cure completion flag.....	188

M12 Test of cure completion date.....	189
Group N: Provider data items	190
N1 Medicare provider number of provider requesting a test.....	191
N2 Healthcare provider identifier – individual (HPI-I) of provider requesting a test.....	193
N3 Healthcare provider identifier – organisation (HPI-O) of provider requesting a test	194
N4 Australian state/territory of provider requesting a test.....	195
N5 Australian postcode of provider requesting a test.....	196
N6 Medicare provider number of provider collecting a specimen	197
N7 Non-medical provider number of provider collecting a specimen.....	199
N8 Healthcare provider identifier – individual (HPI-I) of provider collecting a specimen	200
N9 Healthcare provider identifier – organisation (HPI-O) of provider collecting a specimen	201
N10 Type of provider collecting a specimen	202
N11 Australian state/territory of provider collecting a specimen	203
N12 Australian postcode of provider collecting a specimen	204
Group O: Pathology laboratory data items.....	205
O1 Pathology laboratory identifier.....	206
O2 Pathology laboratory name	207
O3 Pathology laboratory accession number/identifier	208
O4 Pathology laboratory Australian state/territory.....	209
O5 Pathology laboratory Australian postcode	210
Group P: Screening history data items.....	211
P1 Previously screened flag	212
P2 Date of last screening test.....	213
P3 Last screening test type	215
P4 Number of days since last screening test	216
4 Classification schemes	217
5 Performance indicators.....	226

Terminology

The change in primary screening test for the National Cervical Screening Program (NCSP) from a Pap test to an HPV test with partial genotyping and reflex LBC triage has led to the introduction of new terminology and new concepts. Here, the more important terms and concepts have been defined.

Cervical screening: This term describes the process of screening for the prevention of cervical cancer. The term 'HPV screening' should not be used.

Cervical Screening Test (CST): The agreed term to describe the screening test of the renewed NCSP, which is an HPV test with partial genotyping and a reflex LBC test if this is indicated by the result of the HPV test.

Co-test: This term indicates that an HPV test and LBC are both performed on the sample, irrespective of the result of the HPV test.

Follow-up episode: Is a term that encompasses a **follow-up HPV test** (repeat HPV test after negative or pLSIL/LSIL reflex LBC) and an LBC if this is required.

HPV: This term is used to indicate oncogenic HPV (otherwise known as high-risk HPV), which are the types of HPV associated with cervical cancer.

HPV types: HPV types should be referred to as **oncogenic** or **non-oncogenic** and not high risk and low risk. This is to avoid confusion with the risk of significant cervical abnormality.

HPV test: Performed as part of the screening round to test for the presence of oncogenic HPV types; this is defined as either a **screening HPV test** when it is part of the screening episode, or a **follow-up HPV test** if it is performed 12 months or 24 months after the screening episode (this is also sometimes referred to as a repeat HPV test). An HPV test is also performed to test for the presence of oncogenic HPV types as part of a **co-test**.

HPV test result: An HPV test result will be reported as **detected** or **not detected** in line with molecular testing terminology (where detection levels are based on a set threshold) rather than HPV positive or HPV negative. The HPV test result groupings are:

- HPV 16/18 detected
- Oncogenic HPV (not 16/18) detected
- Oncogenic HPV not detected
- Unsatisfactory (test cannot be performed due to technical reasons).

People: In the context of National Cervical Screening Program data, 'people' refers to any person with a cervix. This may include women, transgender men, intersex people, and non-binary people.

Negative co-test: A single cervical sample for which oncogenic HPV is not detected and LBC is reported negative.

If more than one sample is collected and tested on the same day, none of these samples can have oncogenic HPV or a cytological abnormality detected.

Negative HPV is defined as 'oncogenic HPV not detected'.

Negative cytology is defined as per the previous Pap test program, and requires that the squamous cell component is '*S1 Cell numbers and preservation satisfactory. No abnormality or only reactive changes*' and the endocervical (glandular) component is either '*E0 No endocervical component*' or '*E1 Endocervical component present. No abnormality or only reactive changes*'.

Reflex test: LBC test following an HPV test that detected oncogenic HPV.

Risk of significant cervical abnormality: There are three risk classifications:

- people who are classified at **low risk** will be invited to re-screen in five years
- people who are classified at **intermediate risk** will be invited to have another HPV test in 12 months. This is to check that the HPV infection has cleared. This second HPV test is a **follow-up test**, not a screening test because people at intermediate risk are not at average population risk
- people classified at **higher risk** will be referred directly to colposcopy for further investigation.

Screening episode: Is a term that encompasses a primary screening HPV test and a reflex LBC if this is required.

Screening round: Covers the entire screening pathway for a person from their primary HPV test through to a final screening outcome; a screening round is only completed when a person returns to routine 5 yearly screening or has a diagnosis of cervical cancer or a cervical abnormality that requires treatment.

Self-collected sample: A vaginal sample taken by a person.

1 Introduction

1.1 National Cervical Screening Program

The National Cervical Screening Program (NCSP) is a highly successful public health initiative in Australia, halving cervical cancer incidence and mortality since it was introduced in 1991. Until December 2017, this has been achieved through organised, population-based cervical screening using 2-yearly Pap tests to detect precancerous changes to cervical cells, allowing treatment before any progression to cervical cancer, thereby preventing this disease. Cervical screening using Pap tests has been supported by high-quality cervical cytology through pathology laboratories, and by state and territory cervical cytology registers, that supported appropriate recommendations for clinical management, and provided a safety net to people who participated in cervical screening.

Improvements in technology, a greater understanding of the role of human papillomavirus (HPV) in the development of cervical cancer, and the introduction of an HPV vaccine that is now administered to girls and boys under the National Immunisation Program, led to the NCSP being reviewed and 'renewed', to ensure that the NCSP continued to provide Australians with safe and effective cervical screening. As a result of this process, on 1 December 2017, a 'renewed' NCSP was introduced.

The renewed NCSP means changes to the way that people are screened. Instead of people aged 20–69 having a Pap test every 2 years, people aged 25–74 now have a Cervical Screening Test (CST) every 5 years (the CST is an HPV test, followed by a cytology test if HPV is found). Another change is the collection of cervical screening data by the National Cancer Screening Register (NCSR), which is now the sole source of cervical screening data.

1.2 Development of the National Cervical Screening Program data dictionary

The development of the first data dictionary for the NCSP started when NCSP program managers and data managers saw the implementation of *Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen-detected abnormalities* (NHMRC 2005) as an opportunity to standardise data collections across jurisdictions through the development of a national cervical screening data dictionary.

The then-called *Standardised cervical screening data dictionary* was originally developed as three sub-sets; the first sub-set comprised data items related to demographic information for program participants, practitioners, and laboratories as well as cytology and HPV testing results, and was published on the Department of Health (Health) website in April 2007. The second sub-set comprised data items for procedures for obtaining histology specimens and reporting of histology codes. The third sub-set was developed concurrently with the incorporation of the three sub-sets into a single document and comprised definitions and algorithms for the performance indicators reported nationally in the annual monitoring report for the NCSP, *Cervical Screening in Australia*.

At an NCSP program managers meeting held in June 2008, it was decided that the dictionary should be further developed into a comprehensive document, comprising *Essential*, *Desirable* and *Aspirational* data elements to support the NCSP as a whole. The original dictionary was expanded into the *National cervical cancer prevention data dictionary* in July 2008, with the final data dictionary published in 2014.

This data dictionary promoted and supported national consistency in state and territory data collection and national reporting by the Australian Institute of Health and Welfare (AIHW) for the NCSP until 30 November 2017. After which the renewed NCSP that commenced on 1 December 2017 was supported by a new data dictionary – the *National Cervical Screening Program data dictionary version 1.0*.

Work on this data dictionary commenced in 2015, soon after the onset of the renewal process for the NCSP, as it was seen as a key document to support data collection and reporting for the renewed program. The *National Cervical Screening Program data dictionary version 1.0* was developed by the AIHW with the assistance of state and territory cervical screening programs, and the National Cervical Screening data dictionary working group, convened specifically for this purpose, with additional input into specific elements of the data dictionary provided by the NCSP Quality and Safety Monitoring Committee, the Colposcopy Working Group convened to progress the collection and reporting of colposcopy data in the renewed NCSP, and cervical screening experts Professor Ian Hammond, Associate Professor Marion Saville, Dr Julia Brotherton, Professor David Roder and Professor Dorota Gertig.

Following a lengthy development process alongside other key documents, including the clinical management guidelines, quality framework, a form for the collection of colposcopy data, and NPAAC standards for pathology laboratories reporting cervical screening tests, the *National Cervical Screening Program data dictionary version 1.0* was endorsed by the Standing Committee on Screening in February 2017 and published in May 2017.

While the early development of this data dictionary was key to the successful implementation of the renewed NCSP on 1 December 2017, because the data dictionary predated the renewed NCSP, it was recognised that the data dictionary would need to be reviewed and updated periodically in the future to ensure it continues to align with and support data and reporting for the renewed NCSP.

This current *National Cervical Screening Program data dictionary version 1.1* is the result of a process to revise and update the data dictionary in line with the renewed NCSP that occurred in 2020, again with the assistance of state and territory cervical screening programs through the National Cervical Screening data dictionary working group and the NCSP Program Management Committee (PMC) more broadly. This was endorsed by the PMC on 5 May 2022 and released by the AIHW on 10 May 2022.

It supersedes the *National Cervical Screening Program data dictionary version 1.0*.

1.3 Role of the National Cervical Screening Program data dictionary

The *National Cervical Screening Program data dictionary* is a key document that has been developed to support AIHW monitoring and reporting for the renewed NCSP, although it has been recognised that this document will support the renewed NCSP and its operation more broadly, including ensuring consistency in data collection and reporting between the AIHW and the state and territory cervical screening programs.

As the primary purpose of this data dictionary is to support monitoring and reporting by the AIHW for the renewed NCSP, only key data items required for this purpose, along with selected others considered important to support the renewed NCSP more broadly are included in this data dictionary. Many more data items exist in the NCSR that are either not provided to the AIHW or do not support AIHW reporting and are therefore not included in this data dictionary.

2 Summary of updates to the National Cervical Screening Program data dictionary

This chapter summarises the updates made to this current *National Cervical Screening Program data dictionary version 1.1* compared to *version 1.0*.

Terminology

Terminology around gender has been changed to be more inclusive of all people who are eligible to screen through the National Cervical Screening Program. Previously the terms 'woman' and 'women' were used throughout this document. These terms have been replaced with the terms 'person', 'people', and 'participants'.

This document uses the terms 'person', 'people' and 'participants' when referring to data collected under the NCSP. These data are not restricted by sex or gender, with all participants in cervical screening included in these data. For NCSP data, 'person' or 'people' is defined as any person with a cervix. This may include women, transgender men, intersex people, and non-binary people.

This document uses the term 'women' to mean 'female' when referring to cancer incidence data and cancer mortality data, as these data sources are based on sex assigned at birth. However, it should be noted that some people may not identify with this term.

New terminology is detailed in Table 2.1.

Table 2.1: New terminology

Terminology	Definition	Reason for addition
Person or people	In the context of National Cervical Screening Program data, 'person' or 'people' refers to any person with a cervix. This may include women, transgender men, intersex people, and non-binary people.	Terminology around gender has been changed to be more inclusive of all people who are eligible to screen through the National Cervical Screening Program
Negative co-test	A single cervical sample for which oncogenic HPV is not detected and LBC is reported negative. If more than one sample is collected and tested on the same day, none of these samples can have oncogenic HPV or a cytological abnormality detected. Negative HPV is defined oncogenic HPV not detected. Negative cytology is defined as per the previous Pap test program, and requires that the squamous cell component is 'S1 Cell numbers and preservation satisfactory. No abnormality or only reactive changes' and the endocervical (glandular) component is either 'E0 No endocervical component' or 'E1 Endocervical component present. No abnormality or only reactive changes'.	A co-test requires both HPV and LBC tests to be performed irrespective of the HPV test result. Practitioners are able to request a co-test for the investigation of symptoms of cervical cancer; for the management of a patient following treatment of high grade squamous intraepithelial lesions (HSIL) of the cervix as part of a 'test of cure' process performed at 12 months after treatment and annually thereafter, until receiving a negative co-test on two separate consecutive occasions; for the follow up management of glandular abnormalities; or for screening a patient exposed to diethylstilboestrol (DES) in utero and daughters of patients exposed to DES in utero. Thus it is important that there is an agreed definition of a negative co-test.

Screening pathway

There has been a significant change to the screening pathway for people at intermediate risk, effective from 1 February 2021. This is detailed in Table 2.2.

Table 2.2: Revised screening pathway

Screening pathway		Reason for change
Version 1.1	Version 1.0	
For people with a cervical screening result of <i>Intermediate risk</i> and recommended to have a follow-up HPV test at 12 months, if HPV (not 16/18) is detected and LBC prediction is negative, pLSIL or LSIL in the follow-up HPV test at 12 months, from 1 February 2021, they will continue to be managed as <i>Intermediate risk</i> and recommended to undertake a second HPV follow-up test at 12 months. This change excludes some groups who may be at higher risk of a high-grade abnormality, who should be referred to colposcopy if any HPV is detected at 12 months. These include: • participants who are 2 or more years overdue for screening at the time of the initial screen; • participants who identify as being Aboriginal and/or Torres Strait Islander; and • participants aged 50 years or older.	People with a cervical screening result of <i>Intermediate risk</i> are recommended to have a follow-up HPV test at 12 months and be managed as <i>Higher risk</i> if any HPV is detected in test.	The Cancer Council Australia Clinical Guidelines working party reviewed new Australian data for the cervical screening pathway recommendation for people with a 12-month follow-up HPV test in which HPV (any type) was detected. In the planning for the change to primary HPV screening, a cautious approach was adopted for management of these people, meaning the pathway for people with this result was universal referral for colposcopy. Current national program data, broken down by HPV type, has shown that the risk of CIN2/3 and cervical cancer is very low for those participants in whom HPV (not 16/18) is detected and the reflex LBC is negative, pLSIL or LSIL. Based on this current evidence, clinical advisors have now recommended that people with a 12-month follow-up HPV test in which HPV (not 16/18) is detected and reflex LBC is negative, pLSIL or LSIL (<i>Intermediate risk</i> result) should be recommended to undertake a second follow-up HPV test in a further 12 months' time following their first follow-up HPV test. Exceptions to this are participants who are 2 or more years overdue for screening at the time of the initial screen, participants who identify as being Aboriginal and/or Torres Strait Islander, and participants aged 50 years or older, who should instead be referred to colposcopy if any HPV is detected at 12 months. This took effect from 1 February 2021.

Data items

New, deleted, and revised data items are detailed in Table 2.3, Table 2.4, and Table 2.5.

Table 2.3: New data items

Data item (version 1.1)	Definition	Reason for addition
B6 Gender	The way a person describes their social and cultural identity, expression and experience as man, or boy, or woman, or girl, or non-binary.	Gender was added at the same time that sex was revised to the 2021 definition to provide clarity of how sex and gender differ as well as updating the appropriate terminology and definitions for these two terms.
C1 Defer flag	An indication as to whether a person has requested that their participation in cervical screening be deferred.	Alert that defer is active.
C5 Opt out flag	An indication as to whether a person has opted out of all participation in the National Cancer Screening Register for the National Cervical Screening Program.	Alert that opt out is active.
C6 Reason for opt out	The reason that a person provides to the National Cancer Screening Register for opting out of all participation in the National Cancer Screening Register for the National Cervical Screening Program.	Participants can choose between three reasons when opting out. This data item has been added to allow this reason to be collected.
C13 DES exposed	An indication of whether a person was exposed to diethylstilboestrol (DES) in utero.	Women exposed to DES in utero are at increased risk of clear cell carcinoma of the vagina and cervix and are offered more frequent screening with co-tests. The addition of this data item allows this to be collected if recorded by a health professional.
C14 Immunocompromised	An indication of whether a person is immunocompromised.	People with HIV and solid organ transplant recipients have been defined as sufficiently immune-deficient to warrant more frequent screening and a lower threshold for colposcopy referral than the general population. People with congenital immune deficiency, being treated with immunosuppressant therapy for autoimmune disease, or being treated for graft versus host disease could also be considered for more frequent screening. The addition of this data item allows this to be collected if recorded by a health professional.
D4 HPV vaccine dose age	The age at which a person received an HPV vaccine dose.	This data item allows the collection of the age of the person for each HPV vaccine dose administered.
H6 HPV test result – secondary oncogenic HPV	The secondary result of an HPV test for oncogenic HPV types.	This data item allows the collection of any secondary HPV types recorded by a pathology laboratory. This is not used to assign risk, but is useful to increase knowledge of all HPV types detected.

(continued)

Table 2.3: New data items (continued)

Data item (version 1.1)	Definition	Reason for addition
K10 Colposcopy data source	An indication as to the source of data that a colposcopy occurred.	There are several sources of colposcopy data in the NCSR with different information available. This data item allows the source of the colposcopy event to be specified.
L8 Histology report text	Text from the report prepared for cervical histology.	This data item allows histology report text to be included that is often required for detailed information when supporting research requests.
L11 Histology data source	An indication as to the source of data that histology occurred.	There are two sources of histology data in the NCSR with different information available. This data item allows the source of the histology test information to be specified.
N6 Medicare provider number of provider collecting a specimen	The provider number of the provider collecting a specimen.	This data item allows the collection of provider number if the provider who collects a specimen did not request the test.
N11 Australian state/territory of provider collecting a specimen	The abbreviated name of the Australian state or territory in which the provider collecting a specimen is located.	This data item allows the collection of the state or territory of the provider who collects a specimen.
N12 Australian postcode of provider collecting a specimen	The code that represents a postal delivery area, aligned with locality, suburb, or place for the practice where a provider collecting a specimen is located.	This data item allows the collection of the postcode of the provider who collects a specimen.
O4 Pathology laboratory Australian state/territory	The abbreviated name of the Australian state or territory in which the pathology laboratory that perform analyses on cervical specimens is located.	This data item allows the collection of the state or territory of the pathology laboratory that analyses a specimen.
O5 Pathology laboratory Australian postcode	The code that represents a postal delivery area, aligned with locality, suburb, or place for the practice where the pathology laboratory that perform analyses on cervical specimens is located.	This data item allows the collection of the postcode of the pathology laboratory that analyses a specimen.

Table 2.4: Deleted data items

Data item (version 1.0)	Definition	Reason for deletion
C1 Active status	An indication as to whether a person's record is currently active.	None of the NCSR data items that are provided to the AIHW align with the current active status of a person.
E10 Mailing geocode – latitude	Latitude of mailing address.	As residential address is available, mailing address is not required.
E11 Mailing geocode – longitude	Longitude of mailing address.	As residential address is available, mailing address is not required.
E12 Mailing geocode – quality	A measure of the quality of geocode for mailing address.	As residential address is available, mailing address is not required.
E13 Mailing SA1	SA1 of mailing address.	As residential address is available, mailing address is not required.

(continued)

Table 2.4: Deleted data items (continued)

Data item (version 1.0)	Definition	Reason for deletion
H6 Secondary HPV test results – HPV 16/18 detected	The secondary HPV test result where the primary HPV test result was 'HPV 16/18 detected' providing additional information about oncogenic test types detected.	This was intended to collect additional information about oncogenic test types detected when the primary HPV test detected oncogenic HPV types 16 or 18, but has been replaced by a single data item ' <i>H6 HPV test result – other oncogenic HPV</i> ' used to collect the HPV test result for a second oncogenic HPV type in the event that one is detected in the same sample, to reflect the NCSR data provided to the AIHW.
H7 Secondary HPV test results – oncogenic HPV (not 16/18) detected	The secondary HPV test result where the primary HPV test result was 'Oncogenic HPV (not 16/18) detected' providing additional information about oncogenic HPV types detected.	This was intended to collect additional information about oncogenic test types detected when the primary HPV test detected oncogenic HPV types other than 16 or 18, but has been replaced by a single data item ' <i>H6 HPV test result – other oncogenic HPV</i> ' used to collect the HPV test result for a second oncogenic HPV type in the event that one is detected in the same sample, to reflect the NCSR data provided to the AIHW.
K1 Colposcopy episode identifier	A unique identifier allocated to a colposcopy episode to distinguish it from all other colposcopy episodes.	The data item ' <i>Colposcopy episode identifier</i> ' has been removed, as colposcopy data are part of the NCSR, which removes the need for the episode identifier to be included in the data dictionary (a unique identifier is not included as a data item for other test types in the data dictionary).

Table 2.5: Revised data items

Data item		Reason for change
Version 1.1	Version 1.0	
Group A Participant identifier data items	Group A Client identifier data items	Group A has been changed from <i>Client identifier</i> data items to <i>Participant identifier</i> data items to align with terminology changes that have been made within this version of the data dictionary.
A1 Participant identifier	A1 Client identifier	Name change only.
A2 Previous participant identifier	A2 Previous client identifier	Name change only.
Group B Participant data items	Group B Client data items	Group B has been changed from <i>Client</i> data items to <i>Participant</i> data items to align with terminology changes that have been made within this version of the data dictionary.
Group C Participant status data items	Group C Client status data items	Group C has been changed from <i>Client status</i> data items to <i>Participant status</i> data items to align with terminology changes that have been made within this version of the data dictionary.
C3 Reason to defer screening	C2 Reason for temporary inactivation	Terminology changed from <i>temporary inactivation</i> to <i>defer</i> .
C4 Defer start date	C3 Date of temporary inactivation	Terminology changed from <i>temporary inactivation</i> to <i>defer</i> .
C5 Defer end date	C4 Date of reactivation	Terminology changed from <i>reactivation</i> to <i>defer end</i> .

(continued)

Table 2.5: Revised data items (continued)

Data item		Reason for change
Version 1.1	Version 1.0	
C8 Opt out date	C5 Withdrawn date	Terminology changed from <i>withdrawn</i> to <i>opt out</i> .
C9 Opt in date	C6 Withdrawn rescinded date	Terminology changed from <i>withdrawn rescinded</i> to <i>opt in</i> , noting that to opt in means to withdraw a request to opt out rather than to opt in <i>per se</i> .
Group D Participant vaccination status data items	Group D Client vaccination status data items	Group D has been changed from <i>Client vaccination status</i> data items to <i>Participant vaccination status</i> data items to align with terminology changes that have been made within this version of the data dictionary.
D1 HPV vaccination clinical completion status	D1 HPV vaccination status	Name change only.
D2 HPV vaccination clinical completion date	D2 HPV vaccination completion date	Name change only.
D3 HPV vaccine dose date	D3 HPV vaccination episode date	Name change only.
D5 HPV vaccine implied dose number	D4 HPV vaccine dose number	Changed from actual dose number to implied dose number, which is the clinically relevant dose number.
D6 HPV vaccine type	D5 HPV vaccine type	Addition of the nonavalent HPV vaccine type Gardasil9.
Group E Participant demographic data items	Group E Client demographic data items	Group E has been changed from <i>Client demographic</i> data items to <i>Participant demographic</i> data items to align with terminology changes that have been made within this version of the data dictionary.
Group F Correspondence data items	Group F Contact data items	Group F has been changed from <i>Contact</i> data items to <i>Correspondence</i> data items to reflect the data items collected.
F1 Correspondence type	F1 Type of contact	Terminology changed from contact to correspondence.
F2 Correspondence date	F2 Date of contact	Terminology changed from contact to correspondence.
F3 Correspondence method	F3 Method of contact	Terminology changed from contact to correspondence.
F4 Correspondence failure flag	F4 Contact failure flag	Terminology changed from contact to correspondence.
F5 Correspondence failure date	F5 Contact failure date	Terminology changed from contact to correspondence.
F6 Correspondence failure type	F6 Contact failure type	Terminology changed from contact to correspondence.
H4 Reason for HPV test	H4 Reason for HPV test	Value 2 <i>Follow-up HPV test (Repeat HPV test after intermediate risk result or unsatisfactory test)</i> changed to <i>Follow-up HPV test (Repeat HPV test after intermediate result)</i> . This reflects a change in <i>NPAAC Requirements for Laboratories Reporting Tests for the National Cervical Screening Program (Second Edition 2019)</i> that restricts a Reason for HPV test of 2 to Repeat HPV test after intermediate result. Pathology laboratories are advised that the repeat test after a prior unsatisfactory screening test should be coded according to the circumstances of the original (unsatisfactory test), rather than using a value of 2.

(continued)

Table 2.5: Revised data items (continued)

Data item		Reason for change
Version 1.1	Version 1.0	
H5 HPV test result – oncogenic HPV	H5 HPV test result – oncogenic HPV	This was intended to collect the oncogenic HPV test result: <i>Unsatisfactory</i> , <i>Oncogenic HPV not detected</i> , <i>HPV 16/18 detected</i> or <i>Oncogenic HPV (not 16/18) detected</i> , with two additional data items collecting the type of oncogenic HPV detected where either <i>HPV 16/18 detected</i> or <i>Oncogenic HPV (not 16/18) detected</i> was the oncogenic HPV test result. These three data items have been replaced by a single data item 'H5 HPV test result – oncogenic HPV', to reflect the NCSR data provided to the AIHW.
K9 Pregnant at time of colposcopy	K10 Pregnancy flag	Name change only.
J9 Follow-up episode risk of significant cervical abnormality	J9 Follow-up episode risk of significant cervical abnormality	From 1 February 2021, people with a 12-month follow-up HPV test in which HPV (not 16/18) is detected and reflex LBC is negative, pLSIL or LSIL (<i>Intermediate risk</i> result) should be recommended to undertake a second follow-up HPV test in a further 12 months' time following their first follow-up HPV test, instead of colposcopy (that is, they remain at intermediate risk instead of changing to higher risk), unless they fall into one of the groups that are an exception to this. An <i>Intermediate</i> follow-up episode risk of significant cervical abnormality has been added to accommodate this change.
M11 Test of cure completion flag		Now includes definition of negative co-test.
M12 Test of cure completion date		Now includes definition of negative co-test.
N1 Medicare provider number of provider requesting a test	N1 Medicare provider number	Name change to specify this is the provider requesting a test.
N2 Healthcare provider identifier – individual (HPI-I) of provider requesting a test	N3 Healthcare provider identifier – individual (HPI-I)	Name change to specify this is the provider requesting a test.
N3 Healthcare provider identifier – organisation (HPI-O) of provider requesting a test	N2 Healthcare provider identifier – organisation (HPI-O)	Name change to specify this is the provider requesting a test.
N4 Australian state/territory of provider requesting a test	N5 Provider Australian state/territory	Name change to specify this is the provider requesting a test.
N5 Australian postcode of provider requesting a test	N6 Provider Australian postcode	Name change to specify this is the provider requesting a test.
N7 Non-medical provider number of provider collecting a specimen	N7 Identifier of a provider collecting specimen	Name change to use the term non-medical provider number instead of identifier.
N8 Healthcare provider identifier – individual (HPI-I) of provider collecting a specimen	N9 Healthcare provider identifier – individual (HPI-I) of a provider collecting specimen	Name change only.
N9 Healthcare provider identifier – organisation (HPI-O) of provider collecting a specimen	N8 Healthcare provider identifier – organisation (HPI-O) of a provider collecting specimen	Name change only.
N10 Type of provider collecting a specimen	N10 Type of provider collecting specimen	Name change only.

Performance indicators

Revised performance indicators are detailed in Table 2.6.

Table 2.6: Revised performance indicators

Performance indicator	Outline of change
Indicator 1 Participation	The definition of <i>Participation</i> was revised in late 2020 to restrict participation to screening HPV tests (primary screening HPV tests and follow-up HPV tests). A second measure called <i>Coverage</i> was also introduced that includes all HPV and cytology tests performed for any reason, which aligns with the definition of participation in the previous National Cervical Screening Program.
Indicator 18 Cervical cancers diagnosed by time since last screen	Version 1.0 of the data dictionary included an error in the definition of this <i>Cervical cancers diagnosed by time since last screen</i> , as the periods listed under <i>Lapsed screening</i> were not mutually exclusive. This has been amended in Version 1.1. The term <i>Adequately screened</i> has been replaced with <i>Recently screened</i> .

Coding sheets

Revised coding sheets are detailed in Table 2.7.

Table 2.7: Revised coding sheets

Coding sheet		Reason for change
Version 1.1	Version 1.0	
HPV Test Group Reason for HPV test = 2 Follow-up HPV test (Repeat HPV test after intermediate risk result)	HPV Test Group Reason for HPV test = 2 Follow-up HPV test (Repeat HPV test after intermediate risk result or unsatisfactory test)	Value 2 <i>Follow-up HPV test (Repeat HPV test after intermediate risk result or unsatisfactory test)</i> changed to <i>Follow-up HPV test (Repeat HPV test after intermediate risk result)</i> . This reflects a change in <i>NPAAC Requirements for Laboratories Reporting Tests for the National Cervical Screening Program (Second Edition 2019)</i> that restricts a Reason for HPV test of 2 to Repeat HPV test after intermediate result. Pathology laboratories are advised that the repeat test after a prior unsatisfactory screening test should be coded according to the circumstances of the original (unsatisfactory test), rather than using a value of 2.
Screening episode Follow-up episode risk Oncogenic HPV (not 16/18) and Cytology test result <i>None</i> = no risk (incomplete) Oncogenic HPV (not 16/18) and Cytology test result <i>Unsatisfactory</i> = no risk (unsatisfactory) Oncogenic HPV (not 16/18) and Cytology test result <i>Negative</i> = Intermediate risk Oncogenic HPV (not 16/18) and Cytology test result <i>Possible or definite low-grade intraepithelial lesion (LSIL)</i> = Intermediate risk	Screening episode Follow-up episode risk Oncogenic HPV (not 16/18) and Cytology test result <i>None</i> = Higher risk Oncogenic HPV (not 16/18) and Cytology test result <i>Unsatisfactory</i> = Higher risk Oncogenic HPV (not 16/18) and Cytology test result <i>Negative</i> = Higher risk Oncogenic HPV (not 16/18) and Cytology test result <i>Possible or definite low-grade intraepithelial lesion (LSIL)</i> = Higher risk	The Cancer Council Australia Clinical Guidelines working party reviewed new Australian data for the cervical screening pathway recommendation for people with a 12-month follow-up HPV test in which HPV (any type) was detected. In the planning for the change to primary HPV screening, a cautious approach was adopted for management of these people, meaning the pathway for people with this result was universal referral for colposcopy. Current national program data, broken down by HPV type, has shown that the risk of CIN2/3 and cervical cancer is very low for those participants in whom HPV (not 16/18) is detected and in whom reflex LBC is negative, pLSIL or LSIL. Based on this current evidence, clinical advisors have now recommended that people with a 12-month follow-up HPV test in which HPV (not 16/18) is detected and reflex LBC is negative, pLSIL or LSIL (<i>Intermediate risk</i> result) should be recommended to undertake a second follow-up HPV test in a further 12 months' time following their first follow-up HPV test. This took effect from 1 February 2021.

3 Data items

3.1 Data item specifications

The data items in the *National Cervical Screening Program data dictionary* are described and defined using a standard metadata format that is designed to ensure that each data item is clear, concise, unambiguous, comprehensive and provides sufficient information to ensure all those who collect, provide, analyse, and use the data understand its meaning.

The format is consistent with that of AIHW's Metadata Online Registry (METeOR), which would allow these items to be imported into METeOR in the future.

Identifying and definitional attributes

Identifying and definitional attributes include the name and definition of the data item, as well as its collection status within the NCSP. Collection status reflects the importance of the data item to the collection, and can be *Essential*, *Desirable* or *Aspirational*. There are also *Conditional* data items, whose inclusion depends on criteria for this data item being met. Essential data items are mandatory for collection; conditional data items may be mandatory, desirable, or aspirational.

Value domain attributes

Representation class refers to the form of the data item, such as identifier, text, date, or code. The data type refers to the type of symbol, character or other designation used to represent the data item (for example, string, date/time, number, text), and the format and character length describe how the value should appear for that data item.

Formats can be alphabetic character (denoted by the letter A), numeric (denoted by the letter N) alphanumeric (denoted by the letter X), or specific to dates (D for day, M for month, Y for year). Characters that are not in brackets denote a value that must be represented. Round brackets are used to indicate the number of repeats if a character is repeated more than 6 times in succession (X(9) indicates 9 alphanumeric characters). Square brackets are used to indicate that characters are optional in any ordered combination ([XXX] indicates 0, 1, 2 or 3 alphanumeric characters). Curly brackets are used to indicate that characters are entirely optional (X{XX} indicates 1 or 3 alphanumeric characters).

Value domain format examples

X(10) – No square/curly brackets, therefore exactly 10 alphanumeric characters must be entered.

{X(10)} – Curly brackets, therefore optional with fixed length. Either 0 or exactly 10 alphanumeric characters must be entered.

[X(10)] – Square brackets, therefore optional with variable length – either 0 or between 1 to 10 alphanumeric characters entered.

X[X(39)] – At least 1 alphanumeric character is required (an X is outside any square/curly brackets) and optionally supports an additional 0 to 39 alphanumeric characters, which means the maximum total length is 40 alphanumeric characters.

{N(10)[N]} – Curly brackets, therefore optional with fixed length. Either 0 or 10 numeric characters with a further optional single numeric character entered. This allows for 0, 10 or a maximum of 11 numeric characters.

{AAX[XXX]} – Curly brackets, therefore optional with fixed length. Either 0 or 2 alphabetic characters followed by a single alphanumeric character with a further optional 0 to 3 alphanumeric characters

allowed. This allows for 0, 3, 4, 5 or a maximum of 6 characters (2 alphabetic, and 4 alphanumeric). If only 3 characters are entered, then they must be 2 alphabetic followed by 1 alphanumeric.

See tables 3.1 and 3.2 for further examples of the use of codes and brackets.

Collection and usage attributes may be included to ensure that data are captured correctly and to aid in the correct interpretation of permissible values.

Data item attributes

This section of the data item may also include a guide for use, which takes the form of additional comments or advice on interpretation or application, and collection methods, which are comments and advice concerning the capture of data for a particular data item.

Additional information relates to source, reference documents, as well as an indication of whether this is a new data item, or whether it supersedes a data item in the previous data dictionary.

Table 3.1: Data item format – codes

Code	Definition	Description	Example
A	Alphabetic	Supports letter characters (including punctuation) only (that is, no numbers)	AAA = ABC not A1C
N	Numeric	Supports numeric digits only (that is, no alphabetic characters)	NNN = 123 not 1B3
X	Alphanumeric	Supports both alphabetic characters (including punctuation) and numeric digits	XXX = ABC or 123 or A1C or 1B3
D	Day	Date specific: day number within a month. Represented as DD in DDMMYYYY date format	23rd day of August 2013 23 <u>0</u> 82013
M	Month	Date specific: month number within a year. Represented as MM in DDMMYYYY date format	8th month of 2013 23 <u>0</u> 82013
Y	Year	Date specific: year number. Represented as YYYY in DDMMYYYY date format.	2013th year 23082 <u>0</u> 13

Table 3.2: Data item format – use of brackets

Bracket type	Description	Example	Notes
No square or curly brackets	Characters must be entered in the format presented. <i>Note:</i> number in round brackets () represents characters repeated 7 or more times in succession.	AAA	Exactly 3 alphabetic characters
		NN	Exactly 2 numeric characters
		X(8)	Exactly 8 alphanumeric characters
Curly brackets /braces { }	Characters are optional, but if entered, they are fixed in length and must match exactly the format presented.	{AAA}	0 or exactly 3 alphabetic characters
		{NN}	0 or exactly 2 numeric characters
		{X(8)}	0 or exactly 8 alphanumeric characters
Square brackets []	Characters are optional, but if entered are variable in length up to the maximum length designated	[AAA]	Either 0, 1, 2 or 3 alphabetic characters
		[NN]	Either 0, 1 or 2 numeric characters
		[N(8)]	Either 0, 1, 2, 3, 4, 5, 6, 7 or 8 numeric characters

3.2 Structure of data items

The following table provides an overview of the data items in this version of the *National Cervical Screening Program data dictionary*. It also maps current data items to their previous number, where data items have been retained across the versions.

Data items are arranged into two main groups – Participant data items which either do not change or do not change very often, and screening pathway data items that will be added to a person’s record each time they screen. This is illustrated in Table 3.3.

Table 3.3: Data item structure

	Associated groups
Participant	Group A: Participant identifier data items
	Group B: Participant data items
	Group C: Participant status data items
	Group D: Participant vaccination status data items
	Group E: Participant demographic data items
Screening pathway	Group F: Correspondence data items
	Group G: Test type data item
	Group H: HPV test data items
	Group I: Cytology test data items
	Group J: Screening episode data items
	Group K: Colposcopy data items
	Group L: Histology test data items
	Group M: Treatment data items
	Group N: Provider data items
	Group O: Pathology laboratory data items
	Group P: Screening history data items

3.3 Summary of data items

The following table provides a summary of the data items in the data dictionary, arranged as 'Participant' data items and 'Screening pathway' data items. To aid in transition from the previous versions of the data dictionary, the number of each data item is shown alongside the number in the previous data dictionaries.

Table 3.4: Summary of data items

<i>Participant</i>				
<i>Group A</i>	<i>Participant identifier data items</i>	<i>Version 1.1</i>	<i>Version 1.0</i>	<i>Pre-renewal</i>
	Participant identifier	A1	A1	A1
	Previous participant identifier	A2	A2	..
	Medicare card number	A3	A3	A2
	Individual healthcare identifier	A4	A4	A3
<i>Group B</i>	<i>Participant data items</i>			
	Family name	B1	B1	A4
	Given name	B2	B2	A5
	Other given names	B3	B3	..
	Date of birth	B4	B4	A7
	Sex	B5	B5	..
	Gender	B6	..	..
	Indigenous status	B7	B6	A8
	Main language other than English spoken at home	B8	B8	A9
	Country of birth	B9	B7	A10
	CALD status	B10	B9	..
<i>Group C</i>	<i>Participant status data items</i>			
	Defer flag	C1	..	..
	Reason to defer screening	C2	C2	..
	Defer start date	C3	C3	..
	Defer end date	C4	C4	..
	Opt out flag	C5	..	..
	Reason for opt out	C6	..	..
	Opt out date	C7	C5	..
	Opt in date	C8	C6	..
	Hysterectomy flag	C9	C7	A21
	Date of hysterectomy	C10	C8	A22
	Death flag	C11	C9	A24
	Date of death	C12	C10	A25
	DES exposed	C13	..	..
	Immunocompromised	C14	..	..

(continued)

Table 3.4: Summary of data items (continued)

Group D Participant vaccination status data items				
HPV vaccination clinical completion status	D1	D1	V2	
HPV vaccination clinical completion date	D2	D2	V3	
HPV vaccine dose date	D3	D3	V4	
HPV vaccine dose age	D4	..	..	
HPV vaccine implied dose number	D5	D4	V5	
HPV vaccine type	D6	D5	V1	
Group E Participant demographic data items				
Residential address	E1	E1	A11	
Residential suburb/town/locality	E2	E2	A12	
Residential alternative or other names for suburb/town/locality	E3	E3	A13	
Residential Australian state/territory	E4	E4	A14	
Residential Australian postcode	E5	E5	A15	
Residential geocode – latitude	E6	E6	..	
Residential geocode – longitude	E7	E7	..	
Residential geocode – quality	E8	E8	..	
Residential SA1	E9	E9	..	
Screening pathway				
Group F Correspondence data items				
Correspondence type	F1	F1	..	
Correspondence date	F2	F2	..	
Correspondence method	F3	F3	..	
Correspondence failure flag	F4	F4	..	
Correspondence failure date	F5	F5	..	
Correspondence failure type	F6	F6	..	
Group G Test type data item				
Type of test	G1	G1	T1	
Group H HPV test data items				
HPV test date	H1	H1	D2	
HPV test collection method	H2	H2	..	
HPV test specimen site	H3	H3	..	
Reason for HPV test	H4	H4	..	
HPV test result – oncogenic HPV	H5	H5	D5	
HPV test result – secondary oncogenic HPV	H6	..	..	
HPV test type	H7	H8	D6	
HPV test sample	H8	H9	..	
HPV test batch information – Control kit lot number	H9	H10	..	

(continued)

Table 3.4: Summary of data items (continued)

Group H HPV test data items				
HPV test batch information – Control kit expiry date	H10	H11	..	
HPV test batch information – Cellular (LBC) extraction kit lot number	H11	H12	..	
HPV test batch information – Cellular (LBC) extraction kit expiry date	H12	H13	..	
HPV test batch information – Nucleic acid extraction kit lot number	H13	H14	..	
HPV test batch information – Nucleic acid extraction kit expiry date	H14	H15	..	
HPV test batch information – Amplification kit lot number	H15	H16	..	
HPV test batch information – Amplification kit expiry date	H16	H17	..	
HPV test batch information – Detection kit lot number	H17	H18	..	
HPV test batch information – Detection kit expiry date	H18	H19	..	
HPV test batch information – Wash buffer lot number	H19	H20	..	
HPV test batch information – Wash buffer expiry date	H20	H21	..	
Group I Cytology test data items				
Cytology test date	I1	I1	C2	
Cytology test specimen type	I2	I2	C4	
Cytology test specimen site	I3	I3	C3	
Reason for cytology test	I4	I4	..	
Cytology test squamous cytology cell analysis	I5	I5	C5	
Cytology test endocervical (glandular) cytology cell analysis	I6	I6	C6	
Cytology test other/non-cervical cytology cell analysis	I7	I7	C7	
Cytology test result	I8	I8	C9	
Group J Screening episode data items				
Primary screening episode commencement date	J1	J1	..	
Primary screening episode completion date	J2	J2	..	
Primary screening episode result	J3	J3	..	
Primary screening episode risk of significant cervical abnormality	J4	J4	..	
Primary screening episode recommendation	J5	J5	..	
Follow-up episode commencement date	J6	J6	..	
Follow-up episode completion date	J7	J7	..	
Follow-up episode result	J8	J8	..	
Follow-up episode risk of significant cervical abnormality	J9	J9	..	
Follow-up episode recommendation	J10	J10	..	
Group K Colposcopy data items				
Date of colposcopy episode	K1	K2	..	
Indication for colposcopy	K2	K3	..	
Indication for colposcopy – other indication free text	K3	K4	..	
General colposcopic assessment – adequacy	K4	K5	..	
General colposcopic assessment – transformation zone visibility	K5	K6	..	

(continued)

Table 3.4: Summary of data items (continued)

Group K	Colposcopy data items			
	Colposcopic impression – primary diagnosis	K6	K7	..
	Colposcopy impression – other finding free text	K7	K8	..
	Biopsy this episode	K8	K9	..
	Pregnant at time of colposcopy	K9	K10	..
	Colposcopy data source	K10	..	..
Group L	Histology test data items			
	Histology test date	L1	L1	H2
	Histology test specimen site	L2	L2	H3
	Procedure used for obtaining specimen for histological analysis	L3	L3	H4
	Squamous histology cell analysis	L4	L4	H5
	Endocervical (glandular) histology cell analysis	L5	L5	H6
	Other/non-cervical histology cell analysis	L6	L6	..
	Histology test result	L7	L7	H9
	Histology report text	L8	..	..
	Histology stain	L9	L8	..
	Histology stain result	L10	L9	..
	Histology data source	L11	..	..
Group M	Treatment data items			
	Treatment this episode	M1	M1	..
	Treatment date	M2	M2	..
	Excision performed this episode	M3	M3	..
	Modality/method used for excision	M4	M4	..
	Ablation performed this episode	M5	M5	..
	Hysterectomy	M6	M6	..
	Treatment anaesthetic type	M7	M7	..
	Location of service	M8	M8	..
	Eligible for test of cure flag	M9	M9	..
	Eligible for test of cure date	M10	M10	..
	Test of cure completion flag	M11	M11	..
	Test of cure completion date	M12	M12	..
Group N	Provider data items			
	Medicare provider number of provider requesting a test	N1	N1	B1
	Healthcare provider identifier – individual (HPI-I) of provider requesting a test	N2	N3	B2
	Healthcare provider identifier – organisation (HPI-O) of provider requesting a test	N3	N2	B3
	Australian state/territory of provider requesting a test	N4	N5	B10
	Australian postcode of provider requesting a test	N5	N6	B11

(continued)

Table 3.4: Summary of data items (continued)

<i>Group N</i>	<i>Provider data items</i>			
	Medicare provider number of provider collecting a specimen	N6	..	..
	Non-medical provider number of provider collecting a specimen	N7	N7	B13
	Healthcare provider identifier – individual (HPI-I) of provider collecting a specimen	N8	N9	B14
	Healthcare provider identifier – organisation (HPI-O) of provider collecting a specimen	N9	N8	B15
	Type of provider collecting a specimen	N10	N10	B12
	Australian state/territory of provider collecting a specimen	N11	..	..
	Australian postcode of provider collecting a specimen	N12	..	..
<i>Group O</i>	<i>Pathology laboratory data items</i>			
	Pathology laboratory identifier	O1	O1	L1
	Pathology laboratory name	O2	O2	..
	Pathology laboratory accession number/identifier	O3	O3	C1
	Pathology laboratory Australian state/territory	O4	..	..
	Pathology laboratory Australian postcode	O5	..	..
<i>Group P</i>	<i>Screening history data items</i>			
	Previously screened flag	P1	P1	..
	Date of last screening test	P2	P2	..
	Last screening test type	P3	P3	..
	Number of days since last screening test	P4	P4	..

3.4 Data items

A1 Participant identifier.....	24
A2 Previous participant identifier.....	25
A3 Medicare card number.....	27
A4 Individual healthcare identifier.....	28
B1 Family name.....	30
B2 Given name.....	31
B3 Other given names.....	32
B4 Date of birth.....	33
B5 Sex.....	34
B6 Gender.....	38
B7 Indigenous status.....	42
B8 Main language other than English spoken at home.....	47
B9 Country of birth.....	50
B10 CALD status.....	52
C1 Defer flag.....	54
C2 Reason to defer screening.....	55
C3 Defer start date.....	56
C4 Defer end date.....	57
C5 Opt out flag.....	58
C6 Reason for opt out.....	59
C7 Opt out date.....	60
C8 Opt in date.....	61
C9 Hysterectomy flag.....	63
C10 Date of hysterectomy.....	64
C11 Death flag.....	65
C12 Date of death.....	66
C13 DES exposed.....	67
C14 Immunocompromised.....	69
D1 HPV vaccination clinical completion status.....	72
D2 HPV vaccination clinical completion date.....	74
D3 HPV vaccine dose date.....	75
D4 HPV vaccine dose age.....	76
D5 HPV vaccine implied dose number.....	77
D6 HPV vaccine type.....	78
E1 Residential address.....	80
E2 Residential suburb/town/locality.....	81

E3 Residential alternative or other names for suburb/town/locality	82
E4 Residential Australian state/territory	83
E5 Residential Australian postcode	84
E6 Residential geocode – latitude	85
E7 Residential geocode – longitude	86
E8 Residential geocode – quality	87
E9 Residential SA1	88
F1 Correspondence type	90
F2 Correspondence date	92
F3 Correspondence method	93
F4 Correspondence failure flag	94
F5 Correspondence failure date	95
F6 Correspondence failure type	96
G1 Type of test	98
H1 HPV test date	100
H2 HPV test collection method	101
H3 HPV test specimen site	102
H4 Reason for HPV test	103
H5 HPV test result – oncogenic HPV	104
H6 HPV test result – secondary oncogenic HPV	106
H7 HPV test type	108
H8 HPV test sample	110
H9 HPV test batch information – Control kit lot number	111
H10 HPV test batch information – Control kit expiry date	112
H11 HPV test batch information – Cellular (LBC) extraction kit lot number	113
H12 HPV test batch information – Cellular (LBC) extraction kit expiry date	114
H13 HPV test batch information – Nucleic acid extraction kit lot number	115
H14 HPV test batch information – Nucleic acid extraction kit expiry date	116
H15 HPV test batch information – Amplification kit lot number	117
H16 HPV test batch information – Amplification kit expiry date	118
H17 HPV test batch information – Detection kit lot number	119
H18 HPV test batch information – Detection kit expiry date	120
H19 HPV test batch information – Wash buffer lot number	121
H20 HPV test batch information – Wash buffer expiry date	122
I1 Cytology test date	124
I2 Cytology test specimen type	125
I3 Cytology test specimen site	126

I4 Reason for cytology test	127
I5 Cytology test squamous cytology cell analysis	128
I6 Cytology test endocervical (glandular) cytology cell analysis	130
I7 Cytology test other/non-cervical cytology cell analysis	132
I8 Cytology test result	134
J1 Primary screening episode commencement date	136
J2 Primary screening episode completion date.....	137
J3 Primary screening episode result	138
J4 Primary screening episode risk of significant cervical abnormality	140
J5 Primary screening episode recommendation	141
J6 Follow-up episode commencement date.....	142
J7 Follow-up episode completion date	143
J8 Follow-up episode result.....	144
J9 Follow-up episode risk of significant cervical abnormality	145
J10 Follow-up episode recommendation.....	147
K1 Date of colposcopy episode	149
K2 Indication for colposcopy	150
K3 Indication for colposcopy – other indication free text.....	151
K4 General colposcopic assessment – adequacy	152
K5 General colposcopic assessment – transformation zone visibility.....	153
K6 Colposcopic impression – primary diagnosis.....	155
K7 Colposcopic impression – other finding free text.....	157
K8 Biopsy this episode	158
K9 Pregnant at time of colposcopy.....	159
K10 Colposcopy data source.....	160
L1 Histology test date	163
L2 Histology test specimen site	164
L3 Procedure used for obtaining specimen for histological analysis	165
L4 Squamous histology cell analysis.....	166
L5 Endocervical (glandular) histology cell analysis	168
L6 Other/non-cervical histology cell analysis	170
L7 Histology test result	171
L8 Histology report text.....	173
L9 Histology stain	174
L10 Histology stain result	175
L11 Histology data source	176
M1 Treatment this episode	178

M2 Treatment date	179
M3 Excision performed this episode	180
M4 Modality/method used for excision	181
M5 Ablation performed this episode	182
M6 Hysterectomy	183
M7 Treatment anaesthetic type	184
M8 Location of service	185
M9 Eligible for test of cure flag	186
M10 Eligible for test of cure date	187
M11 Test of cure completion flag	188
M12 Test of cure completion date	189
N1 Medicare provider number of provider requesting a test	191
N2 Healthcare provider identifier – individual (HPI-I) of provider requesting a test	193
N3 Healthcare provider identifier – organisation (HPI-O) of provider requesting a test	194
N4 Australian state/territory of provider requesting a test	195
N5 Australian postcode of provider requesting a test	196
N6 Medicare provider number of provider collecting a specimen	197
N7 Non-medical provider number of provider collecting a specimen	199
N8 Healthcare provider identifier – individual (HPI-I) of provider collecting a specimen	200
N9 Healthcare provider identifier – organisation (HPI-O) of provider collecting a specimen	201
N10 Type of provider collecting a specimen	202
N11 Australian state/territory of provider collecting a specimen	203
N12 Australian postcode of provider collecting a specimen	204
O1 Pathology laboratory identifier	206
O2 Pathology laboratory name	207
O3 Pathology laboratory accession number/identifier	208
O4 Pathology laboratory Australian state/territory	209
O5 Pathology laboratory Australian postcode	210
P1 Previously screened flag	212
P2 Date of last screening test	213
P3 Last screening test type	215
P4 Number of days since last screening test	216

Group A: Participant identifier data items

- A1 Participant identifier
- A2 Previous participant identifier
- A3 Medicare card number
- A4 Individual healthcare identifier

A1 Participant identifier

Identifying and definitional attributes

<i>Data item name</i>	Participant identifier
<i>Definition</i>	Participant identifier unique within the National Cervical Screening Register.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	String
<i>Format</i>	X[X(19)]
<i>Maximum character length</i>	20

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This data item is used to uniquely identify people who exist on the National Cervical Screening Register and participate in cervical screening.
<i>Collection methods</i>	Assigned by the National Cervical Screening Register.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> A1 Client identifier
-----------------------------------	--

A2 Previous participant identifier

Identifying and definitional attributes

<i>Data item name</i>	Previous participant identifier
<i>Definition</i>	Participant identifier unique within the state or territory cervical screening register from which the record has been migrated to the National Cervical Screening Register.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	String
<i>Format</i>	[X(20)]
<i>Maximum character length</i>	20

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This data item only applies to participants who have been migrated from a state or territory cervical screening register to the National Cervical Screening Register. Therefore, it only applies to 'legacy participants' within the National Cervical Screening Register, and not to new participants within the National Cervical Screening Register.
<i>Collection methods</i>	When the National Cervical Screening Register migrated people from a state or territory cervical screening register, it was important that the participant identifier as it appeared on that register was also migrated. There needed to be the capacity to collect more than one A2 for an individual in the National Cervical Screening Register, as there are people who appeared on more than one state or territory cervical screening register that were migrated to a single A1 Participant identifier in the National Cervical Screening Register, either because a single record was sent by pathology laboratories to more than one state or territory cervical screening register, or because these people resided in more than one state or territory over their screening history. This means that each individual on the National Cervical Screening Register will have zero, one, or many A2 fields, and all these possibilities needed to be able to be captured by the National Cervical Screening Register.

Comments

To prevent a situation whereby participants from different registers have the same identifier, and to avoid losing information about the state or territory from which the participant was migrated, the identifier and state or territory both need to be recorded. To do this, the source state or territory of the record (which is not necessarily the state or territory in which the participant resides) was used as a prefix to the previous participant identifier.

For example, a participant identifier of 123456789 that was migrated from a New South Wales register became NSW123456789.

Relational attributes

Related metadata reference

Supersedes *National Cervical Screening Program data dictionary version 1.0* A2 Previous client identifier

A3 Medicare card number

Identifying and definitional attributes

<i>Data item name</i>	Medicare card number
<i>Definition</i>	A numeric number on a medical card allocated by Medicare Australia for the purpose of identifying those people eligible for specific services.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	Number
<i>Format</i>	{N(10)[N]}
<i>Maximum character length</i>	11

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Format allows the collection of full Medicare number for an individual (that is, family number plus person (individual reference) number), or truncated Medicare number.
<i>Comments</i>	The Medicare card number is printed on a Medicare card and is used to access Medicare records for an eligible person. Up to 9 persons can be included under the one Medicare card number with up to five persons appearing on one physical card. Persons grouped under one Medicare card number are often a family, however, there is no requirement for persons under the same Medicare card number to be related. A person may be shown under separate Medicare card numbers where, for example, a child needs to be included on separate Medicare cards held by their parents. As a person can be identified on more than one Medicare card this is not a unique identifier for a person.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> A3 Medicare card number
------------------------------------	---

A4 Individual healthcare identifier

Identifying and definitional attributes

<i>Data item name</i>	Individual healthcare identifier
<i>Definition</i>	An individual healthcare identifier (IHI) is a unique 16-digit number allocated to each Australian resident and others seeking healthcare in Australia.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	Number
<i>Format</i>	{N(16)}
<i>Maximum character length</i>	16

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	An individual healthcare identifier (IHI) is allocated to all individuals enrolled in the Medicare program or those who are issued with a Department of Veterans' Affairs (DVA) treatment card, and others who seek healthcare in Australia.
<i>Comment</i>	As not all participants will have an IHI or be matched, this does not replace A1 Participant identifier.

Source and reference attributes

<i>Origin</i>	National E-Health Transition Authority (NEHTA)
<i>Reference documents</i>	

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> A4 Individual healthcare identifier
-----------------------------------	---

Group B: Participant data items

B1	Family name
B2	Given name
B3	Other given names
B4	Date of birth
B5	Sex
B6	Gender
B7	Indigenous status
B8	Main language other than English spoken at home
B9	Country of birth
B10	CALD status

B1 Family name

Identifying and definitional attributes

<i>Data item name</i>	Family name
<i>Definition</i>	The text that represents the part of a name a person usually has in common with some other members of their family, as distinguished from their given names
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Text
<i>Data type</i>	String
<i>Format</i>	X[X(39)]
<i>Maximum character length</i>	40

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This should be recorded for all participants. A full history of names should be retained.
<i>Collection methods</i>	Where a person uses multiple names, these should all be recorded to increase data linkage.
<i>Comments</i>	Often people use a variety of names, including legal names, married/maiden names, nicknames, assumed names, traditional names, and so forth. Even small differences in recording – such as the difference between MacIntosh and McIntosh – can make record linkage impossible.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> B1 Family name
------------------------------------	--

B2 Given name

Identifying and definitional attributes

<i>Data item name</i>	Given name
<i>Definition</i>	The person's identifying name within the family group or by which the person is socially identified.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Text
<i>Data type</i>	String
<i>Format</i>	[X(40)]
<i>Maximum character length</i>	40

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This should be recorded for all participants. A full history of names should be retained.
<i>Collection methods</i>	Where a person uses multiple names, these should all be recorded to increase data linkage.
<i>Comments</i>	Often people use a variety of names, including legal names, married/maiden names, nicknames, assumed names, traditional names, and so forth. Even small differences in recording – such as the difference between MacIntosh and McIntosh – can make record linkage impossible.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> B2 Given name
------------------------------------	---

B3 Other given names

Identifying and definitional attributes

<i>Data item name</i>	Other given names
<i>Definition</i>	The person's other identifying name(s) within the family group or by which the person is socially identified.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Text
<i>Data type</i>	String
<i>Format</i>	[X(40)]
<i>Maximum character length</i>	40

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This should be recorded for all participants. A full history of names should be retained.
<i>Collection methods</i>	Where a person uses multiple names, these should all be recorded to increase data linkage.
<i>Comments</i>	Often people use a variety of names, including legal names, married/maiden names, nicknames, assumed names, traditional names, and so forth. Even small differences in recording – such as the difference between MacIntosh and McIntosh – can make record linkage impossible.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> B3 Other given names
------------------------------------	--

B4 Date of birth

Identifying and definitional attributes

<i>Data item name</i>	Date of birth
<i>Definition</i>	The date on which a person was born.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	If date of birth is not known or cannot be obtained, provision should be made to collect or estimate age. If only the year and month is known, date of birth should be set to 01MMYYYY; if only the year is known, date of birth should be set to 0107YYYY.
<i>Collection methods</i>	Date of birth should be in the preferred representational layout DDMMYYYY.
<i>Comments</i>	If there is more than one date of birth, all should be recorded.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> B4 Date of birth
------------------------------------	--

B5 Sex

Identifying and definitional attributes

<i>Data item name</i>	Sex
<i>Definition</i>	The biological sex characteristics of a person.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code								
<i>Data type</i>	Number								
<i>Format</i>	N								
<i>Maximum character length</i>	1								
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>1</td><td>Male</td></tr><tr><td>2</td><td>Female</td></tr><tr><td>3</td><td>Another term</td></tr></table>	Value	Meaning	1	Male	2	Female	3	Another term
Value	Meaning								
1	Male								
2	Female								
3	Another term								
<i>Supplementary values</i>	9 Not stated/Inadequately described								

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	'A person's sex is based upon their sex characteristics, such as their chromosomes, hormones and reproductive organs. While typically based upon the sex characteristics observed and recorded at birth or infancy, a person's sex can change over the course of their lifetime and may differ from their sex recorded at birth' (ABS 2021.) 'Sex refers to the chromosomal, gonadal and anatomical characteristics associated with biological sex. Individuals may have a range of circumstances or undergo a variety of treatments that make it difficult to define a true biological sex' (AG 2015.) The terms sex and gender are interrelated and often used interchangeably; however, they are two distinct concepts: • Sex is understood in relation to sex characteristics. Sex recorded at birth refers to what was determined by sex characteristics observed at birth or infancy • Gender is about social and cultural differences in identity, expression, and experience. While they are two related concepts, caution should be exercised when comparing counts for sex with those for gender. The Australian Government Guidelines on the Recognition of Sex and Gender (AG 2015) recommends the preferred Australian Government approach of collecting and using gender information, with sex only being collected where there is a legitimate need to know the biological characteristics of the target population.
----------------------	--

For statistical purposes, the following category codes, labels, and definitions are preferred:

CODE 1 Male

Individuals who have male or predominantly masculine biological characteristics, had male sex assigned at birth, or report their sex as male.

CODE 2 Female

Individuals who have female or predominantly feminine biological characteristics, had female sex assigned at birth, or report their sex as female.

CODE 3 Another term

Individuals who have mixed or non-binary biological characteristics (if known), had a non-binary sex assigned at birth, or report their sex using another term.

The value meaning of 'Another term' has been assigned to Code 3 for this value domain, which replaces 'Other' and 'Intersex or indeterminate' in previous versions of this element.

Terms such as 'indeterminate', 'intersex', 'non-binary', and 'unspecified', etc., are variously used to describe the 'Another term' category of sex. The label 'Another term' is used because a more descriptive term has not been widely agreed within the general community. Additionally, a small number of people do not have a sex of male or female recorded at birth or infancy. The inclusion of 'Another term' as a third response option recognises that across Australian jurisdictions and elsewhere there are a range of options available on birth certificates (such as indeterminate or unspecified).

CODE 9 Not stated/inadequately described

This supplementary value is used to code inadequately described responses and non-responses for sex. It is not to be used on primary collection forms. It is primarily for use in administrative collections when transferring data from data sets where the item has not been collected.

Collection methods

The Australian Bureau of Statistics (ABS) Standard for sex, gender, variations of sex characteristics and sexual orientation variables (ABS 2021) recommends that where data on sex is collected, the preferred question should relate to sex recorded at birth. Sex recorded at birth refers to what was determined by sex characteristics observed at birth or infancy. This is an important indicator for statistical analysis in births and deaths, health statistics, calculating fertility rates and deriving counts for cis and trans populations.

A data collection may instead collect data on a person's sex at the time of collection, rather than their sex recorded at birth. However, there are advantages of sex recorded at birth as the sex question and further data that can be derived when using sex recorded at birth as the sex question.

Caution should be exercised when comparing counts for sex of a person recorded at birth and the sex of a person at the time of data collection, as a person's sex may change over the course of their lifetime. Also, as the terms sex and gender are often used interchangeably, a respondent might provide a gender response to a sex question.

Data collections using this data element should strive for transparency as to whether the element collects data on sex at time of birth, or sex at time of data collection. It is recommended to record this information in the Data Set Specific Information.

Standard questions

Sex at birth

The ABS recommends the following standard question structure:

What was [your/Person's name/their] sex recorded at birth? Please [tick/mark/select] one box.

☐ Male

☐ Female

☐ Another term (please specify)

Mandatory elements

The following elements must be included:

- The words 'sex recorded at birth' in the question to clearly articulate the concept being collected
- Label the response options 'Male', 'Female', and 'Another term (please specify)'
- A write-in facility is available when the 'Another term (please specify)' response option is selected
- Only one response is permitted
- If this question is interviewer administered, the question must always be asked as written and no assumptions made by the interviewer.

Recommended elements

The following elements are recommended:

- Use inclusive language (for example 'they' or 'their' rather than 'he/she' or 'his/her')
- If both sex and gender questions are included, ask the sex question first and note that a separate question on gender is also asked in the survey
- If both sex and gender questions are included, ask both on the same page of the instrument if practical.

Sex at time of data collection

The ABS recommends the following standard question structure:

What is [your/Person's name/their] sex? Please [tick/mark/select] one box.

☐ Male

☐ Female

[] Another term (please specify)

Mandatory elements

The following elements must be included:

- The word 'sex' in the question to clearly articulate the concept being collected
- Label the response options 'Male', 'Female', and 'Another term (please specify)'
- A write-in facility is available when the 'Another term (please specify)' response option is selected
- Only one response is permitted
- If this question is interviewer administered, the question must always be asked as written and no assumptions made by the interviewer.

Recommended elements

The following elements are recommended for inclusion:

- Use inclusive language (for example 'they' or 'their' rather than 'he/she' or 'his/her')
- If both sex and gender questions are included, ask the sex question first and note that a separate question on gender is also asked in the survey
- If both sex and gender questions are included, ask both on the same page of the instrument if practical.

The Australian Government Guidelines on the Recognition of Sex and Gender recommend 'departments and agencies should refrain from making assumptions about a person's sex and/or gender identity based on indicators such as their name, voice or appearance' (AG 2015.)

The inclusion of the write-in facility for 'Another term' as a third response option recognises that there are a range of terms used to describe sex which is neither male nor female, and enhances data quality.

Source and reference attributes

Origin

Adapted from METeOR candidate Data Element 741686 July 2021.

Reference documents

Australian Bureau of Statistics 2021. Standard for sex, gender, variations of sex characteristics and sexual orientation variables. Canberra: ABS

<https://www.abs.gov.au/statistics/standards/standard-sex-gender-variations-sex-characteristics-and-sexual-orientation-variables/latest-release>

Australian Bureau of Statistics 2016. Standard for Sex and Gender Variables (Cat. no. 1200.0.55.012).

Attorney-General's Department 2015. Australian Government Guidelines on the Recognition of Sex and Gender.

Relational attributes

Related metadata reference

Supersedes *National Cervical Screening Program data dictionary version 1.0 B5 Sex*

B6 Gender

Identifying and definitional attributes

<i>Data item name</i>	Gender
<i>Definition</i>	The way a person describes their social and cultural identity, expression and experience as man, or boy, or woman, or girl, or non-binary.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code														
<i>Data type</i>	Number														
<i>Format</i>	N														
<i>Maximum character length</i>	1														
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>1</td><td>Man, or boy, or male</td></tr><tr><td>2</td><td>Woman, or girl, or female</td></tr><tr><td>3</td><td>Non-binary</td></tr><tr><td>4</td><td>Different term</td></tr><tr><td>5</td><td>Prefer not to answer</td></tr><tr><td>9</td><td>Not stated/Inadequately described</td></tr></table>	Value	Meaning	1	Man, or boy, or male	2	Woman, or girl, or female	3	Non-binary	4	Different term	5	Prefer not to answer	9	Not stated/Inadequately described
Value	Meaning														
1	Man, or boy, or male														
2	Woman, or girl, or female														
3	Non-binary														
4	Different term														
5	Prefer not to answer														
9	Not stated/Inadequately described														
<i>Supplementary values</i>	9 Not stated/Inadequately described														

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Gender is a social and cultural concept. It is about social and cultural differences in identity, expression and experience as a man, woman, or non-binary person. Non-binary is an umbrella term describing gender identities that are not exclusively male or female. Gender includes the following concepts: • Gender identity is about who a person feels themselves to be • Gender expression is the way a person expresses their gender. A person's gender expression may also vary depending on the context, for instance expressing different genders at work and home • Gender experience describes a person's alignment with the sex recorded for them at birth, that is, a cis experience or a trans experience' (ABS 2021). Gender is part of a person's personal and social identity. It refers to the way a person feels, presents, and is recognised within the community. A person's gender may be reflected in outward social markers, including their name, outward appearance, mannerisms and dress' (AGD 2015). The terms sex and gender are interrelated and often used interchangeably; however, they are two distinct concepts:
----------------------	---

- Sex is understood in relation to sex characteristics. Sex recorded at birth refers to what was determined by sex characteristics observed at birth or infancy
- Gender is about social and cultural differences in identity, expression, and experience.

While they are two related concepts, caution should be exercised when comparing counts for sex with those for gender.

The Australian Government Guidelines on the Recognition of Sex and Gender (AG 2015) recommends the preferred Australian Government approach of collecting and using gender information, with sex only being collected where there is a legitimate need to know the biological characteristics of the target population.

This Value Domain is based on the Australian Bureau of Statistics Standard for sex, gender, variations of sex characteristics and sexual orientation variables (ABS 2021). The values are defined as follows:

CODE 1 Man, or boy, or male

Persons who describe their gender as man, or boy, or male.

CODE 2 Woman, or girl, or female

Persons who describe their gender as woman, or girl, or female.

CODE 3 Non-binary

Persons who describe their gender as non-binary.

CODE 4 Different term

Persons who describe their gender as a term other than man/boy/male, woman/girl/female or non-binary.

CODE 5 Prefer not to answer

Persons who prefer not to respond on how they describe their gender.

CODE 9 Not stated or inadequately described.

This supplementary value is used to code inadequately described responses and non-responses for gender. It is not to be used on primary collection forms. It is primarily for use in administrative collections when transferring data from data sets where the item has not been collected.

The ABS Standard also allows for the following Alternative Code system:

CODE M Man, or boy, or male

CODE F Woman, or girl, or female

CODE X Non-binary

CODE T Different term

CODE Z Prefer not to answer

The ABS Standard allows for the following output categories for gender:

Man, or boy

Includes CODE 1 (M)

Woman, or girl

Includes CODE 2 (F)

Non-binary

Includes CODES 3 (X) and 4 (T)

Not stated

Includes CODES 5 (Z) and 9.

Collection methods

Standard Question Module

The Australian Bureau of Statistics Standard for sex, gender, variations of sex characteristics and sexual orientation variables (ABS 2021) recommends the following standard question module:

How [do/does] [you/Person's name/they] describe [your/their] gender?

Gender refers to current gender, which may be different to sex recorded at birth and may be different to what is indicated on legal documents.

Please [tick/mark/select] one box:

☐ Man, or boy, or male

☐ Woman, or girl, or female

☐ Non-binary

☐ [I/They] use a different term (please specify)

☐ Prefer not to answer

Mandatory elements

The following elements must be included:

- The word 'gender' in the question to clearly articulate the concept being collected
- Label the response options 'Man, or boy, or male', 'Woman, or girl, or female', 'Non-binary', '[I/they] use a different term (please specify)', and 'Prefer not to answer'
- A write-in facility is available when the '[I/they] use a different term (please specify)' response option is selected
- Including a note to respondents that 'Gender refers to current gender, which may be different to sex recorded at birth and may be different to what is indicated on legal documents'
- Only one response is permitted

- If this question is interviewer administered, the question must always be asked as written and no assumptions made by the interviewer.

Recommended elements

The following elements are recommended for inclusion:

- Use inclusive language (for example 'they' or 'their' rather than 'he/she' or 'his/her')
- If both sex and gender questions are included, ask the sex question first and note that a separate question on gender is asked in the survey
- If both sex and gender questions are included, ask both on the same page of the instrument if practical.

The Australian Government Guidelines on the Recognition of Sex and Gender recommend 'departments and agencies should refrain from making assumptions about a person's sex and/or gender identity based on indicators such as their name, voice or appearance' (AG 2015).

Comments

Former versions of this Value Domain contained only three permissible values:

CODE 1 Male

CODE 2 Female

CODE 3 Other (formerly 'Gender other/diverse').

Source and reference attributes

Origin

Adapted from METeOR candidate Data Element 741842 July 2021.

Reference documents

Australian Bureau of Statistics 2021. Standard for sex, gender, variations of sex characteristics and sexual orientation variables. Canberra: ABS

<https://www.abs.gov.au/statistics/standards/standard-sex-gender-variations-sex-characteristics-and-sexual-orientation-variables/latest-release>

Australian Bureau of Statistics 2016. Standard for Sex and Gender Variables (Cat. no. 1200.0.55.012).

Attorney-General's Department 2015. Australian Government Guidelines on the Recognition of Sex and Gender.

Relational attributes

Related metadata reference

New data item

B7 Indigenous status

Identifying and definitional attributes

<i>Data item name</i>	Indigenous status
<i>Definition</i>	Whether a person identifies as being of Aboriginal and/or Torres Strait Islander descent.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code												
<i>Data type</i>	Number												
<i>Format</i>	N												
<i>Maximum character length</i>	1												
<i>Permissible values</i>	<table><thead><tr><th>Value</th><th>Meaning</th></tr></thead><tbody><tr><td>1</td><td>Aboriginal but not Torres Strait Islander origin</td></tr><tr><td>2</td><td>Torres Strait Islander but not Aboriginal origin</td></tr><tr><td>3</td><td>Both Aboriginal and Torres Strait Islander origin</td></tr><tr><td>4</td><td>Neither Aboriginal nor Torres Strait Islander origin</td></tr><tr><td>9</td><td>Not stated/inadequately described</td></tr></tbody></table>	Value	Meaning	1	Aboriginal but not Torres Strait Islander origin	2	Torres Strait Islander but not Aboriginal origin	3	Both Aboriginal and Torres Strait Islander origin	4	Neither Aboriginal nor Torres Strait Islander origin	9	Not stated/inadequately described
Value	Meaning												
1	Aboriginal but not Torres Strait Islander origin												
2	Torres Strait Islander but not Aboriginal origin												
3	Both Aboriginal and Torres Strait Islander origin												
4	Neither Aboriginal nor Torres Strait Islander origin												
9	Not stated/inadequately described												
<i>Supplementary values</i>													

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The classification for Indigenous status has a hierarchical structure comprising two levels. There are four categories at the detailed level of the classification which are grouped into two categories at the broad level. There is one supplementary category for 'Not stated/inadequately described' responses. The classification is as follows: Indigenous Australians: • Aboriginal but not Torres Strait Islander origin. • Torres Strait Islander but not Aboriginal origin. • Both Aboriginal and Torres Strait Islander origin. Non-Indigenous Australians: • Neither Aboriginal nor Torres Strait Islander origin. Not stated/inadequately described: This category is not to be available as a valid answer to the questions but is intended for use: • Primarily when importing data from other data collections that do not contain mappable data. • Where the answer cannot be determined without clarification from the respondent (for example, 'No' and 'Yes, Aboriginal' are both selected). • Where an answer was declined.
----------------------	--

- Where the question was not able to be asked because the participant was unable to communicate or a person who knows the participant was not available.

The Indigenous status question allows for more than one response. The procedure for coding multiple responses is as follows:

- If the respondent answers 'Yes, Aboriginal' and 'Yes, Torres Strait Islander', then their response should be coded to 'Yes, both Aboriginal and Torres Strait Islander origin'.
- If the respondent answers 'No' and one or more of the following:
 - 'Yes, Aboriginal'
 - 'Yes, Torres Strait Islander'
 - 'Yes, both Aboriginal and Torres Strait Islander'

then the response should be coded to 'Not stated/inadequately described' if the response cannot be clarified with the respondent.

The following information provides advice on the recommended way to ask the Indigenous status question.

Self-enumerated collections

For self-enumerated collections (for example, self-completed questionnaires or forms), the following question is recommended:

Q1. [Are you] [Is the person] [Is (name)] of Aboriginal or Torres Strait Islander origin?

- No
- Yes, Aboriginal
- Yes, Torres Strait Islander

If [you] [the person] [(name)] are of both Aboriginal and Torres Strait Islander origin, answer using both 'Yes' options.

This approach may be problematic in some data collections, for example when data are collected using screen based data capture systems. An additional response category of 'Yes, both Aboriginal and Torres Strait Islander' may be included if this better suits the data collection practices of the agency or establishment concerned.

If the Indigenous status question has not been completed on a returned form, this should be followed up and confirmed with the person.

Interviewer-conducted collections

For interviewer-conducted collections in which the Indigenous status of one person is collected, the following question set is recommended:

Q1. Are you of Aboriginal or Torres Strait Islander origin?

- Yes
- No (no more questions)

Q2. Are you of Aboriginal origin, Torres Strait Islander origin, or both?

- Aboriginal
- Torres Strait Islander
- Both Aboriginal and Torres Strait Islander

Collection methods

The first question is used to sequence out non-Indigenous Australians. The second question is used to determine the specific Aboriginal and/or Torres Strait Islander origin of the person. A benefit of this approach is that the interviewer is not required to prompt the respondent with response categories. The 'Both Aboriginal and Torres Strait Islander' response category can be included or excluded in interviewer conducted collections depending on which option best suits the data collection practices of the agency concerned. Including the additional response category ensures that respondents are aware of the option to identify as being of both Aboriginal and Torres Strait Islander origin.

Various articulations of the standard question are recommended to address the following circumstances:

Person is present and answers

This question wording is recommended where it is known that the person being interviewed is the subject:

Q1. Are you of Aboriginal or Torres Strait Islander origin?

Q2. Are you of Aboriginal origin, Torres Strait Islander origin, or both?

Person is not present and someone else who knows the person well answers

The following question wording is recommended when another member of the household answers for the person. Examples of such incidents include: parents answering for children, or relatives answering in hospital situations.

Q1. Is [the person] [(name)] of Aboriginal or Torres Strait Islander origin?

Q2. Is [the person] [(name)] of Aboriginal origin, Torres Strait Islander origin, or both?

Person is deceased and someone else answers on their behalf (for example, death information form)

In these circumstances a close relative or friend should answer. Only if a relative or friend is unavailable should the undertaker or other such person answer. The suggested question wording follows:

Q1. Was [the person] [(name)] of Aboriginal or Torres Strait Islander origin?

Q2. Was [the person] [(name)] of Aboriginal origin, Torres Strait Islander origin, or both?

Person is an infant and parents answer (for example perinatal information form)

In this circumstance it is recommended that parents are asked:

Q1. Is [the baby's] [(name)'s] mother of Aboriginal or Torres Strait Islander origin?

Q2. Is [the baby's] [(name)'s] mother of Aboriginal origin, Torres Strait Islander origin, or both?

and

Q1. Is [the baby's] [(name)'s] father of Aboriginal or Torres Strait Islander origin?

Q2. Is [the baby's] [(name)'s] father of Aboriginal origin, Torres Strait Islander origin, or both?

For interview conducted collections in which the Indigenous Status of more than one person is collected from a household representative, the following question set is recommended:

Q1. Is anyone who (usually lives here) (or) (is visiting here) of Aboriginal or Torres Strait Islander origin?

- Yes
- No

Q2. Who are they?

Question 3 is asked of each person identified as being of Aboriginal or Torres Strait Islander origin.

Q3. [Are you] [Is (name)] of Aboriginal origin, Torres Strait Islander origin, or both?

- Aboriginal
- Torres Strait Islander
- Both Aboriginal and Torres Strait Islander

The first question is used to sequence out households in which no Aboriginal and/or Torres Strait Islander people usually live (or are visiting). The second question is used to identify those usual residents (and visitors) of Aboriginal or Torres Strait Islander origin. This approach eliminates the need to repeatedly ask the Indigenous status question of each individual in a household when data are collected on a single household form. It is particularly advantageous when collecting from areas with a large proportion of households with non-Indigenous Australians.

For both self-enumerated collections and interviewer-conducted collections

The Indigenous status question can be used in circumstances where a close relative, friend, or another member of the household is answering on behalf of the subject. It is strongly recommended that the question be asked directly wherever possible.

When the subject person is not present, the person answering for them should be in a position to do so, that is, this person must know the person about whom the question is being asked well and feel confident to provide accurate information about them.

The Indigenous status question must always be asked regardless of data collectors' perceptions based on appearance or other factors.

The Indigenous status question may only be left unanswered in the following circumstances:

- Where the person declined to answer
- Where the question was not able to be asked because the participant was unable to communicate or a person who knows the participant was not available.

Comments

The following definition, commonly known as 'The Commonwealth Definition', was given in a High Court judgement in the case of *Commonwealth v Tasmania* (1983) 46 ALR 625.

'An Aboriginal or Torres Strait Islander is a person of Aboriginal or Torres Strait Islander descent who identifies as an Aboriginal or Torres Strait Islander and is accepted as such by the community in which he or she lives'.

There are three components to the Commonwealth definition:

- descent;
- self-identification; and
- community acceptance.

In practice, it is not feasible to collect information on the community acceptance part of this definition in general purpose statistical and administrative collections and therefore standard questions on Indigenous status relate to descent and self-identification only.

Source and reference attributes

Origin

Adapted from METeOR Data Element 602543.

Reference documents

Australian Bureau of Statistics 2014. Indigenous Status Standard Version 1.5, Canberra. (Cat. no. 1200.0.55.008).

Australian Institute of Health and Welfare 2010. National best practice guidelines for collecting Indigenous status in health data sets. Cat. no. AIHW 29. Canberra: AIHW.

Relational attributes

Related metadata references

Supersedes *National Cervical Screening Program data dictionary version 1.0* B6 Indigenous status

B8 Main language other than English spoken at home

Identifying and definitional attributes

<i>Data item name</i>	Main language other than English spoken at home
<i>Definition</i>	The language reported by a person as the main language other than English spoken by that person in their home (or most recent private residential setting occupied by the person) to communicate with other residents of the home or setting and regular visitors.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code
<i>Data type</i>	Number
<i>Format</i>	{N{NNN}}
<i>Maximum character length</i>	4

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The Australian Standard Classification of Languages (ASCL) has a three-level hierarchical structure. The most detailed level of the classification consists of languages which are represented by four-digit codes. The second level of the classification comprises narrow groups of languages (the Narrow group level), identified by two-digit and three-digit codes. The most general level of the classification consists of broad groups of languages (the Broad group level) and is identified by one-digit codes. The classification includes Australian Indigenous languages and sign languages. For example, the Lithuanian language has a code of 3102. In this case 3 denotes that it is an Eastern European language, while 31 denotes that it is a Baltic language. The Pintupi Aboriginal language is coded as 8713. In this case 8 denotes that it is an Australian Indigenous language and 87 denotes that the language is a Western Desert language. Language data may be output at the Broad group level, Narrow group level or the language level of the classification. Also, significant languages within a Narrow group can be presented separately with the remaining languages of the Narrow group aggregated. The same principle can be adopted to highlight significant Narrow groups within a Broad group
<i>Collection methods</i>	Where extensive data on main language other than English spoken at home is needed, one of the two questions below may be used: Alternative 1 <i>Do you/Does the person/Does (name)/ Will (name of child under two years) speak a language other than English at home? (If more than one language, indicate the language that is spoken most often.)</i>

No, (English only) ☐

Yes, Mandarin ☐

Yes, Italian ☐

Yes, Arabic ☐

Yes, Cantonese ☐

Yes, Greek ☐

Yes, Vietnamese ☐

Yes, Spanish ☐

Yes, Hindi ☐

Yes, Tagalog ☐

Yes, Other (please specify) _____

The above list includes languages based on their statistical frequency in Australia, based on data from the Census of Population and Housing.

Alternative 2

Do you/Does the person/Does (name)/ Will (name of child under two years) speak a language other than English at home?

No, English only ☐

Yes, Other - please specify _____

Where there is no requirement for detailed language data, the following question may be suitable:

Do you/Does the person/Does (name)/ Will (name of child under two years) speak a language other than English at home?

No, English only ☐

Yes, Other ☐

Comments

This data element is important in identifying those people most likely to suffer disadvantage in terms of their ability to access services due to language and/or cultural difficulties. In conjunction with Indigenous status, Proficiency in spoken English and Country of birth this data element forms the minimum core set of cultural and language indicators recommended by the ABS.

Data on main language other than English spoken at home are regarded as an indicator of 'active' ethnicity and also as useful for the study of inter-generational language retention. The availability of such data may help providers of health and community services to effectively target the geographic areas or population groups that need those services. It may be used for the investigation and development of language services such as interpreter/ translation services.

Source and reference attributes

Origin

Adapted from METeOR Data Element 659402.

Reference documents

Australian Bureau of Statistics 2016a. Australian Standard Classification of Languages (ASCL) 2016. ABS cat. no.1267.0. Canberra: ABS.

Australian Bureau of Statistics 2016b. Language Standards 2016. ABS cat. no.1200.0.55.005. Canberra: ABS.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> B8 Main language other than English spoken at home
-----------------------------------	--

B9 Country of birth

Identifying and definitional attributes

<i>Data item name</i>	Country of birth
<i>Definition</i>	The country in which the person was born.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code
<i>Data type</i>	Number
<i>Format</i>	{NNNN}
<i>Maximum character length</i>	4

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The Standard Australian Classification of Countries 2016 is a four-digit, three-level hierarchical structure specifying major group, minor group, and country. A country, even if it comprises other discrete political entities such as states, is treated as a single unit for all data domain purposes. Parts of a political entity are not included in different groups. Thus, Hawaii is included in Northern America (as part of the identified country United States of America), despite being geographically close to and having similar social and cultural characteristics as the units classified to Polynesia.
----------------------	--

<i>Collection methods</i>	Some data collections ask respondents to specify their country of birth. In others, a pre-determined set of countries is specified as part of the question, usually accompanied by an 'other (please specify)' category.
---------------------------	---

Recommended questions are:

In which country were you/was the person/was (name) born?

Australia

Other (please specify) ...

or

In which country were you/was the person/was (name) born?

Australia

England

New Zealand

India

Italy

Vietnam

Philippines

South Africa

Scotland

Malaysia

Other (please specify) ...

The option list for this question includes countries according to their statistical frequency in Australia, according to data from the Census of Population and Housing. Exceptions are made for countries such as 'United Kingdom' and 'China', as they are likely to reduce the level of detail that is possible to be coded to the Standard Australian Classification of Countries.

Source and reference attributes

Origin

Adapted from METeOR Data Element 659454.

Relational attributes

Related metadata reference

Supersedes *National Cervical Screening Program data dictionary version 1.0* B7 Country of birth

B10 CALD status

Identifying and definitional attributes

<i>Data item name</i>	CALD status
<i>Definition</i>	An overall indication of CALD status.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code								
<i>Data type</i>	Number								
<i>Format</i>	N								
<i>Maximum character length</i>	1								
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>1</td><td>CALD</td></tr><tr><td>2</td><td>Not CALD</td></tr><tr><td>9</td><td>Not stated/inadequately described</td></tr></table>	Value	Meaning	1	CALD	2	Not CALD	9	Not stated/inadequately described
Value	Meaning								
1	CALD								
2	Not CALD								
9	Not stated/inadequately described								

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	CALD status is derived from the two data items B8 'Main language other than English spoken at home' and B9 'Country of birth'. CALD is defined as: • people born in Australia whose main language other than English spoken at home is not English (excluding Aboriginal languages). • people born overseas in countries where English is not the main language spoken (that is, people whose country of birth is not Australia and its external territories, New Zealand, the United Kingdom, Ireland, the United States of America, Canada, or South Africa. This selection of countries is based on the main countries from which Australia receives overseas settlers who are likely to speak English); or
<i>Collection methods</i>	CALD status is derived from the two data items B8 'Main language other than English spoken at home' and B9 'Country of birth'.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> B9 CALD status
-----------------------------------	--

Group C: Participant status data items

C1	Defer flag
C2	Reason to defer screening
C3	Defer start date
C4	Defer end date
C5	Opt out flag
C6	Reason for opt out
C7	Opt out date
C8	Opt in date
C9	Hysterectomy flag
C10	Date of hysterectomy
C11	Death flag
C12	Date of death
C13	DES exposed
C14	Immunocompromised

C1 Defer flag

Identifying and definitional attributes

<i>Data item name</i>	Defer flag
<i>Definition</i>	An indication as to whether a person has requested that their participation in cervical screening be deferred
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code				
<i>Data type</i>	Number				
<i>Format</i>	[N]				
<i>Maximum character length</i>	1				
<i>Permissible values</i>	<table><thead><tr><th>Value</th><th>Meaning</th></tr></thead><tbody><tr><td>1</td><td>Defer screening</td></tr></tbody></table>	Value	Meaning	1	Defer screening
Value	Meaning				
1	Defer screening				

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Defer flag should be raised at such time as it is known that a person has requested that their participation in cervical screening be deferred This flag is used to determine if a participant has deferred screening as at the current date.
<i>Rules for use</i>	If C3 Defer start date is not NULL and current date < C4 Defer end date, then C1 Defer flag should = 1.
<i>Collection methods</i>	This is a derived data item.

Relational attributes

<i>Related metadata reference</i>	New data item
-----------------------------------	---------------

C2 Reason to defer screening

Identifying and definitional attributes

<i>Data item name</i>	Reason to defer screening
<i>Definition</i>	The reason that a person provides to the National Cancer Screening Register as to why they requested that their participation in cervical screening be deferred
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code								
<i>Data type</i>	Number								
<i>Format</i>	[N]								
<i>Maximum character length</i>	1								
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>1</td><td>Medical advice to defer</td></tr><tr><td>2</td><td>Living or travelling overseas</td></tr><tr><td>3</td><td>Other</td></tr></table>	Value	Meaning	1	Medical advice to defer	2	Living or travelling overseas	3	Other
Value	Meaning								
1	Medical advice to defer								
2	Living or travelling overseas								
3	Other								

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The National Cancer Screening Register allows participants to defer future screening date and reminders in the National Cancer Screening Register for the National Cervical Screening Program. Three main reasons are provided as options for deferring cervical screening reminders. These are: ‘Medical advice to defer’; ‘Living or travelling overseas’; and ‘Other (please specify)’. As a participant may defer more than once, reason to defer screening needs to be able to be collected multiple times, with each linked to the defer start date.
----------------------	--

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> C2 Reason for temporary inactivation.
-----------------------------------	---

C3 Defer start date

Identifying and definitional attributes

<i>Data item name</i>	Defer start date
<i>Definition</i>	The date from which a person has requested that their participation in cervical screening be deferred.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	{DDMMYYYY}
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The collection of data for this data item is conditional on a person requesting that their participation in cervical screening be deferred. The National Cancer Screening Register allows participants to defer future screening date and reminders in the National Cancer Screening Register for the National Cervical Screening Program. As a participant may defer more than once, defer start date needs to be able to be collected multiple times. While it is preferable that this be an accurate date, part of the date may need to be estimated. If this date needs to be estimated, the following guide should be used; if only the year and month is known, date should be set to 01MMYYYY; if only the year is known, date should be set to 0107YYYY.
<i>Collection methods</i>	This data item should always be recorded as an 8-digit valid date comprising day, month, and year. Year should always be recorded in its full 4-digit format. For days and months with a numeric value of less than 10, zeros should be used to ensure that the date contains the required 8 digits. For example, a date of 1 July 2015 should be recorded as 01072015 as specified in the representational layout.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> C3 Date of temporary inactivation.
-----------------------------------	--

C4 Defer end date

Identifying and definitional attributes

<i>Data item name</i>	Defer end date
<i>Definition</i>	The date from which a person requests their participation in cervical screening no longer be deferred
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	{DDMMYYYY}
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The collection of data for this data item is conditional on a person requesting that their participation in cervical screening be deferred. The National Cancer Screening Register allows participants to defer future screening date and reminders in the National Cancer Screening Register for the National Cervical Screening Program. As a participant may defer more than once, defer end date needs to be able to be collected multiple times. While it is preferable that this be an accurate date, part of the date may need to be estimated. If this date needs to be estimated, the following guide should be used; if only the year and month is known, date should be set to 01MMYYYY; if only the year is known, date should be set to 0107YYYY.
<i>Collection methods</i>	This data item should always be recorded as an 8-digit valid date comprising day, month, and year. Year should always be recorded in its full 4-digit format. For days and months with a numeric value of less than 10, zeros should be used to ensure that the date contains the required 8 digits. For example, a date of 1 July 2015 should be recorded as 01072015 as specified in the representational layout.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> C4 Date of reactivation.
-----------------------------------	--

C5 Opt out flag

Identifying and definitional attributes

<i>Data item name</i>	Opt out flag
<i>Definition</i>	An indication as to whether a person has opted out of all participation in the National Cancer Screening Register for the National Cervical Screening Program
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code				
<i>Data type</i>	Number				
<i>Format</i>	[N]				
<i>Maximum character length</i>	1				
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>1</td><td>Opt out</td></tr></table>	Value	Meaning	1	Opt out
Value	Meaning				
1	Opt out				

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The National Cancer Screening Register allows participants to opt out of all participation in the National Cancer Screening Register for the National Cervical Screening Program. This means that: • The person will not be contacted or receive any future correspondence from the National Cancer Screening Register for the National Cervical Screening Program. • No further cervical screening information about the person will be recorded on the National Cancer Screening Register. Opt out flag should be raised at such time as it is known that a person has requested to opt out of all participation in the National Cancer Screening Register for the National Cervical Screening Program. This flag is used to determine if a participant has opted out as at the current date.
<i>Rules for use</i>	If C7 Opt out date is not NULL and current date < C8 Opt in date, then C5 Opt out flag should = 1.
<i>Collection methods</i>	This is a derived data item.

Relational attributes

<i>Related metadata reference</i>	New data item
-----------------------------------	---------------

C6 Reason for opt out

Identifying and definitional attributes

<i>Data item name</i>	Reason for opt out
<i>Definition</i>	The reason that a person provides to the National Cancer Screening Register for opting out of all participation in the National Cancer Screening Register for the National Cervical Screening Program
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code								
<i>Data type</i>	Number								
<i>Format</i>	[N]								
<i>Maximum character length</i>	1								
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>1</td><td>Not interested</td></tr><tr><td>2</td><td>Privacy concerns</td></tr><tr><td>3</td><td>Other</td></tr></table>	Value	Meaning	1	Not interested	2	Privacy concerns	3	Other
Value	Meaning								
1	Not interested								
2	Privacy concerns								
3	Other								

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The National Cancer Screening Register allows participants to opt out of all participation in the National Cancer Screening Register for the National Cervical Screening Program. This means that: • The person will not be contacted or receive any future correspondence from the National Cancer Screening Register for the National Cervical Screening Program. • No further cervical screening information about the person will be recorded on the National Cancer Screening Register. Three main reasons are provided as options for opting out. These are: ‘Not interested’; ‘Privacy concerns’; and ‘Other (please specify)’. As a participant may opt out more than once, reason for opt out needs to be able to be collected multiple times, with each linked to the opt out date.
----------------------	--

Relational attributes

<i>Related metadata reference</i>	New data item.
-----------------------------------	----------------

C7 Opt out date

Identifying and definitional attributes

<i>Data item name</i>	Opt out date
<i>Definition</i>	The date on which a person opts out of all participation in the National Cancer Screening Register for the National Cervical Screening Program
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	{DDMMYYYY}
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The National Cancer Screening Register allows participants to opt out of all participation in the National Cancer Screening Register for the National Cervical Screening Program. This means that: • The person will not be contacted or receive any future correspondence from the National Cancer Screening Register for the National Cervical Screening Program. • No further cervical screening information about the person will be recorded on the National Cancer Screening Register. As a participant may opt out more than once, opt out date needs to be able to be collected multiple times. While it is preferable that this be an accurate date the participant opts out of the National Cancer Screening Register, part of the date may need to be estimated. If this date needs to be estimated, the following guide should be used; if only the year and month is known, date should be set to 01MMYYYY; if only the year is known, date should be set to 0107YYYY.
<i>Collection methods</i>	This data item should always be recorded as an 8-digit valid date comprising day, month, and year. Year should always be recorded in its full 4-digit format. For days and months with a numeric value of less than 10, zeros should be used to ensure that the date contains the required 8 digits. For example, a date of 1 July 2015 should be recorded as 01072015 as specified in the representational layout.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> C5 Withdrawn date.
-----------------------------------	--

C8 Opt in date

Identifying and definitional attributes

<i>Data item name</i>	Opt in date
<i>Definition</i>	The date on which a person withdraws their request to opt out of all participation in the National Cancer Screening Register for the National Cervical Screening Program
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	{DDMMYYYY}
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The National Cancer Screening Register allows participants to opt out of all participation in the National Cancer Screening Register for the National Cervical Screening Program. This means that: • The person will not be contacted or receive any future correspondence from the National Cancer Screening Register for the National Cervical Screening Program. • No further cervical screening information about the person will be recorded on the National Cancer Screening Register. Participants are subsequently able to opt back into participation in the National Cancer Screening Register for the National Cervical Screening Program, by withdrawing their request to opt out. As a participant may opt in more than once, opt in date needs to be able to be collected multiple times. While it is preferable that this be an accurate date the participant opts back into the National Cancer Screening Register, part of the date may need to be estimated. If this date needs to be estimated, the following guide should be used; if only the year and month is known, date should be set to 01MMYYYY; if only the year is known, date should be set to 0107YYYY.
<i>Collection methods</i>	This data item should always be recorded as an 8-digit valid date comprising day, month, and year. Year should always be recorded in its full 4-digit format. For days and months with a numeric value of less than 10, zeros should be used to ensure that the date contains the required 8 digits. For example, a date of 1 July 2015 should be recorded as 01072015 as specified in the representational layout.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> C6 Withdrawn rescinded date.
-----------------------------------	--

C9 Hysterectomy flag

Identifying and definitional attributes

<i>Data item name</i>	Hysterectomy flag
<i>Definition</i>	An indication as to whether a person has had a total hysterectomy (removal of uterus and cervix).
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code				
<i>Data type</i>	Number				
<i>Format</i>	[N]				
<i>Maximum character length</i>	1				
<i>Permissible values</i>	<table><thead><tr><th>Value</th><th>Meaning</th></tr></thead><tbody><tr><td>1</td><td>Total hysterectomy</td></tr></tbody></table>	Value	Meaning	1	Total hysterectomy
Value	Meaning				
1	Total hysterectomy				

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Hysterectomy flag should be raised at such time as it is known that a person has had a total hysterectomy.
<i>Rules for use</i>	If C10 'Date of hysterectomy' is not NULL, C9 'Hysterectomy flag' should be = 1.
<i>Collection methods</i>	While this can be communicated by the practitioner or participant procedure code for total hysterectomy should also trigger the hysterectomy flag.
<i>Comments</i>	Whether or not a person who had had a total hysterectomy will require further follow-up within the National Cervical Screening Program should be according to clinical recommendations in the <i>National Cervical Screening Program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding</i> (as per 'Flowchart 13.1 Vaginal screening after total hysterectomy') (Cancer Council Australia and Cervical Cancer Screening Guidelines Working Party 2016).

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> C7 Hysterectomy flag
------------------------------------	--

C10 Date of hysterectomy

Identifying and definitional attributes

<i>Data item name</i>	Date of hysterectomy
<i>Definition</i>	The date a person underwent a total hysterectomy (removal of uterus and cervix).
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	{DDMMYYYY}
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The collection of data for this data item is conditional on a person having had a total hysterectomy. While it is preferable that this be an accurate date of a reported total hysterectomy, part of the date may need to be estimated. If this date needs to be estimated, the following guide should be used; if only the year and month is known, date should be set to 01MMYYYY; if only the year is known, date should be set to 0107YYYY.
<i>Rules for use</i>	If C9 'Hysterectomy flag' = 1, C10 'Date of hysterectomy' should not be NULL.
<i>Collection methods</i>	This data item should always be recorded as an 8-digit valid date comprising day, month, and year. Year should always be recorded in its full 4-digit format. For days and months with a numeric value of less than 10, zeros should be used to ensure that the date contains the required 8 digits. For example, a date of 1 July 2015 should be recorded as 01072015 as specified in the representational layout.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> C8 Date of hysterectomy
------------------------------------	---

C11 Death flag

Identifying and definitional attributes

<i>Data item name</i>	Death flag
<i>Definition</i>	An indication as to whether a person is deceased.
<i>Context</i>	These data are essential to ensure that correspondence is not sent to deceased people to avoid potential distress for the person's family or friends.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code				
<i>Data type</i>	Number				
<i>Format</i>	[N]				
<i>Maximum character length</i>	1				
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>1</td><td>Deceased</td></tr></table>	Value	Meaning	1	Deceased
Value	Meaning				
1	Deceased				

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	
<i>Rules for use</i>	If C12 'Date of death' is not NULL, C11 'Death flag' should be = 1.
<i>Collection methods</i>	Frequent linking to the National Death Index or similar source of identified deaths data.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> C9 Death flag
------------------------------------	---

C12 Date of death

Identifying and definitional attributes

<i>Data item name</i>	Date of death
<i>Definition</i>	The date of death of a person.
<i>Context</i>	Required to prevent screening reminder letters or other correspondence being sent to deceased people.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	{DDMMYYYY}
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	While it is preferable that this be an accurate date of death, part of the date may need to be estimated. If this date needs to be estimated, the following guide should be used; if only the year and month is known, date should be set to 01MMYYYY; if only the year is known, date should be set to 0107YYYY.
<i>Rules for use</i>	If C11 'Death flag' = 1, C12 'Date of death' should not be NULL.
<i>Collection methods</i>	This data item should always be recorded as an 8-digit valid date comprising day, month, and year. Year should always be recorded in its full 4-digit format. For days and months with a numeric value of less than 10, zeros should be used to ensure that the date contains the required 8 digits. For example, a date of 1 July 2015 should be recorded as 01072015 as specified in the representational layout.
<i>Comments</i>	Depending on how this information is collected, day or even month may not be known. The death flag should be used as soon as it is known that a person has died, as it is important individuals who are deceased are not sent correspondence (this is more important than recording the day and month of death).

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> C10 Date of death
------------------------------------	---

C13 DES exposed

Identifying and definitional attributes

<i>Data item name</i>	DES exposed
<i>Definition</i>	An indication of whether a person was exposed to diethylstilboestrol (DES) in utero
<i>Context</i>	People exposed to DES in utero are at increased risk of clear cell carcinoma of the vagina and cervix.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code				
<i>Data type</i>	Number				
<i>Format</i>	[N]				
<i>Maximum character length</i>	1				
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>1</td><td>DES exposed</td></tr></table>	Value	Meaning	1	DES exposed
Value	Meaning				
1	DES exposed				

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	DES exposed should be coded to '1' at such time as it is known that a person was exposed to DES in utero. The Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding (Cancer Council Australia and Cervical Cancer Screening Guidelines Working Party 2016) include recommendations specific for cervical screening in DES-exposed people. These recommendations are that people exposed to DES in utero should be offered an annual co-test and colposcopic examination of both the cervix and vagina indefinitely, and that people exposed to DES in utero who have a screen-detected abnormality should be managed by an experienced colposcopist. There is very little evidence on the risk of cervical cancer in daughters of people exposed to DES in utero. Therefore the Guidelines note that they should be screened with 5-yearly HPV testing unless they have concerns, in which case annual co-testing (similar to their DES-exposed mothers) could be offered by clinicians on an individual basis to provide reassurance.
<i>Collection methods</i>	A medical practitioner is likely to note that a person was exposed to DES in utero given the higher risk of cervical and vaginal cancer and the need for a different cervical screening process.
<i>Comments</i>	DES is a synthetic oestrogen that was prescribed predominantly to pregnant people in the first trimester from the 1940s until the early 1970s. There is substantial evidence indicating that people exposed in utero to DES have a markedly increased risk of clear cell carcinoma of the vagina and cervix (IARC 2012).

Relational attributes

<i>Related metadata references</i>	New data item
------------------------------------	---------------

C14 Immunocompromised

Identifying and definitional attributes

<i>Data item name</i>	Immunocompromised
<i>Definition</i>	An indication of whether a person is immunocompromised
<i>Context</i>	People with HIV and solid organ transplant recipients have been defined as sufficiently immune-deficient to warrant more frequent screening and a lower threshold for colposcopy referral than the general population.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code						
<i>Data type</i>	Number						
<i>Format</i>	[N]						
<i>Maximum character length</i>	1						
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>1</td><td>Immunocompromised due to HIV or solid organ transplant</td></tr><tr><td>2</td><td>Immunocompromised due to other reason</td></tr></table>	Value	Meaning	1	Immunocompromised due to HIV or solid organ transplant	2	Immunocompromised due to other reason
Value	Meaning						
1	Immunocompromised due to HIV or solid organ transplant						
2	Immunocompromised due to other reason						

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Immunocompromised should be coded to '1' at such time as it is known that a person is immunocompromised due to HIV or solid organ transplant. Immunocompromised should be coded to '2' at such time as it is known that a person is immunocompromised due to other reasons (such as congenital immune deficiency, being treated with immunosuppressant therapy for autoimmune disease, or being treated for graft versus host disease). The Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding (Cancer Council Australia and Cervical Cancer Screening Guidelines Working Party 2016) include recommendations specific for cervical screening in people with HIV and solid organ transplant recipients. These recommendations are that people that are immunocompromised due to HIV or solid organ transplant who have an HPV test in which oncogenic HPV types are not detected should be screened every 3 years with an HPV test, and those who have a positive oncogenic HPV (any type) test result should be referred for colposcopic assessment informed by the reflex LBC.
----------------------	---

People with congenital immune deficiency, being treated with immunosuppressant therapy for autoimmune disease, or being treated for graft versus host disease could also be considered for 3-yearly cervical screening.

Collection methods

A medical practitioner is likely to note that a person is immunocompromised and for what reason.

Comments

Refer to the many 'Practice point' entries for immunocompromised people for further information.

Relational attributes

Related metadata references

New data item

Group D: Participant vaccination status data items

- D1 HPV vaccination clinical completion status
- D2 HPV vaccination clinical completion date
- D3 HPV vaccine dose date
- D4 HPV vaccination dose age
- D5 HPV vaccine implied dose number
- D6 HPV vaccine type

D1 HPV vaccination clinical completion status

Identifying and definitional attributes

<i>Data item name</i>	HPV vaccination clinical completion status
<i>Definition</i>	An indication as to whether a person is vaccinated against HPV
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code												
<i>Data type</i>	Number												
<i>Format</i>	N												
<i>Maximum character length</i>	1												
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>0</td><td>Unvaccinated</td></tr><tr><td>1</td><td>Vaccinated – complete</td></tr><tr><td>2</td><td>Vaccinated – incomplete</td></tr><tr><td>3</td><td>Vaccinated – too close</td></tr><tr><td>4</td><td>Vaccinated – no valid status</td></tr></table>	Value	Meaning	0	Unvaccinated	1	Vaccinated – complete	2	Vaccinated – incomplete	3	Vaccinated – too close	4	Vaccinated – no valid status
Value	Meaning												
0	Unvaccinated												
1	Vaccinated – complete												
2	Vaccinated – incomplete												
3	Vaccinated – too close												
4	Vaccinated – no valid status												

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Vaccination status is according to clinical completion status, which is derived from HPV vaccination data held by the Australian Immunisation Register based on an algorithm that considers number of doses and length of time between doses. ‘Unvaccinated’ refers to individuals who have never received a dose of HPV vaccine. ‘Complete’ refers to people who received a full course of HPV vaccine at adequate intervals. ‘Incomplete’ refers to people who received less than a full course of HPV vaccine. ‘Too close’ refers to people who received their HPV vaccine doses too close together, and as such their clinical status is uncertain. Definitions of ‘complete’, ‘incomplete’ and ‘too close’ are subject to change based on future research findings. ‘No valid status’ is to be used for people who have data items recorded for HPV vaccination but do not have a valid clinical completion status. These people should not be interpreted as ‘unvaccinated’, which is to be reserved for people who have never received a dose of HPV vaccine.
<i>Comments</i>	The National HPV Vaccination Program Register ceased on 31 December 2018; all HPV vaccinations are now recorded on the Australian Immunisation Register.

Source and reference attributes

Origin Australian Immunisation Register

Relational attributes

Related metadata reference Supersedes *National Cervical Screening Program data dictionary version 1.0* D1 HPV vaccination status

D2 HPV vaccination clinical completion date

Identifying and definitional attributes

<i>Data item name</i>	HPV vaccination clinical completion date
<i>Definition</i>	The date on which a person is considered completely vaccinated with HPV vaccine.
<i>Collection status</i>	Conditional for vaccinated participants

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	{DDMMYYYY}
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Record the date that a person received an HPV vaccine dose that changed their status to 'complete', according to their clinical completion status, as shown in D1 'HPV vaccination clinical completion status'. This data item should always be recorded as an 8-digit valid date comprising day, month, and year. Year should always be recorded in its full 4-digit format. For days and months with a numeric value of less than 10, zeros should be used to ensure that the date contains the required 8 digits. For example, 1 July 2007 should be recorded as 01072007 as specified in the representational layout.
<i>Rules for use</i>	If D1 'HPV vaccination clinical completion status' = 1 ('Complete'), D2 'HPV vaccination clinical completion date' should be populated. If D1 'HPV vaccination clinical completion status' NOT = 1 ('Complete') then D2 'HPV vaccination clinical completion date' should NOT be populated.
<i>Comments</i>	The National HPV Vaccination Program Register ceased on 31 December 2018; all HPV vaccinations are now recorded on the Australian Immunisation Register.

Source and reference attributes

<i>Origin</i>	Australian Immunisation Register
---------------	----------------------------------

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> D2 HPV vaccination completion date
-----------------------------------	--

D3 HPV vaccine dose date

Identifying and definitional attributes

<i>Data item name</i>	HPV vaccine dose date
<i>Definition</i>	The date on which a person received an HPV vaccine dose.
<i>Collection status</i>	Essential for vaccinated participants

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Record the date of a person's vaccine dose. A separate date should be recorded for each dose a person receives. It is usual for each person to receive more than one dose – each dose received requires a D3 'HPV vaccine dose date'. Record date for ALL doses, not just implied doses. This data item should always be recorded as an 8-digit valid date comprising day, month, and year. Year should always be recorded in its full 4-digit format. For days and months with a numeric value of less than 10, zeros should be used to ensure that the date contains the required 8 digits. For example, 1 July 2007 should be recorded as 01072007 as specified in the representational layout.
<i>Comments</i>	This data item will not be populated for unvaccinated people. The National HPV Vaccination Program Register ceased on 31 December 2018; all HPV vaccinations are now recorded on the Australian Immunisation Register.

Source and reference attributes

<i>Origin</i>	Australian Immunisation Register
---------------	----------------------------------

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> D3 HPV vaccination episode date
-----------------------------------	---

D4 HPV vaccine dose age

Identifying and definitional attributes

<i>Data item name</i>	HPV vaccine dose age
<i>Definition</i>	The age at which a person received an HPV vaccine dose.
<i>Collection status</i>	Essential for vaccinated participants

Value domain attributes

<i>Representation class</i>	Code
<i>Data type</i>	Number
<i>Format</i>	[NNN]
<i>Maximum character length</i>	3

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Record a person's age at the time of a vaccine dose. A separate age should be recorded for each dose a person receives. It is usual for each person to receive more than one dose – each dose received requires a D4 'HPV vaccine dose age'. Record age for ALL doses, not just implied doses. Age should be determined by subtracting the person's date of birth from the date on which the dose was administered D3 'HPV vaccine dose date'.
<i>Comments</i>	This data item will not be populated for unvaccinated people. The National HPV Vaccination Program Register ceased on 31 December 2018; All HPV vaccinations are now recorded on the Australian Immunisation Register.

Source and reference attributes

<i>Origin</i>	Australian Immunisation Register
---------------	----------------------------------

Relational attributes

<i>Related metadata reference</i>	New data item
-----------------------------------	---------------

D5 HPV vaccine implied dose number

Identifying and definitional attributes

<i>Data item name</i>	HPV vaccine implied dose number
<i>Definition</i>	The clinically valid dose number of HPV vaccine.
<i>Collection status</i>	Essential for vaccinated participants

Value domain attributes

<i>Representation class</i>	Code
<i>Data type</i>	Number
<i>Format</i>	[NN]
<i>Maximum character length</i>	2

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Implied dose number is the clinically valid dose number, and takes into account the length of time between doses. It uses the same algorithm used for D1 'HPV vaccination clinical completion status' to determine the number of clinically valid doses administered. Implied dose number of 1 will be the same as the actual dose number, but may differ from actual dose number for subsequent doses. Implied dose number will also remain the same for any doses that are received after they are clinically completely vaccinated. For example: <table><thead><tr><th>Actual dose number</th><th>Implied dose number</th></tr></thead><tbody><tr><td>1</td><td>1</td></tr><tr><td>2</td><td>1</td></tr><tr><td>3</td><td>2</td></tr><tr><td>4</td><td>3</td></tr><tr><td>5</td><td>3</td></tr></tbody></table>	Actual dose number	Implied dose number	1	1	2	1	3	2	4	3	5	3
Actual dose number	Implied dose number												
1	1												
2	1												
3	2												
4	3												
5	3												
<i>Comments</i>	This data item will not be populated for unvaccinated people. The National HPV Vaccination Program Register ceased on 31 December 2018; all HPV vaccinations are now recorded on the Australian Immunisation Register.												

Source and reference attributes

<i>Origin</i>	Australian Immunisation Register
---------------	----------------------------------

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> D4 HPV vaccine dose number
-----------------------------------	--

D6 HPV vaccine type

Identifying and definitional attributes

<i>Data item name</i>	HPV vaccine type
<i>Definition</i>	The specific type of HPV vaccine administered at each dose.
<i>Collection status</i>	Essential for vaccinated participants

Value domain attributes

<i>Representation class</i>	Code												
<i>Data type</i>	String												
<i>Format</i>	N[XX]												
<i>Maximum character length</i>	3												
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>1i</td><td>Gardasil</td></tr><tr><td>1ii</td><td>Gardasil9</td></tr><tr><td>2</td><td>Cervarix</td></tr><tr><td>88</td><td>Generic</td></tr><tr><td>99</td><td>Unknown</td></tr></table>	Value	Meaning	1i	Gardasil	1ii	Gardasil9	2	Cervarix	88	Generic	99	Unknown
Value	Meaning												
1i	Gardasil												
1ii	Gardasil9												
2	Cervarix												
88	Generic												
99	Unknown												

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Record the type of HPV vaccine administered for each dose. A separate HPV vaccine type should be recorded for each dose a person receives. It is usual for each person to receive more than one dose – each dose received requires a D6 ‘HPV vaccine type’. Record type for ALL actual doses, not just all implied doses. The permissible values reflect the types of HPV vaccine administered in Australia at the time of preparation. Further HPV vaccine types will be added to this document as required. ‘Generic’ should be used when the HPV vaccine type is known, but not one of ‘Gardasil’, ‘Gardasil9’ or ‘Cervarix’ (for example if the HPV vaccine was administered overseas). ‘Unknown’ should be used when the HPV vaccine type is not known.
<i>Comments</i>	This data item will not be populated for unvaccinated people. The National HPV Vaccination Program Register ceased on 31 December 2018; all HPV vaccinations are now recorded on the Australian Immunisation Register.

Source and reference attributes

<i>Origin</i>	Australian Immunisation Register
---------------	----------------------------------

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> D5 vaccine type
-----------------------------------	---

Group E: Participant demographic data items

Demographic analysis is performed on the address attributed to a related cervical test.

Participants may have differing addresses across multiple tests, all of which need to be captured, with the ability to identify a specific address for a given cervical test.

While it is preferable that demographic analyses are performed on place of residence, this may not be known, in which case an alternative address may be used. However, address data items are all specified as *residential* to reflect that this is the appropriate address for demographic analyses.

E1	Residential address
E2	Residential suburb/town/locality
E3	Residential alternative or other names for suburb/town/locality
E4	Residential Australian state/territory
E5	Residential Australian postcode
E6	Residential geocode – latitude
E7	Residential geocode – longitude
E8	Residential geocode – quality
E9	Residential SA1

E1 Residential address

Identifying and definitional attributes

<i>Data item name</i>	Residential address
<i>Definition</i>	The address where a person usually resides.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Text
<i>Data type</i>	String
<i>Format</i>	[X(180)]
<i>Maximum character length</i>	180

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Address is a composite of one or more standard address components that describes a low level of geographical/physical description of a location. Used in conjunction with the other high-level address components, that is, Suburb/town/locality, Postcode – Australian, Australian state/territory, and Country, forms a complete geographical/physical address of a person. Residential or a postal (mailing) address should be provided for a person.
----------------------	---

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> E1 Residential address
------------------------------------	--

E2 Residential suburb/town/locality

Identifying and definitional attributes

<i>Data item name</i>	Residential suburb/town/locality
<i>Definition</i>	The suburb/town/locality where a person usually resides.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Text
<i>Data type</i>	String
<i>Format</i>	[A(50)]
<i>Maximum character length</i>	50

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Suburb/town/locality is the text that represents the full name of the locality contained within the specific address of a person. The suburb/town/locality name may be a town, city, suburb, or commonly used location name such as a large agricultural property or Aboriginal community. The Australian Bureau of Statistics has suggested that a maximum field length of 50 characters should be sufficient to record the vast majority of locality names. This metadata item may be used to describe the location of person, organisation, or event. It can be a component of a street or postal address. If there is no data for this item, please refer to E3 'Residential alternative or other names for suburb/town/locality' as this may contain an alternative name the locality can be known by. Residential or a postal (mailing) address should be provided for a person.
----------------------	--

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> E2 Residential suburb/town/locality
------------------------------------	---

E3 Residential alternative or other names for suburb/town/locality

Identifying and definitional attributes

<i>Data item name</i>	Residential alternative or other names for suburb/town/locality
<i>Definition</i>	The alternative name or other name of the suburb/town/locality (for example, an Indigenous name or a colloquial name for a locality that is different to the official or commonly used name) where a person usually resides.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Text
<i>Data type</i>	String
<i>Format</i>	[A(50)]
<i>Maximum character length</i>	50

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The alternative name or other name of the suburb/town/locality is, for example, an Indigenous name or a colloquial name for a locality that is different to the official or commonly used name, that is contained within the specific address of a person. The alternative or other name for a suburb/town/locality may be used instead of, or in addition to, the official or commonly used name of the locality.
<i>Collection methods</i>	If there is not an alternative or other name for a locality other than the official or commonly used name, then do not enter any data for this item.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> E3 Residential alternative or other names for suburb/town/locality
------------------------------------	--

E4 Residential Australian state/territory

Identifying and definitional attributes

<i>Data item name</i>	Residential Australian state/territory
<i>Definition</i>	The Australian state or territory in which a person usually resides.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																		
<i>Data type</i>	Text																		
<i>Format</i>	{AA[A]}																		
<i>Maximum character length</i>	3																		
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>NSW</td><td>New South Wales</td></tr><tr><td>VIC</td><td>Victoria</td></tr><tr><td>QLD</td><td>Queensland</td></tr><tr><td>WA</td><td>Western Australia</td></tr><tr><td>SA</td><td>South Australia</td></tr><tr><td>TAS</td><td>Tasmania</td></tr><tr><td>ACT</td><td>Australian Capital Territory</td></tr><tr><td>NT</td><td>Northern Territory</td></tr></table>	Value	Meaning	NSW	New South Wales	VIC	Victoria	QLD	Queensland	WA	Western Australia	SA	South Australia	TAS	Tasmania	ACT	Australian Capital Territory	NT	Northern Territory
Value	Meaning																		
NSW	New South Wales																		
VIC	Victoria																		
QLD	Queensland																		
WA	Western Australia																		
SA	South Australia																		
TAS	Tasmania																		
ACT	Australian Capital Territory																		
NT	Northern Territory																		

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This data item is important for national reporting by the Australian Institute of Health and Welfare. The order presented here is the standard for the Australian Institute of Health and Welfare, and reflects the current order of states and territories in order of most populated to least populated. Residential or a postal (mailing) address should be provided for a person.
----------------------	--

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> E4 Residential Australian state/territory
-----------------------------------	---

E5 Residential Australian postcode

Identifying and definitional attributes

<i>Data item name</i>	Residential Australian postcode
<i>Definition</i>	The code that represents a postal delivery area, aligned with locality, suburb, or place for the address where a person usually resides.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code
<i>Data type</i>	Number
<i>Format</i>	{NNNN}
<i>Maximum character length</i>	4

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This data item is important for national reporting by the Australian Institute of Health and Welfare.
<i>Comments</i>	Must accept zero as the leading digit to accommodate all Australian postcodes. Australian Postcode may be used in the analysis of data on a geographical basis, which involves a conversion from postcodes to the Australian Bureau of Statistics (ABS) postal areas. This conversion results in some inaccuracy of information. However, in some data sets postcode is the only geographic identifier, therefore the use of other more accurate indicators is not always possible.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> E5 Residential Australian postcode
------------------------------------	--

E6 Residential geocode – latitude

Identifying and definitional attributes

<i>Data item name</i>	Residential geocode – latitude
<i>Definition</i>	Latitude of place of residence.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	Geospatial
<i>Format</i>	XN[N][.N(9)]
<i>Maximum character length</i>	13

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The 'X' in the latitude format symbolises the designator symbol '+' or '-' and should be placed prior to the first number. Latitudes north of the equator are positive and shall be designated by use of the plus sign (+), latitudes south of the equator are negative and shall be designated by use of the minus sign (-). The equator shall be designated by use of the plus sign (+). The format XN[N][.N(9)] allows for 1- or 2-digit latitudes (that is, degree values) with the option of 0 to 9 decimal places (that is, decimal degree values). Usage examples: • +14.091360569 • +2 • -50.321
----------------------	---

Source and reference attributes

<i>Origin</i>	Standards Australia 2006. AS 4590–2006 Interchange of client information. Sydney: Standards Australia.
<i>Reference documents</i>	

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> E6 Residential geocode – latitude
-----------------------------------	---

E7 Residential geocode – longitude

Identifying and definitional attributes

<i>Data item name</i>	Residential geocode – longitude
<i>Definition</i>	Longitude of place of residence.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	Geospatial
<i>Format</i>	XN[N][.N(9)]
<i>Maximum character length</i>	13

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The 'X' in the longitude format symbolises the designator symbol '+' or '-' and should be placed prior to the first number. The designator symbol for longitudes east of Greenwich are positive and shall be designated by use of the plus sign (+), while longitudes west of Greenwich are negative and shall be designated by use of the minus sign (-). The Prime Meridian shall be designated by use of the plus sign (+). The 180th meridian shall be designated by use of the minus sign (-). The format XN[N][.N(9)] allows for 1-, 2- and 3-digit longitudes (that is, degrees) with the option of 0 to 9 decimal places (that is, decimal degrees). Usage examples: • +149.091360569 • +2 • -50.321
----------------------	--

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> E7 Residential geocode – longitude
-----------------------------------	--

E8 Residential geocode – quality

Identifying and definitional attributes

<i>Data item name</i>	Residential geocode – quality
<i>Definition</i>	A measure of the quality of geocode for place of residence.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code
<i>Data type</i>	Number
<i>Format</i>	N
<i>Maximum character length</i>	1

Data item attributes

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> E8 Residential geocode – quality
-----------------------------------	--

E9 Residential SA1

Identifying and definitional attributes

<i>Data item name</i>	Residential SA1
<i>Definition</i>	SA1 of place of residence.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code
<i>Data type</i>	String
<i>Format</i>	N(11)
<i>Maximum character length</i>	11

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	SA1 coding structure: SA1s are identified by an 11-digit fully hierarchical code. The SA1 identifier is a 2-digit code, assigned within an SA2. An SA1 code is only unique within a state/territory when it is preceded by the state/territory identifier.
----------------------	---

For example:

State/territory	SA4	SA3	SA2	SA1
N	NN	NN	NNNN	NN

<i>Comments</i>	There are approximately 55,000 SA1s. In aggregate, they cover the whole of Australia without gaps or overlaps. SA1 can be used in geospatial analyses to assign individuals to any geography that is larger than this, such as SA2, SA3, SA4, or to geographies of interest such as Primary Health Network (PHN).
-----------------	--

Source and reference attributes

<i>Origin</i>	1270.0.55.001 – Australian Statistical Geography Standard (ASGS): Volume 1 – Main Structure and Greater Capital City Statistical Areas
<i>Reference documents</i>	

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> E9 Residential SA1
-----------------------------------	--

Group F: Correspondence data items

F1	Correspondence type
F2	Correspondence date
F3	Correspondence method
F4	Correspondence failure flag
F5	Correspondence failure date
F6	Correspondence failure type

F1 Correspondence type

Identifying and definitional attributes

<i>Data item name</i>	Correspondence type
<i>Definition</i>	An indication of the type of correspondence between the National Cancer Screening Register and a person.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																								
<i>Data type</i>	Number																								
<i>Format</i>	AN																								
<i>Maximum character length</i>	2																								
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>A1</td><td>Screening invitation</td></tr><tr><td>A2</td><td>Screening reminder</td></tr><tr><td>B1</td><td>Screening invitation – self-collection eligible</td></tr><tr><td>B2</td><td>Screening reminder – self-collection eligible</td></tr><tr><td>C1</td><td>Rescreening invitation</td></tr><tr><td>C2</td><td>Rescreening reminder</td></tr><tr><td>D1</td><td>Rescreening invitation – self-collection eligible</td></tr><tr><td>D2</td><td>Rescreening reminder – self-collection eligible</td></tr><tr><td>E1</td><td>Exit letter</td></tr><tr><td>F0</td><td>Follow-up</td></tr><tr><td>G0</td><td>Other</td></tr></table>	Value	Meaning	A1	Screening invitation	A2	Screening reminder	B1	Screening invitation – self-collection eligible	B2	Screening reminder – self-collection eligible	C1	Rescreening invitation	C2	Rescreening reminder	D1	Rescreening invitation – self-collection eligible	D2	Rescreening reminder – self-collection eligible	E1	Exit letter	F0	Follow-up	G0	Other
Value	Meaning																								
A1	Screening invitation																								
A2	Screening reminder																								
B1	Screening invitation – self-collection eligible																								
B2	Screening reminder – self-collection eligible																								
C1	Rescreening invitation																								
C2	Rescreening reminder																								
D1	Rescreening invitation – self-collection eligible																								
D2	Rescreening reminder – self-collection eligible																								
E1	Exit letter																								
F0	Follow-up																								
G0	Other																								

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Screening refers to a person's first screen in the program; rescreening refers to any screen that is not their first. This is based on the 'business as usual' protocol of action for the National Cervical Screening Program. A1 & A2 applies to: • People turning 25 who have never screened before (or were screened prior to 24 years and 9 months); • People aged between 25 and <30 who have been newly identified from Medicare enrolment data and who have not been sent an invitation previously; and • People aged between 25 and <30 who have never previously had a Pap test.
----------------------	---

B1 & B2 applies to:

- People aged ≥ 30 and < 75 who have been newly identified from Medicare enrolment data who have never screened and who have not been sent an invitation previously.

C1 & C2 applies to:

- People aged between ≥ 30 to < 75 years of age who have a screening history and are less than 2 years overdue for their next screening test.

D1 & D2 applies to:

- People aged between 30 and < 75 years of age who have a screening history and are 2 years or more overdue for their next screening test.

E1 refers to a letter that is sent to people aged 70–74 who are invited to have an HPV test and oncogenic HPV is not detected in their HPV test, as they will no longer be invited to rescreen.

F0 refers to any follow-up contact with a person.

G0 refers to other correspondence sent to a person, such as a welcome letter or a letter to acknowledge opt out.

Comments

This data item relates only to correspondence sent by the National Cancer Screening Register to a person.

Relational attributes

Related metadata reference

Supersedes *National Cervical Screening Program data dictionary version 1.0* F1 Type of contact

F2 Correspondence date

Identifying and definitional attributes

<i>Data item name</i>	Date of correspondence
<i>Definition</i>	The date on which the National Cancer Screening Register sent correspondence to a person.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The date of correspondence is the date that the National Cancer Screening Register sent correspondence to a person. This may not be the same date that the person received the correspondence, as there can be a delay between the date a letter, email or SMS is sent by the National Cancer Screening Register and the date a person receives this correspondence.
<i>Comments</i>	This data item relates only to correspondence sent from the National Cancer Screening Register to a person, and not to a practitioner or other medical professional.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> F2 Date of contact
-----------------------------------	--

F3 Correspondence method

Identifying and definitional attributes

<i>Data item name</i>	Method of correspondence
<i>Definition</i>	The method by which National Cancer Screening Register sent correspondence to a person.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code										
<i>Data type</i>	Number										
<i>Format</i>	N										
<i>Maximum character length</i>	1										
<i>Permissible values</i>	<table><thead><tr><th>Value</th><th>Meaning</th></tr></thead><tbody><tr><td>1</td><td>Mail</td></tr><tr><td>2</td><td>Telephone</td></tr><tr><td>3</td><td>SMS</td></tr><tr><td>4</td><td>Email</td></tr></tbody></table>	Value	Meaning	1	Mail	2	Telephone	3	SMS	4	Email
Value	Meaning										
1	Mail										
2	Telephone										
3	SMS										
4	Email										

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Method of correspondence is likely to differ depending on the type of correspondence as specified in F1 'Correspondence type'.
<i>Comments</i>	This data item relates only to correspondence sent by the National Cancer Screening Register to a person.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> F3 Method of contact
-----------------------------------	--

F4 Correspondence failure flag

Identifying and definitional attributes

<i>Data item name</i>	Correspondence failure flag
<i>Definition</i>	An indication that a person's contact details for the purpose of sending correspondence are not valid.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code				
<i>Data type</i>	Number				
<i>Format</i>	{N}				
<i>Maximum character length</i>	1				
<i>Permissible values</i>	<table><thead><tr><th>Value</th><th>Meaning</th></tr></thead><tbody><tr><td>1</td><td>Correspondence failure</td></tr></tbody></table>	Value	Meaning	1	Correspondence failure
Value	Meaning				
1	Correspondence failure				

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	'Correspondence failure' flag is to be used in any instance where a person's contact details are found to be invalid. This may take the form of a letter marked 'return to sender', an email address that 'bounces', or verbal communication via telephone that the participant no longer resides or works at the site of the designated telephone number. This flag can be used several times for one person, if more than one method of contact is determined to be invalid. A person may only have one method of contact (usually a mailing address). If there are no other valid contact details recorded for a person, they will be lost to follow-up/will be unable to be invited to screen or rescreen until such time as new contact information is received.
----------------------	--

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> F4 Contact failure flag
-----------------------------------	---

F5 Correspondence failure date

Identifying and definitional attributes

<i>Data item name</i>	Correspondence failure date
<i>Definition</i>	Date on which correspondence failure notification was received by the National Cervical Screening Register.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	{DDMMYYYY}
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The date a letter marked 'return to sender' was received, or the date of an email or verbal indication of invalid contact details.
----------------------	--

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> F5 Contact failure date
-----------------------------------	---

F6 Correspondence failure type

Identifying and definitional attributes

<i>Data item name</i>	Correspondence failure type
<i>Definition</i>	The type of details found to be invalid for the purpose of correspondence between the National Cancer Screening Register and a person.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code												
<i>Data type</i>	Number												
<i>Format</i>	{N}												
<i>Maximum character length</i>	1												
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>1</td><td>Mailing address</td></tr><tr><td>2</td><td>Telephone number – home</td></tr><tr><td>3</td><td>Telephone number – work</td></tr><tr><td>4</td><td>Telephone number – mobile</td></tr><tr><td>5</td><td>Email address</td></tr></table>	Value	Meaning	1	Mailing address	2	Telephone number – home	3	Telephone number – work	4	Telephone number – mobile	5	Email address
Value	Meaning												
1	Mailing address												
2	Telephone number – home												
3	Telephone number – work												
4	Telephone number – mobile												
5	Email address												

Data item attributes

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> F6 Contact failure type
-----------------------------------	---

Group G: Test type data item

G1 Type of test

G1 Type of test

Identifying and definitional attributes

<i>Data item name</i>	Type of test
<i>Definition</i>	Whether the test of interest is an HPV test, a cytology test (either LBC or conventional Pap test), colposcopy, or histology test.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code										
<i>Data type</i>	String										
<i>Format</i>	A										
<i>Maximum character length</i>	1										
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>V</td><td>HPV test</td></tr><tr><td>C</td><td>Cytology test</td></tr><tr><td>P</td><td>Colposcopy</td></tr><tr><td>H</td><td>Histology test</td></tr></table>	Value	Meaning	V	HPV test	C	Cytology test	P	Colposcopy	H	Histology test
Value	Meaning										
V	HPV test										
C	Cytology test										
P	Colposcopy										
H	Histology test										

Data item attributes

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> G1 Type of test
------------------------------------	---

Group H: HPV test data items

H1	HPV test date
H2	HPV test collection method
H3	HPV test specimen site
H4	Reason for HPV test
H5	HPV test result – oncogenic HPV
H6	HPV test result – secondary oncogenic HPV
H7	HPV test type
H8	HPV test sample
H9	HPV test batch information – Control kit lot number
H10	HPV test batch information – Control kit expiry date
H11	HPV test batch information – Cellular (LBC) extraction kit lot number
H12	HPV test batch information – Cellular (LBC) extraction kit expiry date
H13	HPV test batch information – Nucleic acid extraction kit lot number
H14	HPV test batch information – Nucleic acid extraction kit expiry date
H15	HPV test batch information – Amplification kit lot number
H16	HPV test batch information – Amplification kit expiry date
H17	HPV test batch information – Detection kit lot number
H18	HPV test batch information – Detection kit expiry date
H19	HPV test batch information – Wash buffer lot number
H20	HPV test batch information – Wash buffer expiry date

H1 HPV test date

Identifying and definitional attributes

<i>Data item name</i>	HPV test date
<i>Definition</i>	The date a specimen for an HPV test was collected.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This is an important date, as it is used to determine other features of interest that occur 'at time of test', such as age at test, remoteness area and socioeconomic area of residence at time of test, HPV vaccination status at time of test, etcetera.
<i>Collection methods</i>	For a single cervical test, there can be a test request date, a test collection date, a laboratory receipt date, a laboratory report date, and a laboratory transmission date. The date of interest for reporting is the test collection date, as this is the date on which the specimen was collected. If test collection date is unknown, another date can be used instead, and will be treated as the test date. The order of priority for an alternative date is: • test request date • laboratory receipt date • laboratory report date • laboratory transmission date.
<i>Comments</i>	The National Cancer Screening Register needs to collect all dates associated with a test (test request date, test collection date, laboratory receipt date, laboratory report date and laboratory transmission date) to ensure timely progression of a specimen, for instance by determining the time between the laboratory receipt date, the laboratory report date, and the laboratory transmission date.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H1 HPV test date
-----------------------------------	--

H2 HPV test collection method

Identifying and definitional attributes

<i>Data item name</i>	HPV test collection method
<i>Definition</i>	An indication of whether an HPV test sample is collected by a practitioner or self-collected.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code						
<i>Data type</i>	String						
<i>Format</i>	AN						
<i>Maximum character length</i>	2						
<i>Permissible values</i>	<table><thead><tr><th>Value</th><th>Meaning</th></tr></thead><tbody><tr><td>A1</td><td>Practitioner-collected sample</td></tr><tr><td>A2</td><td>Self-collected sample</td></tr></tbody></table>	Value	Meaning	A1	Practitioner-collected sample	A2	Self-collected sample
Value	Meaning						
A1	Practitioner-collected sample						
A2	Self-collected sample						

Data item attributes

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H2 HPV test collection method
-----------------------------------	---

H3 HPV test specimen site

Identifying and definitional attributes

<i>Data item name</i>	HPV test specimen site
<i>Definition</i>	An indication as to the site from which the specimen was collected.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code										
<i>Data type</i>	String										
<i>Format</i>	AN										
<i>Maximum character length</i>	2										
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>B0</td><td>Not stated</td></tr><tr><td>B1</td><td>Cervical</td></tr><tr><td>B2</td><td>Vaginal</td></tr><tr><td>B3</td><td>Other gynaecological site</td></tr></table>	Value	Meaning	B0	Not stated	B1	Cervical	B2	Vaginal	B3	Other gynaecological site
Value	Meaning										
B0	Not stated										
B1	Cervical										
B2	Vaginal										
B3	Other gynaecological site										

Data item attributes

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H3 HPV test specimen site
-----------------------------------	---

H4 Reason for HPV test

Identifying and definitional attributes

<i>Data item name</i>	Reason for HPV test
<i>Definition</i>	The reason why an HPV test is performed.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code	
<i>Data type</i>	String	
<i>Format</i>	AN{XXX}	
<i>Maximum character length</i>	5	
<i>Permissible values</i>	Value	Meaning
	C1	Primary screening HPV test
	C2	Follow-up HPV test (repeat HPV test after intermediate risk result)
	C3i	Co-test – test of cure
	C3ii	Co-test – investigation of signs or symptoms
	C3iii	Co-test – other, as recommended in guidelines
	C4	Other
<i>Comments</i>	'C2' originally indicated it should be used for repeat HPV tests after an intermediate risk result and repeat HPV tests after an unsatisfactory test. However, since early 2018, pathology laboratories have used 'C2' for repeat HPV tests after an intermediate risk result ONLY. Repeat HPV tests after an unsatisfactory test are allocated the same 'Reason for HPV test' as the original test. This data item has been updated accordingly.	

Data item attributes

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H4 Reason for HPV test
-----------------------------------	--

H5 HPV test result – oncogenic HPV

Identifying and definitional attributes

<i>Data item name</i>	HPV test result – oncogenic HPV
<i>Definition</i>	The result of an HPV test for oncogenic HPV types.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																				
<i>Data type</i>	String																				
<i>Format</i>	AN{XXX}																				
<i>Maximum character length</i>	5																				
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>DU</td><td>Unsatisfactory</td></tr><tr><td>D0</td><td>Oncogenic HPV not detected</td></tr><tr><td>D1</td><td>HPV 16/18 detected</td></tr><tr><td>D1i</td><td>Type 16 detected</td></tr><tr><td>D1ii</td><td>Type 18 detected</td></tr><tr><td>D1iii</td><td>Type 18/45 detected</td></tr><tr><td>D2</td><td>Oncogenic HPV (not 16/18) detected</td></tr><tr><td>D2i</td><td>One or more of the following types detected: 31, 33, 45, 52, or 58</td></tr><tr><td>D2ii</td><td>One or more of the following types detected: 35, 39, 51, 56, 59, 66, or 68</td></tr></table>	Value	Meaning	DU	Unsatisfactory	D0	Oncogenic HPV not detected	D1	HPV 16/18 detected	D1i	Type 16 detected	D1ii	Type 18 detected	D1iii	Type 18/45 detected	D2	Oncogenic HPV (not 16/18) detected	D2i	One or more of the following types detected: 31, 33, 45, 52, or 58	D2ii	One or more of the following types detected: 35, 39, 51, 56, 59, 66, or 68
Value	Meaning																				
DU	Unsatisfactory																				
D0	Oncogenic HPV not detected																				
D1	HPV 16/18 detected																				
D1i	Type 16 detected																				
D1ii	Type 18 detected																				
D1iii	Type 18/45 detected																				
D2	Oncogenic HPV (not 16/18) detected																				
D2i	One or more of the following types detected: 31, 33, 45, 52, or 58																				
D2ii	One or more of the following types detected: 35, 39, 51, 56, 59, 66, or 68																				

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	'DU Unsatisfactory' indicates that the HPV test was unsatisfactory. 'D0 Oncogenic HPV not detected' indicates that no oncogenic HPV types were detected. 'D1 HPV 16/18 detected' indicates that one or more of the oncogenic HPV types 16 or 18 were detected. '1i Type 16 detected' indicates that the oncogenic HPV type 16 was detected. 'D1ii Type 18 detected' indicates that the oncogenic HPV type 18 was detected. 'D1iii Type 18/45 detected' indicates that oncogenic HPV types 18 or 45 were detected (specific to HPV tests that cannot distinguish between the detection of 18 and 45). 'D2 Oncogenic HPV (not 16/18) detected' indicates that one or more of the oncogenic HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, or 68 were detected.
----------------------	---

	'D2i One or more of the following types detected: 31, 33, 45, 52, or 58' indicates that one or more of the oncogenic HPV types 31, 33, 45, 52, or 58 were detected. 'D2ii One or more of the following types detected: 35, 39, 51, 56, 59, 66, or 68' indicates that one or more of the oncogenic HPV types 35, 39, 51, 56, 59, 66, or 68 were detected.
<i>Collection methods</i>	The National Cancer Screening Register uses an algorithm to determine the most serious HPV type for each HPV test, which is recorded in this data item.
<i>Comments</i>	This data item combines three data items from the previous version of this data dictionary – H5 HPV test result – oncogenic HPV, H6 Secondary HPV test result – HPV 16/18 detected and H7 Secondary HPV test result – oncogenic HPV (not 16/18) detected.
Relational attributes	
<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H5 HPV test result – oncogenic HPV

H6 HPV test result – secondary oncogenic HPV

Identifying and definitional attributes

<i>Data item name</i>	HPV test result – secondary oncogenic HPV
<i>Definition</i>	The secondary result of an HPV test for oncogenic HPV types.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code																
<i>Data type</i>	String																
<i>Format</i>	AAN{XXX}																
<i>Maximum character length</i>	6																
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>DS1</td><td>HPV 16/18 detected</td></tr><tr><td>DS1i</td><td>Type 16 detected</td></tr><tr><td>DS1ii</td><td>Type 18 detected</td></tr><tr><td>DS1iii</td><td>Type 18/45 detected</td></tr><tr><td>DS2</td><td>Oncogenic HPV (not 16/18) detected</td></tr><tr><td>DS2i</td><td>One or more of the following types detected: 31, 33, 45, 52, or 58</td></tr><tr><td>DS2ii</td><td>One or more of the following types detected: 35, 39, 51, 56, 59, 66, or 68</td></tr></table>	Value	Meaning	DS1	HPV 16/18 detected	DS1i	Type 16 detected	DS1ii	Type 18 detected	DS1iii	Type 18/45 detected	DS2	Oncogenic HPV (not 16/18) detected	DS2i	One or more of the following types detected: 31, 33, 45, 52, or 58	DS2ii	One or more of the following types detected: 35, 39, 51, 56, 59, 66, or 68
Value	Meaning																
DS1	HPV 16/18 detected																
DS1i	Type 16 detected																
DS1ii	Type 18 detected																
DS1iii	Type 18/45 detected																
DS2	Oncogenic HPV (not 16/18) detected																
DS2i	One or more of the following types detected: 31, 33, 45, 52, or 58																
DS2ii	One or more of the following types detected: 35, 39, 51, 56, 59, 66, or 68																

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	While the most serious HPV type for each HPV test is recorded in H5 'HPV test result – oncogenic HPV', more rarely a secondary HPV type is detected by the pathology laboratory. This data item allows the collection of this secondary oncogenic HPV type. 'DS1 HPV 16/18 detected' indicates that one or more of the oncogenic HPV types 16 or 18 were detected as the secondary HPV type. 'DS1i Type 16 detected' indicates that the oncogenic HPV type 16 was detected as the secondary HPV type. 'DS1ii Type 18 detected' indicates that the oncogenic HPV type 18 was detected as the secondary HPV type. 'DS1iii Type 18/45 detected' indicates that one or more of the oncogenic HPV types 18 or 45 were detected (specific to HPV tests that cannot distinguish between the detection of 18 and 45). 'DS2 Oncogenic HPV (not 16/18) detected' indicates that one or more of the oncogenic HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, or 68 were detected as the secondary HPV type.
----------------------	---

'DS2i One or more of the following types detected: 31, 33, 45, 52, or 58' indicates that one or more of the oncogenic HPV types 31, 33, 45, 52, or 58 were detected as the secondary type.

'DS2ii One or more of the following types detected: 35, 39, 51, 56, 59, 66, or 68' indicates that one or more of the oncogenic HPV types 35, 39, 51, 56, 59, 66, or 68 were detected as the secondary HPV type.

Comments

In reality, neither 'DS1 HPV 16/18 detected' nor 'DS1i Type 16 detected' will ever be valid values for this data item as these will always be the most serious HPV type recorded at H5 'HPV test result – oncogenic HPV'. They have been included here to allow the permissible values for the data item to align with permissible values for H5 'HPV test result – oncogenic HPV'.

Relational attributes

<i>Related metadata reference</i>	New data item
-----------------------------------	---------------

H7 HPV test type

Identifying and definitional attributes

<i>Data item name</i>	HPV test type
<i>Definition</i>	The type of test used to determine the oncogenic HPV test result.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																																
<i>Data type</i>	String																																
<i>Format</i>	AN[XXX]																																
<i>Maximum character length</i>	5																																
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>T0</td><td>Not stated</td></tr><tr><td>T1i</td><td>Qiagen – Hybrid capture II</td></tr><tr><td>T2i</td><td>Roche – cobas 4800</td></tr><tr><td>T2ii</td><td>Roche – cobas 6800</td></tr><tr><td>T2iii</td><td>Roche – cobas 8800</td></tr><tr><td>T3i</td><td>Abbott – m2000</td></tr><tr><td>T3ii</td><td>Abbott – Alinity m</td></tr><tr><td>T4i</td><td>Becton Dickinson – Onclarity</td></tr><tr><td>T5i</td><td>Cepheid – Xpert</td></tr><tr><td>T6i</td><td>Hologic – Cervista</td></tr><tr><td>T6ii</td><td>Hologic – Aptima</td></tr><tr><td>T7i</td><td>Seegene – Anyplex</td></tr><tr><td>T8i</td><td>Genera – PapType</td></tr><tr><td>T9i</td><td>Euroimmun – Euroarray</td></tr><tr><td>T999</td><td>Other</td></tr></table>	Value	Meaning	T0	Not stated	T1i	Qiagen – Hybrid capture II	T2i	Roche – cobas 4800	T2ii	Roche – cobas 6800	T2iii	Roche – cobas 8800	T3i	Abbott – m2000	T3ii	Abbott – Alinity m	T4i	Becton Dickinson – Onclarity	T5i	Cepheid – Xpert	T6i	Hologic – Cervista	T6ii	Hologic – Aptima	T7i	Seegene – Anyplex	T8i	Genera – PapType	T9i	Euroimmun – Euroarray	T999	Other
Value	Meaning																																
T0	Not stated																																
T1i	Qiagen – Hybrid capture II																																
T2i	Roche – cobas 4800																																
T2ii	Roche – cobas 6800																																
T2iii	Roche – cobas 8800																																
T3i	Abbott – m2000																																
T3ii	Abbott – Alinity m																																
T4i	Becton Dickinson – Onclarity																																
T5i	Cepheid – Xpert																																
T6i	Hologic – Cervista																																
T6ii	Hologic – Aptima																																
T7i	Seegene – Anyplex																																
T8i	Genera – PapType																																
T9i	Euroimmun – Euroarray																																
T999	Other																																

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	HPV test types have been grouped according to manufacture, with the specific platforms listed. This will provide detailed information about HPV test type for quality monitoring of this screening test, as well as enabling additional HPV test types to be added in the future.
<i>Comments</i>	The HPV test types listed here will be tests that are registered on the ARTG for HPV testing of cervical samples. It is not an indication of which tests are suitable for use in the National Cervical Screening Program. Only those HPV tests that meet the requirements set out in the NPAAC Standards and Performance Measures for cervical screening should be used in the National Cervical Screening Program. Tests that do not meet the

requirements now may meet them in future and therefore all tests listed on the ARTG will be coded. The HPV tests currently listed are tests which were known to be registered on the ARTG at the time of developing the data dictionary. There may be others that are on the ARTG and were not identified at the time of development or will be added in future. Any tests that are listed on the ARTG will be added to the data dictionary if the National Cervical Screening Program is informed.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H8 HPV test type
------------------------------------	--

H8 HPV test sample

Identifying and definitional attributes

<i>Data item name</i>	HPV test sample
<i>Definition</i>	Information about the sample collected for an HPV test.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code														
<i>Data type</i>	Number														
<i>Format</i>	AN{N}														
<i>Maximum character length</i>	3														
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>F0</td><td>Not stated</td></tr><tr><td>F1</td><td>PreservCyt Solution</td></tr><tr><td>F2</td><td>SurePath medium</td></tr><tr><td>F97</td><td>Other commercial self-collection device</td></tr><tr><td>F98</td><td>Specimen transport medium</td></tr><tr><td>F99</td><td>Flocked or cotton swab</td></tr></table>	Value	Meaning	F0	Not stated	F1	PreservCyt Solution	F2	SurePath medium	F97	Other commercial self-collection device	F98	Specimen transport medium	F99	Flocked or cotton swab
Value	Meaning														
F0	Not stated														
F1	PreservCyt Solution														
F2	SurePath medium														
F97	Other commercial self-collection device														
F98	Specimen transport medium														
F99	Flocked or cotton swab														

Data item attributes

Collection and usage attributes

Guide for use	This data item is intended to provide information about the sample that is provided, and whether it is suitable for HPV testing and reflex LBC testing, or whether it is suitable only for HPV testing, with a second sample required for reflex LBC testing (if indicated). Values ≥90 will be suitable for HPV testing only, either due the sample being self-collected, or due to an inappropriate sampling device or sampling media being used.
Collection methods	If the head of a swab is received by the laboratory in sampling media such as PreservCyt or SurePath, then it must be coded as '99 Flocked or cotton swab'.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H9 HPV test sample
-----------------------------------	--

H9 HPV test batch information – Control kit lot number

Identifying and definitional attributes

<i>Data item name</i>	HPV test batch information – Control kit lot number
<i>Definition</i>	Lot number from the control kit
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	String
<i>Format</i>	X[X(19)]
<i>Maximum character length</i>	20

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	For each of these codes one or more Lot numbers and associated expiry dates need to be reported. The fields need to be able to accept both letters and numbers as well as N/A (in the case of LBC extraction on a self-collected sample). Where a 'kit' includes reagents for multiple testing steps the Lot numbers and expiry dates should be repeated for each of the codes.
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H10 HPV test batch information – Control kit lot number
-----------------------------------	---

H10 HPV test batch information – Control kit expiry date

Identifying and definitional attributes

<i>Data item name</i>	HPV test batch information – Control kit expiry date
<i>Definition</i>	The expiry date of the control kit.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	For each of these codes one or more Lot numbers and associated expiry dates need to be reported. The fields need to be able to accept both letters and numbers as well as N/A (in the case of LBC extraction on a self-collected sample). Where a 'kit' includes reagents for multiple testing steps the Lot numbers and expiry dates should be repeated for each of the codes.
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H11 HPV test batch information – Control kit expiry date
-----------------------------------	--

H11 HPV test batch information – Cellular (LBC) extraction kit lot number

Identifying and definitional attributes

<i>Data item name</i>	HPV test batch information – Cellular (LBC) extraction kit lot number
<i>Definition</i>	Lot number from the cellular (LBC) extraction kit.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	String
<i>Format</i>	X[X(19)]
<i>Maximum character length</i>	20

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	For each of these codes one or more Lot numbers and associated expiry dates need to be reported. The fields need to be able to accept both letters and numbers as well as N/A (in the case of LBC extraction on a self-collected sample). Where a 'kit' includes reagents for multiple testing steps the Lot numbers and expiry dates should be repeated for each of the codes.
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H12 HPV test batch information – Cellular (LBC) extraction kit lot number
-----------------------------------	---

H12 HPV test batch information – Cellular (LBC) extraction kit expiry date

Identifying and definitional attributes

<i>Data item name</i>	HPV test batch information – Cellular (LBC) extraction kit expiry date
<i>Definition</i>	The expiry date of the cellular (LBC) extraction kit.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	For each of these codes one or more Lot numbers and associated expiry dates need to be reported. The fields need to be able to accept both letters and numbers as well as N/A (in the case of LBC extraction on a self-collected sample). Where a 'kit' includes reagents for multiple testing steps the Lot numbers and expiry dates should be repeated for each of the codes.
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H13 HPV test batch information – Cellular (LBC) extraction kit expiry date
-----------------------------------	--

H13 HPV test batch information – Nucleic acid extraction kit lot number

Identifying and definitional attributes

<i>Data item name</i>	HPV test batch information – Nucleic acid extraction kit lot number
<i>Definition</i>	Lot number from the nucleic acid extraction kit.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	String
<i>Format</i>	X[X(19)]
<i>Maximum character length</i>	20

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	For each of these codes one or more Lot numbers and associated expiry dates need to be reported. The fields need to be able to accept both letters and numbers as well as N/A (in the case of LBC extraction on a self-collected sample). Where a 'kit' includes reagents for multiple testing steps the Lot numbers and expiry dates should be repeated for each of the codes.
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H14 HPV test batch information – Nucleic acid extraction kit lot number
-----------------------------------	---

H14 HPV test batch information – Nucleic acid extraction kit expiry date

Identifying and definitional attributes

<i>Data item name</i>	HPV test batch information – Nucleic acid extraction kit expiry date
<i>Definition</i>	The expiry date of the nucleic acid extraction kit.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	For each of these codes one or more Lot numbers and associated expiry dates need to be reported. The fields need to be able to accept both letters and numbers as well as N/A (in the case of LBC extraction on a self-collected sample). Where a 'kit' includes reagents for multiple testing steps the Lot numbers and expiry dates should be repeated for each of the codes.
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H15 HPV test batch information – Nucleic acid extraction kit expiry date
-----------------------------------	--

H15 HPV test batch information – Amplification kit lot number

Identifying and definitional attributes

<i>Data item name</i>	HPV test batch information – Amplification kit lot number
<i>Definition</i>	Lot number from the amplification kit.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	String
<i>Format</i>	X[X(19)]
<i>Maximum character length</i>	20

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	For each of these codes one or more Lot numbers and associated expiry dates need to be reported. The fields need to be able to accept both letters and numbers as well as N/A (in the case of LBC extraction on a self-collected sample). Where a 'kit' includes reagents for multiple testing steps the Lot numbers and expiry dates should be repeated for each of the codes.
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H16 HPV test batch information – Amplification kit lot number
-----------------------------------	---

H16 HPV test batch information – Amplification kit expiry date

Identifying and definitional attributes

<i>Data item name</i>	HPV test batch information – Amplification kit expiry date
<i>Definition</i>	The expiry date of the amplification kit.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	For each of these codes one or more Lot numbers and associated expiry dates need to be reported. The fields need to be able to accept both letters and numbers as well as N/A (in the case of LBC extraction on a self-collected sample). Where a 'kit' includes reagents for multiple testing steps the Lot numbers and expiry dates should be repeated for each of the codes.
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H17 HPV test batch information – Amplification kit expiry date
-----------------------------------	--

H17 HPV test batch information – Detection kit lot number

Identifying and definitional attributes

<i>Data item name</i>	HPV test batch information – Detection kit lot number
<i>Definition</i>	Lot number from the detection kit.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	String
<i>Format</i>	X[X(19)]
<i>Maximum character length</i>	20

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	For each of these codes one or more Lot numbers and associated expiry dates need to be reported. The fields need to be able to accept both letters and numbers as well as N/A (in the case of LBC extraction on a self-collected sample). Where a 'kit' includes reagents for multiple testing steps the Lot numbers and expiry dates should be repeated for each of the codes.
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H18 HPV test batch information – Detection kit lot number
-----------------------------------	---

H18 HPV test batch information – Detection kit expiry date

Identifying and definitional attributes

<i>Data item name</i>	HPV test batch information – Detection kit expiry date
<i>Definition</i>	The expiry date of the detection kit.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	For each of these codes one or more Lot numbers and associated expiry dates need to be reported. The fields need to be able to accept both letters and numbers as well as N/A (in the case of LBC extraction on a self-collected sample). Where a 'kit' includes reagents for multiple testing steps the Lot numbers and expiry dates should be repeated for each of the codes.
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H19 HPV test batch information – Detection kit expiry date
-----------------------------------	--

H19 HPV test batch information – Wash buffer lot number

Identifying and definitional attributes

<i>Data item name</i>	HPV test batch information – Wash buffer lot number
<i>Definition</i>	Lot number from the wash buffer.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	String
<i>Format</i>	X[X(19)]
<i>Maximum character length</i>	20

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	For each of these codes one or more Lot numbers and associated expiry dates need to be reported. The fields need to be able to accept both letters and numbers as well as N/A (in the case of LBC extraction on a self-collected sample). Where a 'kit' includes reagents for multiple testing steps the Lot numbers and expiry dates should be repeated for each of the codes.
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H20 HPV test batch information – Wash buffer lot number
-----------------------------------	---

H20 HPV test batch information – Wash buffer expiry date

Identifying and definitional attributes

<i>Data item name</i>	HPV test batch information – Wash buffer expiry date
<i>Definition</i>	The expiry date of the wash buffer.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	For each of these codes one or more Lot numbers and associated expiry dates need to be reported. The fields need to be able to accept both letters and numbers as well as N/A (in the case of LBC extraction on a self-collected sample). Where a 'kit' includes reagents for multiple testing steps the Lot numbers and expiry dates should be repeated for each of the codes.
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> H21 HPV test batch information – Wash buffer expiry date
-----------------------------------	--

Group I: Cytology test data items

- I1 Cytology test date
- I2 Cytology test specimen type
- I3 Cytology test specimen site
- I4 Reason for cytology test
- I5 Cytology test squamous cytology cell analysis
- I6 Cytology test endocervical (glandular) cytology cell analysis
- I7 Cytology test other/non-cervical cytology cell analysis
- I8 Cytology test result

I1 Cytology test date

Identifying and definitional attributes

<i>Data item name</i>	Cytology test date
<i>Definition</i>	The date when a specimen for a cytology test was collected.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This is an important date, as it is used to determine other features of interest that occur 'at time of test', such as age at test, remoteness area and socioeconomic area of residence at time of test, HPV vaccination status at time of test, etcetera.
<i>Collection methods</i>	For a single cervical test, there can be a test request date, a test collection date, a laboratory receipt date, a laboratory report date, and a laboratory transmission date. The date of interest for reporting is the test collection date, as this is the date on which the specimen was collected. If test collection date is unknown, another date can be used instead, and will be treated as the test date. The order of priority for an alternative date is: • test request date • laboratory receipt date • laboratory report date • laboratory transmission date.
<i>Comments</i>	The National Cervical Screening Register needs to collect all dates associated with a specimen so that analyses can be performed to ensure timely progression of a specimen, for instance by determining the time between the laboratory receipt date, the laboratory report date, and the laboratory transmission date. Collected by pathology laboratories. If the cytology test is a reflex LBC, the cytology test date will be the same as the HPV test date.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> I1 Cytology test date
------------------------------------	---

I2 Cytology test specimen type

Identifying and definitional attributes

<i>Data item name</i>	Cytology test specimen type
<i>Definition</i>	An indication as to whether the cytology specimen is liquid-based cytology (LBC) or a conventional Pap test.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code										
<i>Data type</i>	String										
<i>Format</i>	AN										
<i>Maximum character length</i>	2										
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>A0</td><td>Not stated</td></tr><tr><td>A1</td><td>Conventional smear</td></tr><tr><td>A2</td><td>Liquid-based specimen</td></tr><tr><td>A3</td><td>Conventional smear and liquid-based specimen</td></tr></table>	Value	Meaning	A0	Not stated	A1	Conventional smear	A2	Liquid-based specimen	A3	Conventional smear and liquid-based specimen
Value	Meaning										
A0	Not stated										
A1	Conventional smear										
A2	Liquid-based specimen										
A3	Conventional smear and liquid-based specimen										

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	While the renewed National Cervical Screening Program uses reflex LBC as part of the screening test rather than a conventional Pap test, it is likely that some people will have a conventional Pap test after the renewed National Cervical Screening Program commences, and it is important that the National Cancer Screening Register can record details of these tests.
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> I2 Cytology test specimen type
------------------------------------	--

I3 Cytology test specimen site

Identifying and definitional attributes

<i>Data item name</i>	Cytology test specimen site
<i>Definition</i>	An indication as to the site from which the sample was collected.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code										
<i>Data type</i>	String										
<i>Format</i>	AN										
<i>Maximum character length</i>	2										
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>B0</td><td>Not stated</td></tr><tr><td>B1</td><td>Cervical</td></tr><tr><td>B2</td><td>Vaginal</td></tr><tr><td>B3</td><td>Other gynaecological site</td></tr></table>	Value	Meaning	B0	Not stated	B1	Cervical	B2	Vaginal	B3	Other gynaecological site
Value	Meaning										
B0	Not stated										
B1	Cervical										
B2	Vaginal										
B3	Other gynaecological site										

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	To code a vault smear, record B2 for item 'I3 Cytology test – specimen site' and E- for item 'I6 Cytology test – endocervical (glandular) cell analysis'
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> I3 Cytology test specimen site
------------------------------------	--

I4 Reason for cytology test

Identifying and definitional attributes

<i>Data item name</i>	Reason for cytology test
<i>Definition</i>	The reason why a cytology test is performed.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																				
<i>Data type</i>	String																				
<i>Format</i>	AX[XXX]																				
<i>Maximum character length</i>	5																				
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>C1</td><td>Reflex LBC cytology after detection of oncogenic HPV in primary screening HPV test</td></tr><tr><td>C2</td><td>Cytology after detection of oncogenic HPV in self-collected sample</td></tr><tr><td>C3</td><td>Reflex LBC after detection of oncogenic HPV in follow-up HPV test</td></tr><tr><td>C4</td><td>Cytology at colposcopy</td></tr><tr><td>C5i</td><td>Co-test – test of cure</td></tr><tr><td>C5ii</td><td>Co-test – investigation of signs or symptoms</td></tr><tr><td>C5iii</td><td>Co-test – other, as recommended in guidelines</td></tr><tr><td>C6</td><td>Other</td></tr><tr><td>CP</td><td>Conventional Pap test to screen for cervical cancer precursors</td></tr></table>	Value	Meaning	C1	Reflex LBC cytology after detection of oncogenic HPV in primary screening HPV test	C2	Cytology after detection of oncogenic HPV in self-collected sample	C3	Reflex LBC after detection of oncogenic HPV in follow-up HPV test	C4	Cytology at colposcopy	C5i	Co-test – test of cure	C5ii	Co-test – investigation of signs or symptoms	C5iii	Co-test – other, as recommended in guidelines	C6	Other	CP	Conventional Pap test to screen for cervical cancer precursors
Value	Meaning																				
C1	Reflex LBC cytology after detection of oncogenic HPV in primary screening HPV test																				
C2	Cytology after detection of oncogenic HPV in self-collected sample																				
C3	Reflex LBC after detection of oncogenic HPV in follow-up HPV test																				
C4	Cytology at colposcopy																				
C5i	Co-test – test of cure																				
C5ii	Co-test – investigation of signs or symptoms																				
C5iii	Co-test – other, as recommended in guidelines																				
C6	Other																				
CP	Conventional Pap test to screen for cervical cancer precursors																				

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	'Conventional Pap test to screen for cervical cancer precursors' has been allocated to a code of CP, as it is anticipated that, in time, this code may no longer be required, and will be subsequently dropped.
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> I4 Reason for cytology test
-----------------------------------	---

I5 Cytology test squamous cytology cell analysis

Identifying and definitional attributes

<i>Data item name</i>	Cytology test squamous cytology cell analysis
<i>Definition</i>	The squamous result of the cytology analysis.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code	
<i>Data type</i>	String	
<i>Format</i>	AX	
<i>Maximum character length</i>	2	
<i>Permissible values</i>	Value	Meaning
	S1	Cell numbers and preservation satisfactory. No abnormality or only reactive changes
	S2	Possible low-grade squamous intraepithelial lesion (LSIL)
	S3	Low-grade squamous intraepithelial lesion (LSIL) (HPV and/or CIN 1)
	S4	Possible high-grade squamous intraepithelial lesion (HSIL)
	S5	High-grade squamous intraepithelial lesion (HSIL) (CIN 2/CIN 3)
	S6	High-grade squamous intraepithelial lesion (HSIL) with possible microinvasion/invasion
	S7	Squamous carcinoma
	SU	Unsatisfactory for evaluation

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	S1 Cell numbers and preservation satisfactory. No abnormality or only reactive changes Record this code where there is no abnormality detected and cell numbers and preservation are satisfactory. S2 Possible low-grade squamous intraepithelial lesion (LSIL) This code encompasses changes in squamous cells where the reporting cytologist/pathologist believes the changes may represent a low-grade squamous intraepithelial lesion, but no definitive changes are present. S3 Low-grade squamous intraepithelial lesion (LSIL) (HPV and/or CIN 1)
----------------------	---

Record this code where the cytologist/pathologist observes changes which would have been described as HPV effect or CIN 1 (that is, incorporates HPV effect and/or CIN 1).

S4 Possible high-grade squamous intraepithelial lesion (HSIL)

Record this code when the presence of a high-grade squamous abnormality, such as CIN 2, CIN 3 or SCC is suspected, but the changes are insufficient to justify a confident cytological prediction of a high-grade lesion.

S5 High-grade squamous intraepithelial lesion (HSIL) (CIN 2/CIN 3)

Record this code where the changes observed would have previously been described as CIN 2 or CIN 3 (that is, code S5 incorporates CIN 2 and CIN 3.)

S6 High-grade squamous intraepithelial lesion (HSIL) with possible microinvasion/invasion

Record this code when a definite HSIL is present, but the possibility of invasion cannot be excluded.

S7 Squamous carcinoma

Record this when squamous carcinoma is present.

SU Unsatisfactory for evaluation

Record this code if the specimen is unable to be assessed due to poor cellularity, poor preservation, cell detail obscured by inflammation/blood/degenerate cells.

Comments

Collected by pathology laboratories.

Relational attributes

Related metadata reference

Supersedes *National Cervical Screening Program data dictionary version 1.0* I5 Cytology test squamous cytology cell analysis

I6 Cytology test endocervical (glandular) cytology cell analysis

Identifying and definitional attributes

<i>Data item name</i>	Cytology test endocervical (glandular) cytology cell analysis
<i>Definition</i>	The endocervical result of the cytology analysis.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																				
<i>Data type</i>	String																				
<i>Format</i>	AX																				
<i>Maximum character length</i>	2																				
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>E0</td><td>No endocervical component</td></tr><tr><td>E-</td><td>Not applicable: vault smear/previous hysterectomy</td></tr><tr><td>E1</td><td>Endocervical component present. No abnormality or only reactive changes</td></tr><tr><td>E2</td><td>Atypical endocervical cells of uncertain significance</td></tr><tr><td>E3</td><td>Possible high-grade endocervical glandular lesion</td></tr><tr><td>E4</td><td>Endocervical adenocarcinoma-in-situ</td></tr><tr><td>E5</td><td>Endocervical adenocarcinoma-in-situ with possible microinvasion/invasion</td></tr><tr><td>E6</td><td>Endocervical adenocarcinoma</td></tr><tr><td>EU</td><td>Due to unsatisfactory nature of the specimen, no assessment has been made</td></tr></table>	Value	Meaning	E0	No endocervical component	E-	Not applicable: vault smear/previous hysterectomy	E1	Endocervical component present. No abnormality or only reactive changes	E2	Atypical endocervical cells of uncertain significance	E3	Possible high-grade endocervical glandular lesion	E4	Endocervical adenocarcinoma-in-situ	E5	Endocervical adenocarcinoma-in-situ with possible microinvasion/invasion	E6	Endocervical adenocarcinoma	EU	Due to unsatisfactory nature of the specimen, no assessment has been made
Value	Meaning																				
E0	No endocervical component																				
E-	Not applicable: vault smear/previous hysterectomy																				
E1	Endocervical component present. No abnormality or only reactive changes																				
E2	Atypical endocervical cells of uncertain significance																				
E3	Possible high-grade endocervical glandular lesion																				
E4	Endocervical adenocarcinoma-in-situ																				
E5	Endocervical adenocarcinoma-in-situ with possible microinvasion/invasion																				
E6	Endocervical adenocarcinoma																				
EU	Due to unsatisfactory nature of the specimen, no assessment has been made																				

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	E0 No endocervical component Record this code when there is no endocervical component. E- Not applicable: vault smear/previous hysterectomy Record this code when it is a vault smear or there has been a previous total hysterectomy. E1 Endocervical component present. No abnormality or only reactive changes Record this code if no abnormality is detected and cell numbers and preservation is satisfactory. E2 Atypical endocervical cells of uncertain significance
----------------------	---

Record this code when abnormal glandular cells are identified in a cervical cytology sample, but where the degree of abnormality is not sufficient for a diagnosis of adenocarcinoma-in-situ to be made.

E3 Possible high-grade endocervical glandular lesion

Record this code if adenocarcinoma-in-situ is suspected but a confident prediction is not possible.

E4 Endocervical adenocarcinoma-in-situ

Record this code when the reporting cytologist/pathologist is confident of the presence of an adenocarcinoma-in-situ.

E5 Endocervical adenocarcinoma-in-situ with possible microinvasion /invasion

Record this code when a definite adenocarcinoma-in-situ is present, but the possibility of invasion cannot be excluded.

E6 Endocervical adenocarcinoma

Record this code when a definite adenocarcinoma is present.

EU Due to the unsatisfactory nature of the cytology specimen, no assessment has been made.

Unable to be assessed due to poor cellularity, poor preservation, cell detail obscured by blood/inflammation/degenerate cells. If a cytology specimen is sub optimal but atypical/abnormal cells are detected, the abnormality overrides the unsatisfactory coding and should be coded to reflect the abnormality detected.

Comments

Collected by pathology laboratories.

Relational attributes

Related metadata reference

Supersedes *National Cervical Screening Program data dictionary version 1.0* I6 Cytology test endocervical (glandular) cytology cell analysis

I7 Cytology test other/non-cervical cytology cell analysis

Identifying and definitional attributes

<i>Data item name</i>	Cytology test other/non-cervical cytology cell analysis
<i>Definition</i>	The other/non-cervical result from the cytology analysis.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																						
<i>Data type</i>	String																						
<i>Format</i>	AX																						
<i>Maximum character length</i>	2																						
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>O1</td><td>No other abnormal cells.</td></tr><tr><td>O2</td><td>Atypical endometrial cells of uncertain significance</td></tr><tr><td>O3</td><td>Atypical glandular cells of uncertain significance – site unknown</td></tr><tr><td>O4</td><td>Possible endometrial adenocarcinoma</td></tr><tr><td>O5</td><td>Possible high-grade lesion – non-cervical</td></tr><tr><td>O6</td><td>Malignant cells – uterine body</td></tr><tr><td>O7</td><td>Malignant cells – vagina</td></tr><tr><td>O8</td><td>Malignant cells – ovary</td></tr><tr><td>O9</td><td>Malignant cells – other</td></tr><tr><td>OU</td><td>Due to the unsatisfactory nature of the specimen, no assessment has been made</td></tr></table>	Value	Meaning	O1	No other abnormal cells.	O2	Atypical endometrial cells of uncertain significance	O3	Atypical glandular cells of uncertain significance – site unknown	O4	Possible endometrial adenocarcinoma	O5	Possible high-grade lesion – non-cervical	O6	Malignant cells – uterine body	O7	Malignant cells – vagina	O8	Malignant cells – ovary	O9	Malignant cells – other	OU	Due to the unsatisfactory nature of the specimen, no assessment has been made
Value	Meaning																						
O1	No other abnormal cells.																						
O2	Atypical endometrial cells of uncertain significance																						
O3	Atypical glandular cells of uncertain significance – site unknown																						
O4	Possible endometrial adenocarcinoma																						
O5	Possible high-grade lesion – non-cervical																						
O6	Malignant cells – uterine body																						
O7	Malignant cells – vagina																						
O8	Malignant cells – ovary																						
O9	Malignant cells – other																						
OU	Due to the unsatisfactory nature of the specimen, no assessment has been made																						

Data element attributes

Collection and usage attributes

<i>Guide for use</i>	O1 No other abnormal cells Record this code where there is no abnormality detected and cell numbers and preservation are satisfactory. O2 Atypical endometrial cells of uncertain significance Record this code where there are changes in endometrial cells, but insufficient to raise the possibility of an endometrial carcinoma. O3 Atypical glandular cells of uncertain significance – site unknown Record this code where there is uncertainty about whether the abnormal cells were endocervical or endometrial in origin. Use where changes are insufficient to raise the possibility of a neoplasm but are beyond a reactive process. O4 Possible endometrial adenocarcinoma
----------------------	---

Record this code if endometrial adenocarcinoma is suspected, but a confident prediction is not possible.

O5 Possible high-grade lesion – non cervical

Record this code if abnormal cells are present but do not appear to be cervical in origin.

O6 Malignant cells – uterine body

Record this code when malignant endometrial cells are present.

O7 Malignant cells – vagina

Record this code if malignant cells are present in a vaginal or vault cytology specimen.

O8 Malignant cells – ovary

Record this code if malignant ovarian cells are present.

O9 Malignant cells – other

Record this code if malignant cells are present which belong to none of the above categories.

OU Due to the unsatisfactory nature of the cytology specimen, no assessment has been made

Record this code when the specimen is unable to be assessed due to poor cellularity, poor preservation, cell detail obscured by blood/inflammation/degenerate cells. If a specimen is sub optimal but atypical/abnormal cells are detected, the abnormality overrides the unsatisfactory coding and should be coded to reflect the abnormality detected.

Comments

Collected by pathology laboratories.

Relational attributes

Related metadata reference

Supersedes *National Cervical Screening Program data dictionary version 1.0* 17 Cytology test other/non-cervical cytology cell analysis

I8 Cytology test result

Identifying and definitional attributes

<i>Data item name</i>	Cytology test result
<i>Definition</i>	The overall cytology result assigned to a cytology test.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code												
<i>Data type</i>	Number												
<i>Format</i>	AX												
<i>Maximum character length</i>	2												
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>DU</td><td>Unsatisfactory</td></tr><tr><td>D1</td><td>Negative</td></tr><tr><td>D2</td><td>pLSIL/LSIL</td></tr><tr><td>D3</td><td>pHSIL/HSIL+</td></tr><tr><td>D4</td><td>Any glandular abnormality</td></tr></table>	Value	Meaning	DU	Unsatisfactory	D1	Negative	D2	pLSIL/LSIL	D3	pHSIL/HSIL+	D4	Any glandular abnormality
Value	Meaning												
DU	Unsatisfactory												
D1	Negative												
D2	pLSIL/LSIL												
D3	pHSIL/HSIL+												
D4	Any glandular abnormality												

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	When cytology takes the form of a reflex LBC to be combined with an HPV test to assign a screening episode result, cytology test results are summarised into: • Unsatisfactory: I5 = SU and I6 = (EU or E- or E0 or E1) • Negative: I5 = S1 and I6 = (E- or E0 or E1) • pLSIL/LSIL: I5 = S2 or S3 and I6 < E2 • pHSIL/HSIL+: I5 = S4 or S5 or S6 or S7 and I6 < E2 • Any glandular abnormality: I6 = E2 or E3 or E4 or E5 or E6
<i>Comments</i>	Collected by pathology laboratories.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> I8 Cytology test result
-----------------------------------	---

Group J: Screening episode data items

J1	Primary screening episode commencement date
J2	Primary screening episode completion date
J3	Primary screening episode result
J4	Primary screening episode risk of significant cervical abnormality
J5	Primary screening episode recommendation
J6	Follow-up episode commencement date
J7	Follow-up episode completion date
J8	Follow-up episode result
J9	Follow-up episode risk of significant cervical abnormality
J10	Follow-up episode recommendation

J1 Primary screening episode commencement date

Identifying and definitional attributes

<i>Data item name</i>	Primary screening episode commencement date
<i>Definition</i>	The date the primary screening episode commenced.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The primary screening episode date is the date on which the sample was collected for the primary screening HPV test. Where the HPV test is on a self-collected sample and a second sample for LBC collected by a healthcare provider, the primary screening episode date should be the date of the HPV test and not the LBC test.
<i>Collection methods</i>	This date can be derived by H1 'HPV test date' where H4 'Reason for HPV test' = C1

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> J1 Primary screening episode commencement date
-----------------------------------	--

J2 Primary screening episode completion date

Identifying and definitional attributes

<i>Data item name</i>	Primary screening episode completion date
<i>Definition</i>	The date the primary screening episode was completed.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The primary screening episode completion date is the date on which there was a valid HPV test and a valid LBC test (where this is required) to allow a risk rating to be assigned. For most people the primary screening episode completion date will be identical to the primary screening episode commencement date. Where a second sample for LBC needs to be collected by a healthcare provider, either because of an unsatisfactory LBC test or because the HPV test was on a self-collected sample, there can be some time between the primary screening episode commencement date and the primary screening episode completion date.
<i>Collection methods</i>	This is a derived date.
<i>Comments</i>	This data item should be used when determining time between primary screening episode and follow-up events.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> J2 Primary screening episode completion date
-----------------------------------	--

J3 Primary screening episode result

Identifying and definitional attributes

<i>Data item name</i>	Primary screening episode result
<i>Definition</i>	The overall primary screening episode result that is a combination of an HPV test and an LBC test (where this is required).
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																														
<i>Data type</i>	String																														
<i>Format</i>	X[XX]																														
<i>Maximum character length</i>	3																														
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>U</td><td>Unsatisfactory HPV test</td></tr><tr><td>1</td><td>Oncogenic HPV not detected</td></tr><tr><td>2.X</td><td>Oncogenic HPV (not 16/18) + LBC not performed</td></tr><tr><td>2.0</td><td>Oncogenic HPV (not 16/18) + unsatisfactory LBC</td></tr><tr><td>2.1</td><td>Oncogenic HPV (not 16/18) + negative LBC</td></tr><tr><td>2.2</td><td>Oncogenic HPV (not 16/18) + pLSIL/LSIL LBC</td></tr><tr><td>2.3</td><td>Oncogenic HPV (not 16/18) + pHSIL/HSIL+ LBC</td></tr><tr><td>2.4</td><td>Oncogenic HPV (not 16/18) + any glandular abnormality LBC</td></tr><tr><td>3.X</td><td>HPV16/18 + LBC not performed</td></tr><tr><td>3.0</td><td>HPV16/18 + unsatisfactory LBC</td></tr><tr><td>3.1</td><td>HPV16/18 + negative LBC</td></tr><tr><td>3.2</td><td>HPV16/18 + pLSIL/LSIL LBC</td></tr><tr><td>3.3</td><td>HPV16/18 + pHSIL/HSIL+ LBC</td></tr><tr><td>3.4</td><td>HPV16/18 + any glandular abnormality LBC</td></tr></table>	Value	Meaning	U	Unsatisfactory HPV test	1	Oncogenic HPV not detected	2.X	Oncogenic HPV (not 16/18) + LBC not performed	2.0	Oncogenic HPV (not 16/18) + unsatisfactory LBC	2.1	Oncogenic HPV (not 16/18) + negative LBC	2.2	Oncogenic HPV (not 16/18) + pLSIL/LSIL LBC	2.3	Oncogenic HPV (not 16/18) + pHSIL/HSIL+ LBC	2.4	Oncogenic HPV (not 16/18) + any glandular abnormality LBC	3.X	HPV16/18 + LBC not performed	3.0	HPV16/18 + unsatisfactory LBC	3.1	HPV16/18 + negative LBC	3.2	HPV16/18 + pLSIL/LSIL LBC	3.3	HPV16/18 + pHSIL/HSIL+ LBC	3.4	HPV16/18 + any glandular abnormality LBC
Value	Meaning																														
U	Unsatisfactory HPV test																														
1	Oncogenic HPV not detected																														
2.X	Oncogenic HPV (not 16/18) + LBC not performed																														
2.0	Oncogenic HPV (not 16/18) + unsatisfactory LBC																														
2.1	Oncogenic HPV (not 16/18) + negative LBC																														
2.2	Oncogenic HPV (not 16/18) + pLSIL/LSIL LBC																														
2.3	Oncogenic HPV (not 16/18) + pHSIL/HSIL+ LBC																														
2.4	Oncogenic HPV (not 16/18) + any glandular abnormality LBC																														
3.X	HPV16/18 + LBC not performed																														
3.0	HPV16/18 + unsatisfactory LBC																														
3.1	HPV16/18 + negative LBC																														
3.2	HPV16/18 + pLSIL/LSIL LBC																														
3.3	HPV16/18 + pHSIL/HSIL+ LBC																														
3.4	HPV16/18 + any glandular abnormality LBC																														

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	An HPV test is the primary screening test of the renewed National Cervical Screening Program. However, this is used in conjunction with partial genotyping of the HPV test to distinguish between oncogenic HPV 16/18 and oncogenic HPV (not 16/18), as well as triage of all oncogenic HPV results (16/18 and not 16/18) with reflex liquid-based cytology (LBC). This means that the overall screening episode result is a combination of the primary screening HPV test result and the LBC result (where performed). It also means that it is possible for a person to have an incomplete screening episode (and therefore no overall result or risk rating assigned). This can be either due to an unsatisfactory HPV test or
----------------------	---

	LBC test (in which case this can be rectified by a repeat test), or due to a person with a self-collected sample testing positive for HPV who then did not have a sample collected for the reflex LBC test. Complete primary screening episode results are comprised of an HPV test result and (unless the result was 'oncogenic HPV not detected') a reflex LBC test result.
<i>Collection methods</i>	Primary screening HPV test results and LBC test results are derived from the HPV test and cytology test sections.
<i>Comments</i>	Categories that include 'not performed' or 'unsatisfactory' can change as tests that are required are performed. This means that more than one primary screening episode result will need to be able to be collected within each screening round. The primary screening episode is not complete until receipt of a valid test, or after a specified period of time if no test result is received.
Relational attributes	
<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> J3 Primary screening episode result

J4 Primary screening episode risk of significant cervical abnormality

Identifying and definitional attributes

<i>Data item name</i>	Primary screening episode risk of significant cervical abnormality
<i>Definition</i>	Risk of significant cervical abnormality determined from a primary screening episode result, comprised of a primary HPV test with partial genotyping and LBC triage (where this is required).
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code										
<i>Data type</i>	String										
<i>Format</i>	AX										
<i>Maximum character length</i>	2										
<i>Permissible values</i>	<table><thead><tr><th>Value</th><th>Meaning</th></tr></thead><tbody><tr><td>RU</td><td>Unsatisfactory</td></tr><tr><td>R1</td><td>Low risk</td></tr><tr><td>R2</td><td>Intermediate risk</td></tr><tr><td>R3</td><td>Higher risk</td></tr></tbody></table>	Value	Meaning	RU	Unsatisfactory	R1	Low risk	R2	Intermediate risk	R3	Higher risk
Value	Meaning										
RU	Unsatisfactory										
R1	Low risk										
R2	Intermediate risk										
R3	Higher risk										

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This primary screening episode result is used to assign a risk of significant cervical abnormality. This is based on the test results from this screening episode only and does not take into consideration previous test results or other screening history.
<i>Collection methods</i>	Risk is allocated as follows: RU Unsatisfactory: J3 'Primary screening episode result' = U or 2.0 R1 Low risk: J3 'Primary screening episode result' = 1 R2 Intermediate risk: J3 'Primary screening episode result' = 2.1 or 2.2 R3 Higher risk: J3 'Primary screening episode result' = 2.3, 2.4, 3.X, 3.0, 3.1, 3.2, 3.3, or 3.4.
<i>Comments</i>	Risk is unable to be assigned for 2.X.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> J4 Primary screening episode risk of significant cervical abnormality
-----------------------------------	---

J5 Primary screening episode recommendation

Identifying and definitional attributes

<i>Data item name</i>	Primary screening episode recommendation
<i>Definition</i>	The appropriate management based on the risk level of the primary screening episode result.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																										
<i>Data type</i>	String																										
<i>Format</i>	AXX																										
<i>Maximum character length</i>	3																										
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>M0</td><td>No recommendation</td></tr><tr><td>M1</td><td>Rescreen in 5 years</td></tr><tr><td>M2</td><td>Rescreen in 3 years</td></tr><tr><td>M3</td><td>Repeat HPV test in 12 months</td></tr><tr><td>M4</td><td>Co-test in 12 months</td></tr><tr><td>M5</td><td>Retest in 6 weeks</td></tr><tr><td>M6</td><td>Refer for colposcopic assessment</td></tr><tr><td>M7</td><td>Test taken at time of colposcopy, no recommendation</td></tr><tr><td>M8</td><td>Discharge from program</td></tr><tr><td>M9</td><td>Other management recommendation</td></tr><tr><td>MS</td><td>Symptomatic – clinical management required</td></tr><tr><td>MP</td><td>Rescreen in 2 years</td></tr></table>	Value	Meaning	M0	No recommendation	M1	Rescreen in 5 years	M2	Rescreen in 3 years	M3	Repeat HPV test in 12 months	M4	Co-test in 12 months	M5	Retest in 6 weeks	M6	Refer for colposcopic assessment	M7	Test taken at time of colposcopy, no recommendation	M8	Discharge from program	M9	Other management recommendation	MS	Symptomatic – clinical management required	MP	Rescreen in 2 years
Value	Meaning																										
M0	No recommendation																										
M1	Rescreen in 5 years																										
M2	Rescreen in 3 years																										
M3	Repeat HPV test in 12 months																										
M4	Co-test in 12 months																										
M5	Retest in 6 weeks																										
M6	Refer for colposcopic assessment																										
M7	Test taken at time of colposcopy, no recommendation																										
M8	Discharge from program																										
M9	Other management recommendation																										
MS	Symptomatic – clinical management required																										
MP	Rescreen in 2 years																										

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	Determined by pathology laboratories as per clinical management guidelines and incorporating screening history.
---------------------------	---

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> J5 Primary screening episode recommendation
-----------------------------------	---

J6 Follow-up episode commencement date

Identifying and definitional attributes

<i>Data item name</i>	Follow-up episode commencement date
<i>Definition</i>	The date the follow-up episode commenced.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The follow-up episode date is the date on which the sample was collected for the follow-up HPV test.
<i>Collection methods</i>	This date can be derived by H1 'HPV test date' where H4 'Reason for HPV test' = 2.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> J6 Follow-up episode commencement date
-----------------------------------	--

J7 Follow-up episode completion date

Identifying and definitional attributes

<i>Data item name</i>	Follow-up episode completion date
<i>Definition</i>	The date the follow-up episode was completed.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The follow-up episode completion date is the date on which there was a valid HPV test and a valid LBC test (where this is required) to allow a risk rating to be assigned. For most people the follow-up episode completion date will be identical to or similar to the follow-up episode commencement date. Where a second sample for LBC needs to be collected by a healthcare provider, either because of an unsatisfactory LBC test or because the HPV test was on a self-collected sample (noting that it is preferable that the sample for a follow-up test is clinician-collected rather than self-collected), there can be some time between the follow-up episode commencement date and the follow-up episode completion date.
<i>Collection methods</i>	This is a derived date.
<i>Comments</i>	'When follow-up HPV testing is required after an initial positive oncogenic HPV test result, the sample should be collected by a clinician, where possible. Participants should be advised that a clinician-collected sample is preferred because it is more effective and reflex LBC can be performed on the same sample, which avoids a further visit to collect a cervical sample for LBC. If the participant declines the clinician-collected sample, they can have a self-collected sample and are eligible for reimbursement under the Medical Benefits Schedule.' (Cancer Council Australia and Cervical Cancer Screening Guidelines Working Party 2016)

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> J7 Follow-up episode completion date
-----------------------------------	--

J8 Follow-up episode result

Identifying and definitional attributes

<i>Data item name</i>	Follow-up episode result
<i>Definition</i>	The follow-up episode result is a combination of an HPV test and an LBC test (where this is performed), where the HPV test is a repeat HPV test performed 12 months after the screening episode.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code																														
<i>Data type</i>	String																														
<i>Format</i>	X[XX]																														
<i>Maximum character length</i>	3																														
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>U</td><td>Unsatisfactory HPV test</td></tr><tr><td>1</td><td>Oncogenic HPV not detected</td></tr><tr><td>2.X</td><td>Oncogenic HPV (not 16/18) + LBC not performed</td></tr><tr><td>2.0</td><td>Oncogenic HPV (not 16/18) + unsatisfactory LBC</td></tr><tr><td>2.1</td><td>Oncogenic HPV (not 16/18) + negative LBC</td></tr><tr><td>2.2</td><td>Oncogenic HPV (not 16/18) + pLSIL/LSIL LBC</td></tr><tr><td>2.3</td><td>Oncogenic HPV (not 16/18) + pHSIL/HSIL+ LBC</td></tr><tr><td>2.4</td><td>Oncogenic HPV (not 16/18) + any glandular abnormality LBC</td></tr><tr><td>3.X</td><td>HPV16/18 + LBC not performed</td></tr><tr><td>3.0</td><td>HPV16/18 + unsatisfactory LBC</td></tr><tr><td>3.1</td><td>HPV16/18 + negative LBC</td></tr><tr><td>3.2</td><td>HPV16/18 + pLSIL/LSIL LBC</td></tr><tr><td>3.3</td><td>HPV16/18 + pHSIL/HSIL+ LBC</td></tr><tr><td>3.4</td><td>HPV16/18 + any glandular abnormality LBC</td></tr></table>	Value	Meaning	U	Unsatisfactory HPV test	1	Oncogenic HPV not detected	2.X	Oncogenic HPV (not 16/18) + LBC not performed	2.0	Oncogenic HPV (not 16/18) + unsatisfactory LBC	2.1	Oncogenic HPV (not 16/18) + negative LBC	2.2	Oncogenic HPV (not 16/18) + pLSIL/LSIL LBC	2.3	Oncogenic HPV (not 16/18) + pHSIL/HSIL+ LBC	2.4	Oncogenic HPV (not 16/18) + any glandular abnormality LBC	3.X	HPV16/18 + LBC not performed	3.0	HPV16/18 + unsatisfactory LBC	3.1	HPV16/18 + negative LBC	3.2	HPV16/18 + pLSIL/LSIL LBC	3.3	HPV16/18 + pHSIL/HSIL+ LBC	3.4	HPV16/18 + any glandular abnormality LBC
Value	Meaning																														
U	Unsatisfactory HPV test																														
1	Oncogenic HPV not detected																														
2.X	Oncogenic HPV (not 16/18) + LBC not performed																														
2.0	Oncogenic HPV (not 16/18) + unsatisfactory LBC																														
2.1	Oncogenic HPV (not 16/18) + negative LBC																														
2.2	Oncogenic HPV (not 16/18) + pLSIL/LSIL LBC																														
2.3	Oncogenic HPV (not 16/18) + pHSIL/HSIL+ LBC																														
2.4	Oncogenic HPV (not 16/18) + any glandular abnormality LBC																														
3.X	HPV16/18 + LBC not performed																														
3.0	HPV16/18 + unsatisfactory LBC																														
3.1	HPV16/18 + negative LBC																														
3.2	HPV16/18 + pLSIL/LSIL LBC																														
3.3	HPV16/18 + pHSIL/HSIL+ LBC																														
3.4	HPV16/18 + any glandular abnormality LBC																														

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The overall follow-up episode result is a combination of the follow-up HPV test result and the LBC result (where performed).
----------------------	--

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> J8 Follow-up episode result
-----------------------------------	---

J9 Follow-up episode risk of significant cervical abnormality

Identifying and definitional attributes

<i>Data item name</i>	Follow-up episode risk of significant cervical abnormality
<i>Definition</i>	Risk of significant cervical abnormality determined from a follow-up episode result, comprised of a primary HPV test with partial genotyping and LBC triage.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code										
<i>Data type</i>	String										
<i>Format</i>	AX										
<i>Maximum character length</i>	2										
<i>Permissible values</i>	<table><thead><tr><th>Value</th><th>Meaning</th></tr></thead><tbody><tr><td>RU</td><td>Unsatisfactory</td></tr><tr><td>R1</td><td>Low risk</td></tr><tr><td>R2</td><td>Intermediate risk</td></tr><tr><td>R3</td><td>Higher risk</td></tr></tbody></table>	Value	Meaning	RU	Unsatisfactory	R1	Low risk	R2	Intermediate risk	R3	Higher risk
Value	Meaning										
RU	Unsatisfactory										
R1	Low risk										
R2	Intermediate risk										
R3	Higher risk										

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	An HPV test is used in conjunction with partial genotyping of the HPV test to distinguish between oncogenic HPV 16/18 and oncogenic HPV (not 16/18), as well as triage of all oncogenic HPV test results with reflex liquid-based cytology (LBC). This means that the overall final follow-up episode result is a combination of the follow-up HPV test result and the LBC result (where performed). This combined follow-up episode result is used to assign a risk of significant cervical abnormality. This is based on the test results from this follow-up episode only, and does not take into consideration previous test results or other screening history
<i>Collection methods</i>	For the first follow-up HPV test after intermediate risk screening episode, risk should be allocated as: RU Unsatisfactory: J8 'Follow-up episode result' = U R1 Low risk: J8 'Follow-up episode result' = 1 R2 Intermediate risk: J8 'Follow-up episode result' = 2.1 or 2.2 for people who were not overdue for screening by at least 2 years prior to their intermediate risk screening episode, are not Aboriginal and/or Torres Strait Islander, and are not aged 50 or older. R3 Higher risk: J8 'Follow-up episode result' = 2.3, 2.4, 3.X, 3.0, 3.1, 3.2, 3.3, or 3.4; OR J8 'Follow-up episode result' value other than U or 1 for people who were overdue for screening by at least

2 years prior to their intermediate risk screening episode, are Aboriginal and/or Torres Strait Islander, or are aged 50 or older.

For the second follow-up HPV test after intermediate risk screening episode, risk should be allocated as:

RU Unsatisfactory: J8 'Follow-up episode result' = U

R1 Low risk: J8 'Follow-up episode result' = 1

R3 Higher risk: J8 'Follow-up episode result' value other than U or 1

Comments

From 1 February 2021, clinical management for people who, at follow-up HPV test, had oncogenic HPV (not 16/18) detected with a reflex LBC of negative or pLSIL/LSIL and were not overdue for screening by at least 2 years prior to their intermediate risk screening episode, are not Aboriginal and/or Torres Strait Islander, and are not aged 50 or older, are recommended to have a further follow-up HPV test in another 12 months instead of being referred for colposcopy.

Relational attributes

Related metadata reference

Supersedes *National Cervical Screening Program data dictionary version 1.0* J9 Follow-up episode risk of significant cervical abnormality

J10 Follow-up episode recommendation

Identifying and definitional attributes

<i>Data item name</i>	Follow-up episode recommendation
<i>Definition</i>	The appropriate management based on the risk level of the follow-up episode result.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																										
<i>Data type</i>	String																										
<i>Format</i>	AX																										
<i>Maximum character length</i>	2																										
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>M0</td><td>No recommendation</td></tr><tr><td>M1</td><td>Rescreen in 5 years</td></tr><tr><td>M2</td><td>Rescreen in 3 years</td></tr><tr><td>M3</td><td>Repeat HPV test in 12 months</td></tr><tr><td>M4</td><td>Co-test in 12 months</td></tr><tr><td>M5</td><td>Retest in 6 weeks</td></tr><tr><td>M6</td><td>Refer for colposcopic assessment</td></tr><tr><td>M7</td><td>Test taken at time of colposcopy, no recommendation</td></tr><tr><td>M8</td><td>Discharge from program</td></tr><tr><td>M9</td><td>Other management recommendation</td></tr><tr><td>MS</td><td>Symptomatic – clinical management required</td></tr><tr><td>MP</td><td>Rescreen in 2 years</td></tr></table>	Value	Meaning	M0	No recommendation	M1	Rescreen in 5 years	M2	Rescreen in 3 years	M3	Repeat HPV test in 12 months	M4	Co-test in 12 months	M5	Retest in 6 weeks	M6	Refer for colposcopic assessment	M7	Test taken at time of colposcopy, no recommendation	M8	Discharge from program	M9	Other management recommendation	MS	Symptomatic – clinical management required	MP	Rescreen in 2 years
Value	Meaning																										
M0	No recommendation																										
M1	Rescreen in 5 years																										
M2	Rescreen in 3 years																										
M3	Repeat HPV test in 12 months																										
M4	Co-test in 12 months																										
M5	Retest in 6 weeks																										
M6	Refer for colposcopic assessment																										
M7	Test taken at time of colposcopy, no recommendation																										
M8	Discharge from program																										
M9	Other management recommendation																										
MS	Symptomatic – clinical management required																										
MP	Rescreen in 2 years																										

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	Determined by pathology laboratories as per clinical management guidelines and incorporating screening history.
---------------------------	---

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> J10 Follow-up episode recommendation
-----------------------------------	--

Group K: Colposcopy data items

K1	Date of colposcopy episode
K2	Indication for colposcopy
K3	Indication for colposcopy – other indication free text
K4	General colposcopic assessment – adequacy
K5	General colposcopic assessment – transformation zone visibility
K6	Colposcopic impression – primary diagnosis
K7	Colposcopy impression – other finding free text
K8	Biopsy this episode
K9	Pregnant at time of colposcopy
K10	Colposcopy data source

K1 Date of colposcopy episode

Identifying and definitional attributes

<i>Data item name</i>	Date of colposcopy episode
<i>Definition</i>	The date when a colposcopy or treatment was performed.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Collection method</i>	Colposcopy Data Collection Form.
--------------------------	----------------------------------

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> K2 Date of colposcopy episode
-----------------------------------	---

K2 Indication for colposcopy

Identifying and definitional attributes

<i>Data item name</i>	Indication for colposcopy
<i>Definition</i>	Clinical indication as to why colposcopy was performed.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																
<i>Data type</i>	Number																
<i>Format</i>	AN																
<i>Maximum character length</i>	2																
<i>Permissible values:</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>C0</td><td>Not performed</td></tr><tr><td>C1</td><td>New patient with abnormal cervical screening result</td></tr><tr><td>C2</td><td>Follow-up of patient with previous abnormal cervical screening result</td></tr><tr><td>C3</td><td>Symptomatic</td></tr><tr><td>C4</td><td>Abnormal appearance of cervix</td></tr><tr><td>C5</td><td>At time of treatment</td></tr><tr><td>C6</td><td>Other</td></tr></table>	Value	Meaning	C0	Not performed	C1	New patient with abnormal cervical screening result	C2	Follow-up of patient with previous abnormal cervical screening result	C3	Symptomatic	C4	Abnormal appearance of cervix	C5	At time of treatment	C6	Other
Value	Meaning																
C0	Not performed																
C1	New patient with abnormal cervical screening result																
C2	Follow-up of patient with previous abnormal cervical screening result																
C3	Symptomatic																
C4	Abnormal appearance of cervix																
C5	At time of treatment																
C6	Other																

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This item refers to the reason for undertaking the current colposcopy.
<i>Collection methods</i>	Colposcopy Data Collection Form.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> K3 Indication for colposcopy
-----------------------------------	--

K3 Indication for colposcopy – other indication free text

Identifying and definitional attributes

<i>Data item name</i>	Indication for colposcopy – other indication free text
<i>Definition</i>	Clinical indication as to why colposcopy was performed if not one of the coded options in 'Indication for colposcopy'.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Text
<i>Data type</i>	String
<i>Format</i>	[X(250)]
<i>Maximum character length</i>	250

Data item attributes

Collection and usage attributes

<i>Rules for use</i>	If K2 'Indication for colposcopy' = C6 ('Other'), then K3 'Indication for colposcopy – other indication free text' should not be NULL.
<i>Collection methods</i>	Colposcopy Data Collection Form.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> K4 Indication for colposcopy – other indication free text
-----------------------------------	---

K4 General colposcopic assessment – adequacy

Identifying and definitional attributes

<i>Data item name</i>	General colposcopic assessment – adequacy
<i>Definition</i>	An indication as to whether the colposcopy was adequate or inadequate.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code						
<i>Data type</i>	Number						
<i>Format</i>	AN						
<i>Maximum character length</i>	2						
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>Q0</td><td>Inadequate</td></tr><tr><td>Q1</td><td>Adequate</td></tr></table>	Value	Meaning	Q0	Inadequate	Q1	Adequate
Value	Meaning						
Q0	Inadequate						
Q1	Adequate						

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	'Adequate' indicates that the view of the cervix is not obscured. 'Inadequate' indicates that the cervix cannot be adequately visualised, for example due to inflammation, bleeding, atrophy, or scar tissue.
<i>Collection methods</i>	Colposcopy Data Collection Form.
<i>Comments</i>	The terms 'satisfactory' and 'unsatisfactory' for describing a colposcopy have been replaced with a two-tiered system. The first tier relates to the visibility of the cervix, either adequate for the reason or inadequate if it is obscured, such as by blood, inflammation, or scarring, and is the colposcopic assessment captured in this data item. The second tier relates to the visibility of the transformation zone. A Type 1 transformation zone is completely visible and the squamocolumnar junction is completely seen. A Type 2 transformation zone is also completely visible and the squamocolumnar junction is in the endocervical canal, but can be seen. A Type 3 transformation zone is not completely visible and the squamocolumnar junction cannot be seen.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> K5 General colposcopic assessment – adequacy
-----------------------------------	--

K5 General colposcopic assessment – transformation zone visibility

Identifying and definitional attributes

<i>Data item name</i>	General colposcopic assessment – transformation zone visibility
<i>Definition</i>	An indication as to whether the transformation zone and/or squamocolumnar junction is visible.
<i>Collection status</i>	Essential (if colposcopy is adequate)

Value domain attributes

<i>Representation class</i>	Code								
<i>Data type</i>	String								
<i>Format</i>	AAN								
<i>Maximum character length</i>	3								
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>TZ1</td><td>Type 1 transformation zone</td></tr><tr><td>TZ2</td><td>Type 2 transformation zone</td></tr><tr><td>TZ3</td><td>Type 3 transformation zone</td></tr></table>	Value	Meaning	TZ1	Type 1 transformation zone	TZ2	Type 2 transformation zone	TZ3	Type 3 transformation zone
Value	Meaning								
TZ1	Type 1 transformation zone								
TZ2	Type 2 transformation zone								
TZ3	Type 3 transformation zone								

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	'Type 1 transformation zone' indicates that the transformation zone is entirely visible and the squamocolumnar junction is seen. 'Type 2 transformation zone' indicates that the transformation zone extends into the endocervical canal, but the squamocolumnar junction is seen. 'Type 3 transformation zone' indicates that the transformation zone extends into the endocervical canal and either the entire squamocolumnar junction is not seen or the upper limit of the squamocolumnar junction is not seen. A transformation zone type should only be indicated if the colposcopy is considered adequate.
<i>Rules for use</i>	(i) If K4 'General colposcopic assessment – adequacy' = 0 ('Inadequate') then K5 'General colposcopic assessment – transformation zone visibility' should be NULL. (ii) If K4 'General colposcopic assessment – adequacy' = 1 ('Adequate') then K5 'General colposcopic assessment – transformation zone visibility' should not be NULL.
<i>Collection methods</i>	Colposcopy Data Collection Form.
<i>Comments</i>	The terms 'satisfactory' and 'unsatisfactory' for describing a colposcopy have been replaced with a two-tiered system. The first tier relates to the visibility of the cervix, either adequate for the reason or inadequate if it is obscured, such as by blood, inflammation, or scarring.

The second tier relates to the visibility of the transformation zone and is the colposcopic assessment captured in this data item. A Type 1 transformation zone is completely visible and the squamocolumnar junction is completely seen. A Type 2 transformation zone is also completely visible and the squamocolumnar junction is in the endocervical canal, but can be seen. A Type 3 transformation zone is not completely visible and the squamocolumnar junction cannot be seen.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> K6 General colposcopic assessment – transformation zone visibility
-----------------------------------	--

K6 Colposcopic impression – primary diagnosis

Identifying and definitional attributes

<i>Data item name</i>	Colposcopic impression – primary diagnosis
<i>Definition</i>	The clinical diagnosis or impression formed at time of colposcopy.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																
<i>Data type</i>	String																
<i>Format</i>	AN																
<i>Maximum character length</i>	2																
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>D1</td><td>Normal</td></tr><tr><td>D2</td><td>No visible lesion</td></tr><tr><td>D3</td><td>LSIL</td></tr><tr><td>D4</td><td>HSIL</td></tr><tr><td>D5</td><td>Glandular abnormality (adenocarcinoma-in-situ)</td></tr><tr><td>D6</td><td>Cancer</td></tr><tr><td>D7</td><td>Other</td></tr></table>	Value	Meaning	D1	Normal	D2	No visible lesion	D3	LSIL	D4	HSIL	D5	Glandular abnormality (adenocarcinoma-in-situ)	D6	Cancer	D7	Other
Value	Meaning																
D1	Normal																
D2	No visible lesion																
D3	LSIL																
D4	HSIL																
D5	Glandular abnormality (adenocarcinoma-in-situ)																
D6	Cancer																
D7	Other																

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	It is usual for a colposcopist to make a clinical diagnosis/impression and record this impression as the 'result' or diagnosis. This 'diagnosis' is usually made in the terms related to the likely histological outcome or biopsy result. The correlation between the colposcopic diagnosis and the final histological diagnosis is one of the standards for assessment of the colposcopist's diagnostic skill and is used for quality improvement programs. Colposcopists will have the capacity to choose 2–3 impressions as well as the 'Other' category. The National Cancer Screening Register will use rules to determine which impression is recorded (usually the 'worse' finding).
<i>Rules for use</i>	Required if General Colposcopic Assessment is adequate AND transformation zone is Type 1 or 2. (i) If K4 'General colposcopic assessment – adequacy' = 0 ('Inadequate') then K6 'Colposcopic impression – primary diagnosis' should be NULL. (ii) If K4 'General colposcopic assessment – adequacy' = 1 ('Adequate') AND K5 'General colposcopic assessment – transformation zone visibility' = 1 or 2 (Type 1 or Type 2 transformation zone) then K6 'Colposcopic impression – primary diagnosis' should not be NULL.

(iii) If K4 'General colposcopic assessment – adequacy' = 1 ('Adequate') AND K5 'General colposcopic assessment – transformation zone visibility' = 3 ('Type 3') then K6 'Colposcopic impression – primary diagnosis' cannot = 1 ('Normal').

Collection methods

Colposcopy Data Collection Form.

Relational attributes

Related metadata reference

Supersedes *National Cervical Screening Program data dictionary version 1.0* K7 Colposcopic impression – primary diagnosis

K7 Colposcopic impression – other finding free text

Identifying and definitional attributes

<i>Data item name</i>	Colposcopic impression – other finding free text
<i>Definition</i>	Clinical diagnosis or impression formed at time of colposcopy if not one of the coded options in 'Colposcopic impression – primary diagnosis'.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Text
<i>Data type</i>	String
<i>Format</i>	[A(250)]
<i>Maximum character length</i>	250

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	It is usual for a colposcopist to make a clinical diagnosis/impression and record this impression as the 'result' or diagnosis. This 'diagnosis' is usually made in the terms related to the likely histological outcome or biopsy result. This data item is available for a colposcopist to record a colposcopic impression other than those coded in K6 'Colposcopic impression – primary diagnosis' using free text. Colposcopists will have the capacity to choose 2–3 impressions as well as the 'Other' category. The National Cancer Screening Register will use rules to determine which impression is recorded (usually the 'worse' finding).
<i>Rules for use</i>	If K6 'Colposcopic impression – primary diagnosis' = 7 ('Other'), then K7 'Colposcopic impression – other finding free text' should not be NULL.
<i>Collection methods</i>	Colposcopy Data Collection Form.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> K8 Colposcopic impression – other finding free text
-----------------------------------	---

K8 Biopsy this episode

Identifying and definitional attributes

<i>Data item name</i>	Biopsy this episode
<i>Definition</i>	An indication as to whether a biopsy was performed as part of the colposcopy episode.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code						
<i>Data type</i>	String						
<i>Format</i>	AN						
<i>Maximum character length</i>	2						
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>B0</td><td>No – biopsy not performed</td></tr><tr><td>B1</td><td>Yes – biopsy performed</td></tr></table>	Value	Meaning	B0	No – biopsy not performed	B1	Yes – biopsy performed
Value	Meaning						
B0	No – biopsy not performed						
B1	Yes – biopsy performed						

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	Colposcopy Data Collection Form.
---------------------------	----------------------------------

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> K9 Biopsy this episode
-----------------------------------	--

K9 Pregnant at time of colposcopy

Identifying and definitional attributes

<i>Data item name</i>	Pregnant at time of colposcopy
<i>Definition</i>	An indication as to whether the person was pregnant at the time of the colposcopy.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code						
<i>Data type</i>	String						
<i>Format</i>	AN						
<i>Maximum character length</i>	2						
<i>Permissible values</i>	<table><thead><tr><th>Value</th><th>Meaning</th></tr></thead><tbody><tr><td>P0</td><td>Not pregnant</td></tr><tr><td>P1</td><td>Pregnant</td></tr></tbody></table>	Value	Meaning	P0	Not pregnant	P1	Pregnant
Value	Meaning						
P0	Not pregnant						
P1	Pregnant						

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	A person should be recorded as pregnant either as a result of a blood or urine test or if they indicate to the colposcopist verbally or in writing that they are pregnant.
<i>Comment</i>	While it is considered safe to have a colposcopy, there may be some procedures that are not performed, either at the person's request, or at the discretion of the colposcopist.
<i>Collection methods</i>	Colposcopy Data Collection Form.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> K10 Pregnancy flag
-----------------------------------	--

K10 Colposcopy data source

Identifying and definitional attributes

<i>Data item name</i>	Colposcopy data source
<i>Definition</i>	An indication from where the colposcopy data are sourced
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code												
<i>Data type</i>	Number												
<i>Format</i>	N												
<i>Maximum character length</i>	1												
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>1</td><td>Colposcopy Data Collection Form</td></tr><tr><td>2</td><td>MBS</td></tr><tr><td>3</td><td>Abnormal result questionnaire</td></tr><tr><td>4</td><td>Histology</td></tr><tr><td>9</td><td>Unknown</td></tr></table>	Value	Meaning	1	Colposcopy Data Collection Form	2	MBS	3	Abnormal result questionnaire	4	Histology	9	Unknown
Value	Meaning												
1	Colposcopy Data Collection Form												
2	MBS												
3	Abnormal result questionnaire												
4	Histology												
9	Unknown												

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This data item is derived by the AIHW for use in performance indicator reporting that requires colposcopy data. There are four sources of information that a colposcopy has occurred across National Cancer Screening Register data tables. '1 Colposcopy Data Collection Form' indicates that the source is the colposcopy form that is completed and provided to the NCSR. This is the only source that can have all colposcopy and treatment data items populated. '2 MBS' indicates that the source is the Medicare Benefits Scheme. The only data item that can be populated when MBS is the source is 'K1 Date of colposcopy episode'. '3 Abnormal result questionnaire' indicates that the source is the Abnormal result questionnaire. Data items that can be populated from this source are 'K1 Date of colposcopy episode', 'K8 Biopsy this episode' and 'K9 Pregnancy flag'. '4 Histology' indicates that the source is histology data, since if a histological sample was collected there must have been a colposcopy. The only data item that can be populated when histology is the source is 'K1 Date of colposcopy episode'. '9 Unknown' indicates the source of the colposcopy is unknown.
----------------------	--

<i>Comment</i>	This does not prescribe how others collect and use colposcopy data, only how the AIHW collect and use colposcopy data.
<i>Collection methods</i>	Where there is more than one data source for a single colposcopy, an order of priority is used to allow the most information to be collected about the colposcopy. The order of priority would be to select a colposcopy form record over an MBS record, as a greater number of colposcopy and treatment data items can be populated.

Relational attributes

<i>Related metadata reference</i>	New data item
-----------------------------------	---------------

Group L: Histology test data items

L1	Histology test date
L2	Histology test specimen site
L3	Procedure used for obtaining specimen for histological analysis
L4	Squamous histology cell analysis
L5	Endocervical (glandular) histology cell analysis
L6	Other/non-cervical histology cell analysis
L7	Histology test result
L8	Histology report text
L9	Histology stain
L10	Histology stain result
L11	Histology data source

L1 Histology test date

Identifying and definitional attributes

<i>Data item name</i>	Histology test date
<i>Definition</i>	The date when a histology specimen was collected.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	DDMMYYYY
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This is an important date, as it is used to determine other features of interest that occur 'at time of test', such as age at test. For a single cervical test, there can be a test request date, a test collection date, a laboratory receipt date, a laboratory report date, and a laboratory transmission date. The date of interest for reporting is the test collection date, as this is the date on which the specimen was collected. If test collection date is unknown, another date can be used instead, and will be treated as the test date. The order of priority for an alternative date is: • test request date • laboratory receipt date • laboratory report date • laboratory transmission date.
<i>Comments</i>	Registers need to collect all dates to ensure timely progression of a specimen, for instance by determining the time between the laboratory receipt date, the laboratory report date, and the laboratory transmission date.
<i>Collection methods</i>	Pathology laboratories

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> L1 Histology test date
-----------------------------------	--

L2 Histology test specimen site

Identifying and definitional attributes

<i>Data item name</i>	Histology test specimen site
<i>Definition</i>	The site from where a histology specimen has been collected.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code										
<i>Data type</i>	String										
<i>Format</i>	AN										
<i>Maximum character length</i>	2										
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>B0</td><td>Not stated</td></tr><tr><td>B1</td><td>Cervical</td></tr><tr><td>B2</td><td>Vaginal</td></tr><tr><td>B3</td><td>Other gynaecological site</td></tr></table>	Value	Meaning	B0	Not stated	B1	Cervical	B2	Vaginal	B3	Other gynaecological site
Value	Meaning										
B0	Not stated										
B1	Cervical										
B2	Vaginal										
B3	Other gynaecological site										

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Cervical specimen includes all cervical histology including cervical polyps and cervical samples obtained during hysterectomies for benign conditions.
<i>Collection methods</i>	Pathology laboratories

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> L2 Histology test specimen site
-----------------------------------	---

L3 Procedure used for obtaining specimen for histological analysis

Identifying and definitional attributes

<i>Data item name</i>	Procedure used for obtaining specimen for histological analysis
<i>Definition</i>	The type of procedure used to collect a gynaecological specimen for histological analysis for the purpose of assessment of cancer or pre-cancerous changes.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																				
<i>Data type</i>	String																				
<i>Format</i>	AN																				
<i>Maximum character length</i>	2																				
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>A1</td><td>Biopsy (includes directed punch and random punch)</td></tr><tr><td>A2</td><td>Endocervical curettage (includes endocervical tissue obtained during D&C)</td></tr><tr><td>A3</td><td>LLETZ/LEEP loop biopsy</td></tr><tr><td>A4</td><td>Cone biopsy</td></tr><tr><td>A5</td><td>Polypectomy</td></tr><tr><td>A6</td><td>Subtotal hysterectomy</td></tr><tr><td>A7</td><td>Hysterectomy</td></tr><tr><td>A8</td><td>Amputated cervix</td></tr><tr><td>A9</td><td>Other gynaecological site</td></tr></table>	Value	Meaning	A1	Biopsy (includes directed punch and random punch)	A2	Endocervical curettage (includes endocervical tissue obtained during D&C)	A3	LLETZ/LEEP loop biopsy	A4	Cone biopsy	A5	Polypectomy	A6	Subtotal hysterectomy	A7	Hysterectomy	A8	Amputated cervix	A9	Other gynaecological site
Value	Meaning																				
A1	Biopsy (includes directed punch and random punch)																				
A2	Endocervical curettage (includes endocervical tissue obtained during D&C)																				
A3	LLETZ/LEEP loop biopsy																				
A4	Cone biopsy																				
A5	Polypectomy																				
A6	Subtotal hysterectomy																				
A7	Hysterectomy																				
A8	Amputated cervix																				
A9	Other gynaecological site																				

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	Pathology laboratories
---------------------------	------------------------

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> L3 Procedure used for obtaining specimen for histological analysis
-----------------------------------	--

L4 Squamous histology cell analysis

Identifying and definitional attributes

<i>Data item name</i>	Squamous histology cell analysis
<i>Definition</i>	The histological analysis of a cervical specimen (squamous cells of the ectocervix) for the purpose of assessment of cancer or pre-cancerous changes.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																		
<i>Data type</i>	String																		
<i>Format</i>	AX[XX]																		
<i>Maximum character length</i>	4																		
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>S1</td><td>Negative</td></tr><tr><td>S2</td><td>Low-grade intraepithelial lesion (LSIL)</td></tr><tr><td>S3.1</td><td>High-grade intraepithelial lesion (HSIL) (CIN NOS)</td></tr><tr><td>S3.2</td><td>HSIL (CIN 2)</td></tr><tr><td>S3.3</td><td>HSIL (CIN 3)</td></tr><tr><td>S4.1</td><td>Superficially invasive squamous cell carcinoma (SISCCA)</td></tr><tr><td>S4.2</td><td></td></tr><tr><td>SU</td><td>Squamous cell carcinoma (SCC)</td></tr></table>	Value	Meaning	S1	Negative	S2	Low-grade intraepithelial lesion (LSIL)	S3.1	High-grade intraepithelial lesion (HSIL) (CIN NOS)	S3.2	HSIL (CIN 2)	S3.3	HSIL (CIN 3)	S4.1	Superficially invasive squamous cell carcinoma (SISCCA)	S4.2		SU	Squamous cell carcinoma (SCC)
Value	Meaning																		
S1	Negative																		
S2	Low-grade intraepithelial lesion (LSIL)																		
S3.1	High-grade intraepithelial lesion (HSIL) (CIN NOS)																		
S3.2	HSIL (CIN 2)																		
S3.3	HSIL (CIN 3)																		
S4.1	Superficially invasive squamous cell carcinoma (SISCCA)																		
S4.2																			
SU	Squamous cell carcinoma (SCC)																		

Data item attributes

Collection and usage attributes

<i>Comments</i>	Histology nomenclature was revised in the <i>National Cervical Screening Program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding</i> (Cancer Council Australia and Cervical Cancer Screening Guidelines Working Party 2016). A two-tiered nomenclature system has been accepted for non-invasive HPV associated squamous proliferations of the cervix. The two groups are LSIL and HSIL, which may be further characterised by the applicable cervical intraepithelial neoplasia (CIN) subcategory. LSIL is the morphologic expression of acute HPV infection. LSIL encompasses changes previously called 'HPV effect' and 'CIN1'. HSIL is the morphologic expression of persistent HPV infection that has the potential to progress to invasive carcinoma. HSIL encompasses lesions previously called 'CIN2' and 'CIN3'.
-----------------	---

The subcategories HSIL (CIN2) and HSIL (CIN3) should continue to be used.

Where a pathologist is considering a diagnosis of CIN2, p16 staining should be performed. If the p16 stain is negative, the lesion is either LSIL or a mimic of HSIL and should not be diagnosed as HSIL. If the p16 stain is positive, the lesion should be diagnosed as HSIL (CIN2).

The term ‘microinvasive carcinoma’ is no longer recommended, and the term ‘superficially invasive squamous cell carcinoma’ (SISCCA) should be used instead.

Collection methods

Pathology laboratories

Relational attributes

Related metadata references

Supersedes *National Cervical Screening Program data dictionary version 1.0* L4 Squamous histology cell analysis

L5 Endocervical (glandular) histology cell analysis

Identifying and definitional attributes

<i>Data item name</i>	Endocervical (glandular) histology cell analysis
<i>Definition</i>	The histological analysis of an endocervical specimen (glandular/columnar cells of the endocervix) for the purpose of assessment of cancer or pre-cancerous changes.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code	
<i>Data type</i>	String	
<i>Format</i>	AX[XX]	
<i>Maximum character length</i>	4	
<i>Permissible values</i>	Value	Meaning
	E1	Negative
	E2	Endocervical atypia
	E3.1	Endocervical dysplasia
	E3.2	Adenocarcinoma-in-situ
	E3.3	Mixed carcinoma-in-situ/ adenocarcinoma-in-situ
	E4.1	Endocervical adenocarcinoma, microinvasive
	E4.2	Invasive adenocarcinoma of cervix
	E4.3	Adenosquamous carcinoma
	E4.4	Carcinoma of the cervix (other)
	EU	Unsatisfactory
	EN	Not applicable

Data item attributes

Collection and usage attributes

<i>Comments</i>	Histology nomenclature was revised in the <i>National Cervical Screening Program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding</i> (Cancer Council Australia and Cervical Cancer Screening Guidelines Working Party 2016). However, while this states that 'Adenocarcinoma-in-situ' (AIS) is the only currently recommended term in Australasia for glandular mucosal preinvasive lesions, other categories are included to allow the collection of these findings.
<i>Collection methods</i>	Pathology laboratories

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> L5 Endocervical (glandular) histology cell analysis
------------------------------------	---

L6 Other/non-cervical histology cell analysis

Identifying and definitional attributes

<i>Data item name</i>	Other/non-cervical histology cell analysis
<i>Definition</i>	The histological analysis of a non-cervical sample.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																
<i>Data type</i>	String																
<i>Format</i>	AX[XX]																
<i>Maximum character length</i>	4																
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>O1</td><td>Negative/no abnormalities reported or benign changes only</td></tr><tr><td>O2</td><td>Low-grade neoplasia/hyperplasia NOS</td></tr><tr><td>O3.1</td><td>High-grade neoplasia/hyperplasia</td></tr><tr><td>O3.2</td><td>Carcinoma-in-situ</td></tr><tr><td>O4.1</td><td>Carcinoma, microinvasive</td></tr><tr><td>O4.2</td><td>Invasive carcinoma</td></tr><tr><td>ON</td><td>Not applicable</td></tr></table>	Value	Meaning	O1	Negative/no abnormalities reported or benign changes only	O2	Low-grade neoplasia/hyperplasia NOS	O3.1	High-grade neoplasia/hyperplasia	O3.2	Carcinoma-in-situ	O4.1	Carcinoma, microinvasive	O4.2	Invasive carcinoma	ON	Not applicable
Value	Meaning																
O1	Negative/no abnormalities reported or benign changes only																
O2	Low-grade neoplasia/hyperplasia NOS																
O3.1	High-grade neoplasia/hyperplasia																
O3.2	Carcinoma-in-situ																
O4.1	Carcinoma, microinvasive																
O4.2	Invasive carcinoma																
ON	Not applicable																

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	Pathology laboratories
---------------------------	------------------------

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> L6 Other/non-cervical histology cell analysis
-----------------------------------	---

L7 Histology test result

Identifying and definitional attributes

<i>Data item name</i>	Histology test result
<i>Definition</i>	Cervical histology result based on S and E codes as defined by the Australian Institute of Health and Welfare for national reporting purposes.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code														
<i>Data type</i>	String														
<i>Format</i>	AX														
<i>Maximum character length</i>	2														
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>DN</td><td>No result</td></tr><tr><td>DU</td><td>Unsatisfactory</td></tr><tr><td>D1</td><td>Negative</td></tr><tr><td>D2</td><td>Low-grade</td></tr><tr><td>D3</td><td>High-grade</td></tr><tr><td>D4</td><td>Cervical cancer</td></tr></table>	Value	Meaning	DN	No result	DU	Unsatisfactory	D1	Negative	D2	Low-grade	D3	High-grade	D4	Cervical cancer
Value	Meaning														
DN	No result														
DU	Unsatisfactory														
D1	Negative														
D2	Low-grade														
D3	High-grade														
D4	Cervical cancer														

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Note that for the purposes of national reporting of cervical histology by the Australian Institute of Health and Welfare, categories are based only on S and E codes. An unsatisfactory histology result is defined as specified in each state or territory, since the entire pathology result is required to make an evaluation. For instance, the overall findings may be unsatisfactory, even if there are valid squamous and endocervical codes allocated, since a pathologist may code what can be observed, even in the case of an unsatisfactory sample. Hence it is not appropriate to define unsatisfactory histology using S and E codes. Note, however, that if high-grade or malignant cells are seen in an otherwise unsatisfactory specimen, the histology result category should reflect the high-grade or malignant finding, rather than the unsatisfactory nature of the sample. A negative histology result is defined as any histology test that is not unsatisfactory and where there is no evidence of HPV infection, intraepithelial pre-neoplasia, or intraepithelial neoplasia. Note that there is no requirement for both squamous and endocervical components to be sampled and to be negative; a histology result that only samples the squamous component and
----------------------	--

	the squamous component is negative, or a histology result that only samples the endocervical component and the endocervical component is negative, are both counted as negative histology tests. A negative histology result can therefore be represented as (L4 = S1 and L5 = E1) or (L4 = S1 and L5 = EN) or (L4 = SN and L5 = E1), although this may not reflect how negative histology is coded by cervical screening registers. A low-grade histology result is defined as L4 = S2 or L5 = E2 (L4 cannot be >S2 and L5 cannot be >E2). A high-grade histology result is defined as L4 = S3 or L5 = E3 (L4 cannot be >S3 and L5 cannot be >E3). A cervical cancer histology result is defined as L4 = S4 or L5 = E4.
<i>Comments</i>	This is the way that histology results are used for reporting and monitoring purposes. Some histology results do not have valid S and E. Where both the S and E code are invalid (such as 'not applicable'), the code DN can be used to capture these tests for which there is no result.
<i>Collection methods</i>	Pathology laboratories
Relational attributes	
<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> L7 Histology test result

L8 Histology report text

Identifying and definitional attributes

<i>Data item name</i>	Histology report text
<i>Definition</i>	Text from the report prepared for cervical histology.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Text
<i>Data type</i>	String
<i>Format</i>	[X(4,000)]
<i>Maximum character length</i>	4,000

Data item attributes

Collection and usage attributes

<i>Comment</i>	Histology report text is often required for detailed information on clearance margins et cetera when supporting research requests.
----------------	--

Relational attributes

<i>Related metadata reference</i>	New data item
-----------------------------------	---------------

L9 Histology stain

Identifying and definitional attributes

<i>Data item name</i>	Histology stain
<i>Definition</i>	An indication as to what staining was performed on the histology specimen.
<i>Collection status</i>	Aspirational

Value domain attributes

<i>Representation class</i>	Code						
<i>Data type</i>	Number						
<i>Format</i>	N[N]						
<i>Maximum character length</i>	2						
<i>Permissible values</i>	<table><thead><tr><th>Value</th><th>Meaning</th></tr></thead><tbody><tr><td>0</td><td>No stain</td></tr><tr><td>1</td><td>p16</td></tr></tbody></table>	Value	Meaning	0	No stain	1	p16
Value	Meaning						
0	No stain						
1	p16						

Data item attributes

Collection and usage attributes

<i>Comments</i>	This data item will be expanded as more stains are used on cervical histology specimens to aid in the identification of high-grade cervical abnormalities.
<i>Collection methods</i>	Pathology laboratories

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> L8 Histology stain
-----------------------------------	--

L10 Histology stain result

Identifying and definitional attributes

<i>Data item name</i>	Histology stain result
<i>Definition</i>	Result of the histology staining performed.
<i>Collection status</i>	Aspirational

Value domain attributes

<i>Representation class</i>	Code										
<i>Data type</i>	Number										
<i>Format</i>	N										
<i>Maximum character length</i>	1										
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>0</td><td>Not done</td></tr><tr><td>1</td><td>Staining</td></tr><tr><td>2</td><td>No staining</td></tr><tr><td>3</td><td>Equivocal staining</td></tr></table>	Value	Meaning	0	Not done	1	Staining	2	No staining	3	Equivocal staining
Value	Meaning										
0	Not done										
1	Staining										
2	No staining										
3	Equivocal staining										

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The results refer to each of the staining options in L8 'Histology stain', so if L9 = 1 'p16', then the results in L10 are the staining results for p16.
<i>Collection methods</i>	Pathology laboratories

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> L9 Histology stain result
-----------------------------------	---

L11 Histology data source

Identifying and definitional attributes

<i>Data item name</i>	Histology data source
<i>Definition</i>	An indication as to the source of data that histology occurred.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code								
<i>Data type</i>	Number								
<i>Format</i>	N								
<i>Maximum character length</i>	1								
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>1</td><td>Pathology laboratory</td></tr><tr><td>2</td><td>MBS</td></tr><tr><td>9</td><td>Unknown</td></tr></table>	Value	Meaning	1	Pathology laboratory	2	MBS	9	Unknown
Value	Meaning								
1	Pathology laboratory								
2	MBS								
9	Unknown								

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This data item is derived by the AIHW for use in performance indicator reporting that requires histology data. There are two sources of information that a histology has occurred across National Cancer Screening Register data tables. '1 Pathology laboratory' indicates that the source is a pathology laboratory providing histology results to the National Cancer Screening Register. This is the only source that can have all histology data items populated. '2 MBS' indicates that the source is the Medicare Benefits Scheme. The only data item that can be populated when MBS is the source is 'L1 Histology test date'. '9 Unknown' indicates the source of the histology is unknown.
<i>Collection methods</i>	Where there is more than one data source for a single histology test, an order of priority is used to allow the most information to be collected about the histology. The order of priority would be to select a pathology laboratory record over an MBS record as a greater number of histology data items can be populated.

Relational attributes

<i>Related metadata reference</i>	New data item
-----------------------------------	---------------

Group M: Treatment data items

M1	Treatment this episode
M2	Treatment date
M3	Excision performed this episode
M4	Modality/method used for excision
M5	Ablation performed this episode
M6	Hysterectomy
M7	Treatment anaesthetic type
M8	Location of service
M9	Eligible for test of cure flag
M10	Eligible for test of cure date
M11	Test of cure completion flag
M12	Test of cure completion date

M1 Treatment this episode

Identifying and definitional attributes

<i>Data item name</i>	Treatment this episode
<i>Definition</i>	An indication as to whether treatment was performed as part of the colposcopy episode.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code						
<i>Data type</i>	String						
<i>Format</i>	AN						
<i>Maximum character length</i>	2						
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>T0</td><td>No – treatment not performed</td></tr><tr><td>T1</td><td>Yes – treatment performed</td></tr></table>	Value	Meaning	T0	No – treatment not performed	T1	Yes – treatment performed
Value	Meaning						
T0	No – treatment not performed						
T1	Yes – treatment performed						

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	Colposcopy Data Collection Form
---------------------------	---------------------------------

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> M1 Treatment this episode
-----------------------------------	---

M2 Treatment date

Identifying and definitional attributes

<i>Data item name</i>	Treatment date
<i>Definition</i>	An indication as to the date of treatment.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	{DDMMYYYY}
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This is a derived data item, to be populated with K1 'Date of colposcopy episode' when M1 'Treatment this episode' is equal to 1, indicating that treatment was performed during this colposcopy episode.
<i>Collection methods</i>	Derived.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> M2 Treatment date
-----------------------------------	---

M3 Excision performed this episode

Identifying and definitional attributes

<i>Data item name</i>	Excision performed this episode
<i>Definition</i>	Whether or not excision was performed this episode, and if yes, the intended excision type.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code										
<i>Data type</i>	String										
<i>Format</i>	AN{A}										
<i>Maximum character length</i>	3										
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>X0</td><td>No</td></tr><tr><td>X1a</td><td>Yes – Type 1 excision (≤ 10 mm)</td></tr><tr><td>X1b</td><td>Yes – Type 2 excision (> 10 and ≤ 15 mm)</td></tr><tr><td>X1c</td><td>Yes – Type 3 excision (> 15 mm)</td></tr></table>	Value	Meaning	X0	No	X1a	Yes – Type 1 excision (≤ 10 mm)	X1b	Yes – Type 2 excision (> 10 and ≤ 15 mm)	X1c	Yes – Type 3 excision (> 15 mm)
Value	Meaning										
X0	No										
X1a	Yes – Type 1 excision (≤ 10 mm)										
X1b	Yes – Type 2 excision (> 10 and ≤ 15 mm)										
X1c	Yes – Type 3 excision (> 15 mm)										

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Excisions are stratified as Types 1, 2 or 3, according to the length of cervical tissue excised. Treatment types are defined below (modified from the terminology recommended by the International Federation for Cervical Pathology and Colposcopy in 2011). • 'Type 1 excision' (for Type 1 transformation zone): Usually to 8 mm and not more than 10 mm length of cervical tissue excised. • 'Type 2 excision' (for Type 2 transformation zone): Not more than 15 mm length of tissue excised. • 'Type 3 excisions' (for Type 3 transformation zones): Equivalent to 'cone biopsy' and > 15 mm length. Should be used for people with: – suspected invasive disease – proven or suspected glandular disease – Type 3 transformation zones with proven or suspected high-grade disease.
<i>Collection methods</i>	Colposcopy Data Collection Form

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> M3 Excision performed this episode
-----------------------------------	--

M4 Modality/method used for excision

Identifying and definitional attributes

<i>Data item name</i>	Modality/method used for excision
<i>Definition</i>	The modality or method used for excision, where this was performed.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code												
<i>Data type</i>	String												
<i>Format</i>	AAN{A}												
<i>Maximum character length</i>	4												
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>XM0</td><td>Excision not performed</td></tr><tr><td>XM1a</td><td>Loop diathermy</td></tr><tr><td>XM1b</td><td>Scalpel (Cold knife)</td></tr><tr><td>XM1c</td><td>Laser</td></tr><tr><td>XM1d</td><td>Other</td></tr></table>	Value	Meaning	XM0	Excision not performed	XM1a	Loop diathermy	XM1b	Scalpel (Cold knife)	XM1c	Laser	XM1d	Other
Value	Meaning												
XM0	Excision not performed												
XM1a	Loop diathermy												
XM1b	Scalpel (Cold knife)												
XM1c	Laser												
XM1d	Other												

Data item attributes

Collection and usage attributes

<i>Rules for use</i>	If M3 'Excision performed this episode' = 0, then M4 'Modality/method used for excision' should be 0.
<i>Collection methods</i>	Colposcopy Data Collection Form

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> M4 Modality/method used for excision
-----------------------------------	--

M5 Ablation performed this episode

Identifying and definitional attributes

<i>Data item name</i>	Ablation performed this episode
<i>Definition</i>	Whether or not ablation was performed this episode, and if yes, the ablation type.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code										
<i>Data type</i>	String										
<i>Format</i>	AN{A}										
<i>Maximum character length</i>	3										
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>L0</td><td>No</td></tr><tr><td>L1a</td><td>Yes – Laser</td></tr><tr><td>L1b</td><td>Yes – Thermal coagulation (Semm)</td></tr><tr><td>L1c</td><td>Yes – Diathermy</td></tr></table>	Value	Meaning	L0	No	L1a	Yes – Laser	L1b	Yes – Thermal coagulation (Semm)	L1c	Yes – Diathermy
Value	Meaning										
L0	No										
L1a	Yes – Laser										
L1b	Yes – Thermal coagulation (Semm)										
L1c	Yes – Diathermy										

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	Colposcopy Data Collection Form
---------------------------	---------------------------------

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> M5 Ablation performed this episode
-----------------------------------	--

M6 Hysterectomy

Identifying and definitional attributes

<i>Data item name</i>	Hysterectomy
<i>Definition</i>	An indication as to whether hysterectomy was performed.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code						
<i>Data type</i>	String						
<i>Format</i>	AN						
<i>Maximum character length</i>	2						
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>H0</td><td>No – hysterectomy not performed</td></tr><tr><td>H1</td><td>Yes – hysterectomy performed</td></tr></table>	Value	Meaning	H0	No – hysterectomy not performed	H1	Yes – hysterectomy performed
Value	Meaning						
H0	No – hysterectomy not performed						
H1	Yes – hysterectomy performed						

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	Colposcopy Data Collection Form
---------------------------	---------------------------------

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> M6 Hysterectomy
-----------------------------------	---

M7 Treatment anaesthetic type

Identifying and definitional attributes

<i>Data item name</i>	Treatment anaesthetic type
<i>Definition</i>	An indication as to whether the anaesthetic used was local or general.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code										
<i>Data type</i>	Number										
<i>Format</i>	{N}										
<i>Maximum character length</i>	1										
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>0</td><td>Not used/not required</td></tr><tr><td>1</td><td>Local</td></tr><tr><td>2</td><td>Regional</td></tr><tr><td>3</td><td>General</td></tr></table>	Value	Meaning	0	Not used/not required	1	Local	2	Regional	3	General
Value	Meaning										
0	Not used/not required										
1	Local										
2	Regional										
3	General										

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	Colposcopy Data Collection Form
---------------------------	---------------------------------

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> M7 Treatment anaesthetic type
-----------------------------------	---

M8 Location of service

Identifying and definitional attributes

<i>Data item name</i>	Location of service
<i>Definition</i>	An indication as to where treatment was performed.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code										
<i>Data type</i>	Number										
<i>Format</i>	{N}										
<i>Maximum character length</i>	1										
<i>Permissible values</i>	<table><thead><tr><th>Value</th><th>Meaning</th></tr></thead><tbody><tr><td>1</td><td>Public Hospital</td></tr><tr><td>2</td><td>Private Hospital</td></tr><tr><td>3</td><td>Private Rooms</td></tr><tr><td>9</td><td>Unknown/Other</td></tr></tbody></table>	Value	Meaning	1	Public Hospital	2	Private Hospital	3	Private Rooms	9	Unknown/Other
Value	Meaning										
1	Public Hospital										
2	Private Hospital										
3	Private Rooms										
9	Unknown/Other										

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	Colposcopy Data Collection Form
---------------------------	---------------------------------

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> M8 Location of service
-----------------------------------	--

M9 Eligible for test of cure flag

Identifying and definitional attributes

<i>Data item name</i>	Eligible for test of cure flag
<i>Definition</i>	An indication that, following treatment for a high-grade squamous intraepithelial lesion, a person is eligible for test of cure.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code				
<i>Data type</i>	Number				
<i>Format</i>	{N}				
<i>Maximum character length</i>	1				
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>1</td><td>Eligible for test of cure</td></tr></table>	Value	Meaning	1	Eligible for test of cure
Value	Meaning				
1	Eligible for test of cure				

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	Calculate based on the date of the previous histologically-confirmed high-grade squamous intraepithelial lesion.
---------------------------	--

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> M9 Eligible for test of cure flag
-----------------------------------	---

M10 Eligible for test of cure date

Identifying and definitional attributes

<i>Data item name</i>	Eligible for test of cure date
<i>Definition</i>	An indication as to the date a person became eligible for test of cure.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	{DDMMYYYY}
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	Derived from the date of treatment for previous histologically-confirmed high-grade squamous intraepithelial lesion.
---------------------------	--

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> M10 Eligible for test of cure date
-----------------------------------	--

M11 Test of cure completion flag

Identifying and definitional attributes

<i>Data item name</i>	Test of cure completion flag
<i>Definition</i>	An indication that, following treatment for a high-grade squamous intraepithelial lesion, a person has completed test of cure.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code				
<i>Data type</i>	Number				
<i>Format</i>	{N}				
<i>Maximum character length</i>	1				
<i>Permissible values</i>	<table><thead><tr><th>Value</th><th>Meaning</th></tr></thead><tbody><tr><td>1</td><td>Test of cure complete</td></tr></tbody></table>	Value	Meaning	1	Test of cure complete
Value	Meaning				
1	Test of cure complete				

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Successful completion of test of cure is as per the management guidelines and comprises two negative co-test (HPV and LBC) results 12 months apart, commencing 12 months after treatment for a histologically-confirmed high-grade squamous intraepithelial lesion.
<i>Comments</i>	A negative co-test is defined as an HPV test and cytology test performed on the same day where the HPV test result is 'no oncogenic HPV types detected' and the cytology test result is 'S1 Cell numbers and preservation satisfactory. No abnormality or only reactive changes' and 'E0 No endocervical component' or 'E1 Endocervical component present. No abnormality or only reactive changes'.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> M11 Test of cure completion flag
-----------------------------------	--

M12 Test of cure completion date

Identifying and definitional attributes

<i>Data item name</i>	Test of cure completion date
<i>Definition</i>	An indication as to the date the test of cure was complete.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	{DDMMYYYY}
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Collection methods</i>	Derived from the date of the second negative co-test (contingent on test of cure being followed with co-tests at recommended intervals after treatment).
<i>Comments</i>	A negative co-test is defined as an HPV test and cytology test performed on the same day where the HPV test result is 'no oncogenic HPV types detected' and the cytology test result is 'S1 Cell numbers and preservation satisfactory. No abnormality or only reactive changes' and 'E0 No endocervical component' or 'E1 Endocervical component present. No abnormality or only reactive changes'.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> M12 Test of cure completion date
-----------------------------------	--

Group N: Provider data items

Provider data items allow the collection and reporting by provider for all tests that may be performed within a screening round – HPV tests, cytology tests, colposcopy, and histology tests. These can be used in combination with the data item *Type of test* to determine the provider details for each test.

- N1 Medicare provider number of provider requesting a test
- N2 Healthcare provider identifier – individual (HPI-I) of provider requesting a test
- N3 Healthcare provider identifier – organisation (HPI-O) of provider requesting a test
- N4 Australian state/territory of provider requesting a test
- N5 Australian postcode of provider requesting a test
- N6 Medicare provider number of provider collecting a specimen
- N7 Non-medical provider number of provider collecting a specimen
- N8 Healthcare provider identifier – individual (HPI-I) of provider collecting a specimen
- N9 Healthcare provider identifier – organisation (HPI-O) of provider collecting a specimen
- N10 Type of provider collecting a specimen
- N11 Australian state/territory of provider collecting a specimen
- N12 Australian postcode of provider collecting a specimen

N1 Medicare provider number of provider requesting a test

Identifying and definitional attributes

<i>Data item name</i>	Medicare provider number of provider requesting a test
<i>Definition</i>	The Medicare number of the provider requesting a test.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	String
<i>Format</i>	X[X(7)]
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The provider requesting test is the provider responsible for the test. The Medicare provider number of the provider requesting a test is therefore the Medicare provider number of the provider who is responsible for the test. Only general practitioners, nurse practitioners and specialists have a Medicare provider number, and can therefore be considered responsible for the test. A health professional can have more than one Medicare provider number, as they will have a Medicare provider number at each location at which they work. Medicare provider numbers are comprised of 8 characters, the first 6 of which are the same for each provider, with subsequent characters used for different locations. The Medicare provider number is not always known or available. In these cases, a dummy provider number unique to the practitioner may be used. A generic dummy value of 0000000Y may also be used, if there is no requirement for the dummy number to be unique to the practitioner. Following a person being referred to a colposcopist or specialist it may also be necessary for the provider number to be changed for contact purposes to reflect ongoing care by the provider, until any further information is received.
<i>Rules for use</i>	As the provider responsible for the test should have a Medicare provider number this field should always be populated.
<i>Comments</i>	Medicare provider numbers are allocated to individual providers and organisations to support payments and claims through government schemes such as Medicare Benefits and Pharmaceutical Benefits Schemes. For screening tests, the provider requesting the test may not be the provider who collects the specimen; for example, a nurse may collect a sample.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> N1 Medicare provider number
------------------------------------	---

N2 Healthcare provider identifier – individual (HPI-I) of provider requesting a test

Identifying and definitional attributes

<i>Data item name</i>	Healthcare provider identifier – individual (HPI-I) of provider requesting a test
<i>Definition</i>	The healthcare provider identifier – individual (HPI-I) of the provider requesting a test.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	Number
<i>Format</i>	{N(16)}
<i>Maximum character length</i>	16

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	A healthcare provider identifier – individual (HPI-I) is a unique 16-digit number that will be allocated to healthcare providers involved in providing patient care. Collection of this is essential if Medicare provider number is not available.
----------------------	---

Source and reference attributes

<i>Origin</i>	National E-Health Transition Authority (NEHTA)
---------------	--

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> N3 Healthcare provider identifier – individual (HPI-I)
-----------------------------------	--

N3 Healthcare provider identifier – organisation (HPI-O) of provider requesting a test

Identifying and definitional attributes

<i>Data item name</i>	Healthcare provider identifier – organisation (HPI-O) of provider requesting a test
<i>Definition</i>	The healthcare provider identifier – organisation (HPI-O) of the provider requesting a test.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	Number
<i>Format</i>	{N(16)}
<i>Maximum character length</i>	16

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	A healthcare provider identifier – organisation (HPI-O) is a unique 16-digit number that will be allocated to organisations (such as a hospital or medical clinic) where healthcare is provided.
----------------------	--

Source and reference attributes

<i>Origin</i>	National E-Health Transition Authority (NEHTA)
---------------	--

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> N2 Healthcare provider identifier – organisation (HPI-O)
-----------------------------------	--

N4 Australian state/territory of provider requesting a test

Identifying and definitional attributes

<i>Data item name</i>	Australian state/territory of provider requesting a test
<i>Definition</i>	The abbreviated name of the Australian state or territory in which the provider requesting a test is located.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code																		
<i>Data type</i>	Text																		
<i>Format</i>	AA{A}																		
<i>Maximum character length</i>	3																		
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>NSW</td><td>New South Wales</td></tr><tr><td>VIC</td><td>Victoria</td></tr><tr><td>QLD</td><td>Queensland</td></tr><tr><td>WA</td><td>Western Australia</td></tr><tr><td>SA</td><td>South Australia</td></tr><tr><td>TAS</td><td>Tasmania</td></tr><tr><td>ACT</td><td>Australian Capital Territory</td></tr><tr><td>NT</td><td>Northern Territory</td></tr></table>	Value	Meaning	NSW	New South Wales	VIC	Victoria	QLD	Queensland	WA	Western Australia	SA	South Australia	TAS	Tasmania	ACT	Australian Capital Territory	NT	Northern Territory
Value	Meaning																		
NSW	New South Wales																		
VIC	Victoria																		
QLD	Queensland																		
WA	Western Australia																		
SA	South Australia																		
TAS	Tasmania																		
ACT	Australian Capital Territory																		
NT	Northern Territory																		

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The order presented here is the standard for the Australian Institute of Health and Welfare, and reflects the current order of states and then territories in order of most populated to least populated.
----------------------	---

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> N5 Provider state/territory
-----------------------------------	---

N5 Australian postcode of provider requesting a test

Identifying and definitional attributes

<i>Data item name</i>	Australian postcode of provider requesting a test
<i>Definition</i>	The code that represents a postal delivery area, aligned with locality, suburb, or place for the practice where a provider requesting a test is located.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code
<i>Data type</i>	Number
<i>Format</i>	NNNN
<i>Maximum character length</i>	4

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Must accept zero as the leading digit to accommodate all Australian postcodes.
<i>Comments</i>	Australian postcode may be used in the analysis of data on a geographical basis, which involves a conversion from postcodes to the Australian Bureau of Statistics (ABS) postal areas. This conversion results in some inaccuracy of information. However, in some data sets postcode is the only geographic identifier, therefore the use of other more accurate indicators is not always possible. When dealing with aggregate data, postal areas, converted from postcodes, can be mapped to Australian Statistical Geography Standard codes using an ABS concordance.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> N6 Provider Australian postcode
------------------------------------	---

N6 Medicare provider number of provider collecting a specimen

Identifying and definitional attributes

<i>Data item name</i>	Medicare provider number of provider collecting a specimen
<i>Definition</i>	The Medicare provider number of the provider collecting a specimen.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	String
<i>Format</i>	{X[X(7)]}
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The provider collecting a specimen is the provider who actually collected the sample for the cervical screening test. The Medicare provider number of the provider collecting a specimen is therefore the Medicare provider number of the provider who collected the sample. Only general practitioners, nurse practitioners and specialists have a Medicare provider number. A health professional can have more than one Medicare provider number, as they will have a Medicare provider number at each location at which they work. Medicare provider numbers are comprised of 8 characters, the first 6 of which are the same for each provider, with subsequent characters used for different locations. The Medicare provider number is not always known or available. In these cases, a dummy provider number unique to the practitioner may be used. A generic dummy value of 0000000Y may also be used, if there is no requirement for the dummy number to be unique to the practitioner. Following a person being referred to a colposcopist or specialist it may also be necessary for the provider number to be changed for contact purposes to reflect ongoing care by the provider, until any further information is received. If a health professional collecting a specimen does not have a Medicare provider number, their identifier should be collected at N7 'Non-medical provider number of provider collecting specimen'.
<i>Rules for use</i>	This data item should only be populated if the provider collecting a specimen is different to the provider requesting a specimen.

<i>Comments</i>	For screening tests, the provider collecting a specimen may not be the provider who requested the test; for example, a nurse may collect a sample.
-----------------	--

Relational attributes

<i>Related metadata references</i>	New data item
------------------------------------	---------------

N7 Non-medical provider number of provider collecting a specimen

Identifying and definitional attributes

<i>Data item name</i>	Non-medical provider number of provider collecting a specimen
<i>Definition</i>	The non-medical provider number of the provider collecting a specimen.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	String
<i>Format</i>	{X[X(19)]}
<i>Maximum character length</i>	20

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The provider collecting a specimen is the provider who actually collected the sample for the cervical screening test. This data item allows for the collection of an identifier other than Medicare provider number for health professionals collecting a specimen that do not have a Medicare provider number.
<i>Rules for use</i>	This data item should only be populated if the provider collecting a specimen is different to the provider requesting a specimen.
<i>Comments</i>	For screening tests, the provider collecting a specimen may not be the provider who requested the test; for example, a nurse may collect a sample.

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> N7 Identifier of a provider collecting specimen
------------------------------------	---

N8 Healthcare provider identifier – individual (HPI-I) of provider collecting a specimen

Identifying and definitional attributes

<i>Data item name</i>	Healthcare provider identifier – individual (HPI-I) of provider collecting a specimen
<i>Definition</i>	The healthcare provider identifier – individual (HPI-I) of the provider collecting a specimen.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	Number
<i>Format</i>	{N(16)}
<i>Maximum character length</i>	16

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	A healthcare provider identifier – individual (HPI-I) is a unique 16-digit number that will be allocated to healthcare providers involved in providing patient care.
----------------------	--

Source and reference attributes

<i>Origin</i>	National E-Health Transition Authority (NEHTA)
---------------	--

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> N9 Healthcare provider identifier – individual (HPI-I) of a provider collecting specimen
-----------------------------------	--

N9 Healthcare provider identifier – organisation (HPI-O) of provider collecting a specimen

Identifying and definitional attributes

<i>Data item name</i>	Healthcare provider identifier – organisation (HPI-O) of provider collecting a specimen
<i>Definition</i>	The healthcare provider identifier – organisation (HPI-O) of the provider collecting a specimen.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	Number
<i>Format</i>	{N(16)}
<i>Maximum character length</i>	16

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	A healthcare provider identifier – organisation (HPI-O) is a unique 16-digit number that will be allocated to organisations (such as a hospital or medical clinic) where healthcare is provided.
----------------------	--

Source and reference attributes

<i>Origin</i>	National E-Health Transition Authority (NEHTA)
---------------	--

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> N8 Healthcare provider identifier – organisation (HPI-O) of a provider collecting specimen
-----------------------------------	--

N10 Type of provider collecting a specimen

Identifying and definitional attributes

<i>Data item name</i>	Type of provider collecting a specimen
<i>Definition</i>	The occupation of the person who collects a specimen.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code																				
<i>Data type</i>	String																				
<i>Format</i>	{A}																				
<i>Maximum character length</i>	1																				
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>G</td><td>General practitioner</td></tr><tr><td>N</td><td>Nurse Practitioner/Eligible Midwife</td></tr><tr><td>R</td><td>Registered Nurse/Midwife</td></tr><tr><td>E</td><td>Enrolled Nurse</td></tr><tr><td>S</td><td>Specialists (Obstetricians and gynaecologists)</td></tr><tr><td>A</td><td>Aboriginal and/or Torres Strait Islander health care worker</td></tr><tr><td>O</td><td>Other</td></tr><tr><td>X</td><td>None – self-collected (only applicable to HPV test)</td></tr><tr><td>U</td><td>Unassigned</td></tr></table>	Value	Meaning	G	General practitioner	N	Nurse Practitioner/Eligible Midwife	R	Registered Nurse/Midwife	E	Enrolled Nurse	S	Specialists (Obstetricians and gynaecologists)	A	Aboriginal and/or Torres Strait Islander health care worker	O	Other	X	None – self-collected (only applicable to HPV test)	U	Unassigned
Value	Meaning																				
G	General practitioner																				
N	Nurse Practitioner/Eligible Midwife																				
R	Registered Nurse/Midwife																				
E	Enrolled Nurse																				
S	Specialists (Obstetricians and gynaecologists)																				
A	Aboriginal and/or Torres Strait Islander health care worker																				
O	Other																				
X	None – self-collected (only applicable to HPV test)																				
U	Unassigned																				

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The occupation needs to reflect the occupation of the person who collected the specimen, which may differ from the occupation of the provider number under which the specimen was collected (that is, if a registered nurse collects the specimen under a GP's provider number, the occupation needs to be recorded as nurse, not GP).
----------------------	--

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> N10 Type of provider collecting specimen
------------------------------------	--

N11 Australian state/territory of provider collecting a specimen

Identifying and definitional attributes

<i>Data item name</i>	Australian state/territory of provider collecting a specimen
<i>Definition</i>	The abbreviated name of the Australian state or territory in which the provider collecting a specimen is located.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code																		
<i>Data type</i>	Text																		
<i>Format</i>	{AA{A}}																		
<i>Maximum character length</i>	3																		
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>NSW</td><td>New South Wales</td></tr><tr><td>VIC</td><td>Victoria</td></tr><tr><td>QLD</td><td>Queensland</td></tr><tr><td>WA</td><td>Western Australia</td></tr><tr><td>SA</td><td>South Australia</td></tr><tr><td>TAS</td><td>Tasmania</td></tr><tr><td>ACT</td><td>Australian Capital Territory</td></tr><tr><td>NT</td><td>Northern Territory</td></tr></table>	Value	Meaning	NSW	New South Wales	VIC	Victoria	QLD	Queensland	WA	Western Australia	SA	South Australia	TAS	Tasmania	ACT	Australian Capital Territory	NT	Northern Territory
Value	Meaning																		
NSW	New South Wales																		
VIC	Victoria																		
QLD	Queensland																		
WA	Western Australia																		
SA	South Australia																		
TAS	Tasmania																		
ACT	Australian Capital Territory																		
NT	Northern Territory																		

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The order presented here is the standard for the Australian Institute of Health and Welfare, and reflects the current order of states and then territories in order of most populated to least populated.
----------------------	---

Relational attributes

<i>Related metadata reference</i>	New data item
-----------------------------------	---------------

N12 Australian postcode of provider collecting a specimen

Identifying and definitional attributes

<i>Data item name</i>	Australian postcode of provider collecting a specimen
<i>Definition</i>	The code that represents a postal delivery area, aligned with locality, suburb, or place for the practice where a provider collecting a specimen is located.
<i>Collection status</i>	Desirable

Value domain attributes

<i>Representation class</i>	Code
<i>Data type</i>	Number
<i>Format</i>	{NNNN}
<i>Maximum character length</i>	4

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Must accept zero as the leading digit to accommodate all Australian postcodes.
<i>Comments</i>	Australian postcode may be used in the analysis of data on a geographical basis, which involves a conversion from postcodes to the Australian Bureau of Statistics (ABS) postal areas. This conversion results in some inaccuracy of information. However, in some data sets postcode is the only geographic identifier, therefore the use of other more accurate indicators is not always possible. When dealing with aggregate data, postal areas, converted from postcodes, can be mapped to Australian Statistical Geography Standard codes using an ABS concordance.

Relational attributes

<i>Related metadata references</i>	New data item
------------------------------------	---------------

Group O: Pathology laboratory data items

- O1 Pathology laboratory identifier
- O2 Pathology laboratory name
- O3 Pathology laboratory accession number/identifier
- O4 Pathology laboratory Australian state/territory
- O5 Pathology laboratory Australian postcode

O1 Pathology laboratory identifier

Identifying and definitional attributes

<i>Data item name</i>	Pathology laboratory identifier
<i>Definition</i>	A unique accreditation number allocated to the pathology laboratories that perform analyses on cervical specimens as managed by the National Association of Testing Authorities.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	String
<i>Format</i>	XXX
<i>Maximum character length</i>	3

Data item attributes

Source and reference attributes

<i>Origin</i>	Pathology laboratories
---------------	------------------------

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> O1 Pathology laboratory identifier
------------------------------------	--

O2 Pathology laboratory name

Identifying and definitional attributes

<i>Data item name</i>	Pathology laboratory name
<i>Definition</i>	The name of the pathology laboratory.
<i>Collection status</i>	Optional

Value domain attributes

<i>Representation class</i>	Text
<i>Data type</i>	String
<i>Format</i>	[X(250)]
<i>Maximum character length</i>	250

Data item attributes

Source and reference attributes

<i>Origin</i>	Pathology laboratories
---------------	------------------------

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> O2 Pathology laboratory name
-----------------------------------	--

O3 Pathology laboratory accession number/identifier

Identifying and definitional attributes

<i>Data item name</i>	Pathology laboratory accession number/identifier
<i>Definition</i>	A unique record identifier allocated by the pathology laboratory to a cervical specimen to distinguish it from all other specimens analysed by the laboratory.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Identifier
<i>Data type</i>	String
<i>Format</i>	X[X(49)]
<i>Maximum character length</i>	50

Data item attributes

Source and reference attributes

<i>Origin</i>	Pathology laboratories
---------------	------------------------

Relational attributes

<i>Related metadata references</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> O3 Pathology laboratory accession number/identifier
------------------------------------	---

O4 Pathology laboratory Australian state/territory

Identifying and definitional attributes

<i>Data item name</i>	Pathology laboratory Australian state/territory
<i>Definition</i>	The abbreviated name of the Australian state or territory in which the pathology laboratory that perform analyses on cervical specimens is located.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code																		
<i>Data type</i>	Text																		
<i>Format</i>	{AA[A]}																		
<i>Maximum character length</i>	3																		
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>NSW</td><td>New South Wales</td></tr><tr><td>VIC</td><td>Victoria</td></tr><tr><td>QLD</td><td>Queensland</td></tr><tr><td>WA</td><td>Western Australia</td></tr><tr><td>SA</td><td>South Australia</td></tr><tr><td>TAS</td><td>Tasmania</td></tr><tr><td>ACT</td><td>Australian Capital Territory</td></tr><tr><td>NT</td><td>Northern Territory</td></tr></table>	Value	Meaning	NSW	New South Wales	VIC	Victoria	QLD	Queensland	WA	Western Australia	SA	South Australia	TAS	Tasmania	ACT	Australian Capital Territory	NT	Northern Territory
Value	Meaning																		
NSW	New South Wales																		
VIC	Victoria																		
QLD	Queensland																		
WA	Western Australia																		
SA	South Australia																		
TAS	Tasmania																		
ACT	Australian Capital Territory																		
NT	Northern Territory																		

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	The order presented here is the standard for the Australian Institute of Health and Welfare, and reflects the current order of states and then territories in order of most populated to least populated.
----------------------	---

Source and reference attributes

<i>Origin</i>	Pathology laboratories
---------------	------------------------

Relational attributes

<i>Related metadata reference</i>	New data item
-----------------------------------	---------------

O5 Pathology laboratory Australian postcode

Identifying and definitional attributes

<i>Data item name</i>	Pathology laboratory Australian postcode
<i>Definition</i>	The code that represents a postal delivery area, aligned with locality, suburb, or place for the practice where the pathology laboratory that perform analyses on cervical specimens is located.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code
<i>Data type</i>	Number
<i>Format</i>	NNNN
<i>Maximum character length</i>	4

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Must accept zero as the leading digit to accommodate all Australian postcodes.
----------------------	--

Source and reference attributes

<i>Origin</i>	Pathology laboratories
---------------	------------------------

Relational attributes

<i>Related metadata reference</i>	New data item
-----------------------------------	---------------

Group P: Screening history data items

P1	Previously screened flag
P2	Date of last screening test
P3	Last screening test type
P4	Number of days since last screening test

P1 Previously screened flag

Identifying and definitional attributes

<i>Data item name</i>	Previously screened flag
<i>Definition</i>	An indication as to whether a person has ever had a screening test.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code				
<i>Data type</i>	Number				
<i>Format</i>	{N}				
<i>Maximum character length</i>	1				
<i>Permissible values</i>	<table><thead><tr><th>Value</th><th>Meaning</th></tr></thead><tbody><tr><td>1</td><td>Previously screened</td></tr></tbody></table>	Value	Meaning	1	Previously screened
Value	Meaning				
1	Previously screened				

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This flag should be used for all people who have ever had a screening test – either a Pap test through the previous National Cervical Screening Program or an HPV test through the current National Cervical Screening Program. This also needs to be recorded for people under the age of 25, even though they will not be invited to screen until they are aged 25 years. For people who are on the National Cancer Screening Register but never screened, this flag should be raised when a person has their first screening test. Exclude diagnostic or follow-up tests.
<i>Collection methods</i>	This data item is derived.
<i>Rules for use</i>	If P2 'Date of last screening test' is not NULL, P1 'Previously screened flag' should be = 1.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> P1 Previously screened flag
-----------------------------------	---

P2 Date of last screening test

Identifying and definitional attributes

<i>Data item name</i>	Date of last screening test
<i>Definition</i>	The date a sample for a person's last screening test was collected (date of screening test).
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Date
<i>Data type</i>	Date/Time
<i>Format</i>	{DDMMYYYY}
<i>Maximum character length</i>	8

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This will need to be updated each time a person has a screening test so that this reflects their most recent screening test date. If a histology diagnosis of cervical cancer is received by the National Cancer Screening Register with a collection date within 6 months of the date of a previous screening test, this date needs to be replaced with the immediately preceding screening test date until there is a screening test that is not followed by a diagnosis of cervical cancer within 6 months. If this was the person's first screening test date, or if there is no screening test that is not followed by a cancer diagnosis within 6 months, then it should be reverted to NULL, and P1 flag removed. This is to collect screening tests only. Screening tests that lead to a histological diagnosis of cancer within 6 months are likely to be part of the diagnosis process, rather than a true screen. These tests are important to remove, as this data item will be used to determine whether people have interval cancers diagnosed, and the inclusion of these would falsely elevate the number of interval cancers. Diagnosis of cervical cancer must be by histology (L7 = 4). Includes Pap tests under the previous National Cervical Screening Program and screening HPV tests under the current National Cervical Screening Program.
<i>Collection methods</i>	This data item is derived.
<i>Rules for use</i>	If P1 'Previously screened flag' = 1, P2 'Date of last screening test' should not be NULL.
<i>Comments</i>	Date of previous screening test can be combined with date of diagnosis of cervical cancer to assign a screening history to people diagnosed with cervical cancer (for example, never screened, lapsed screening, adequately screened) based on time since last screening test at time of diagnosis with cervical cancer.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> P2 Date of last screening test
-----------------------------------	--

P3 Last screening test type

Identifying and definitional attributes

<i>Data item name</i>	Last screening test type
<i>Definition</i>	An indication as to whether the last screening test was a cytology test or an HPV test.
<i>Collection status</i>	Conditional

Value domain attributes

<i>Representation class</i>	Code						
<i>Data type</i>	String						
<i>Format</i>	{A}						
<i>Maximum character length</i>	1						
<i>Permissible values</i>	<table><tr><th>Value</th><th>Meaning</th></tr><tr><td>V</td><td>HPV test</td></tr><tr><td>C</td><td>Cytology test</td></tr></table>	Value	Meaning	V	HPV test	C	Cytology test
Value	Meaning						
V	HPV test						
C	Cytology test						

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	Cytology test should be selected where the last screening test is a screening cytology test under the previous National Cervical Screening Program. HPV test should be selected where the last screening test is an HPV test under the current National Cervical Screening Program.
<i>Collection methods</i>	The data item is derived.
<i>Rules for use</i>	P3 'Last screening test type' can only be populated if P1 'Previously screened flag' = 1, otherwise this data item should be left blank.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> P3 Last screening test type
-----------------------------------	---

P4 Number of days since last screening test

Identifying and definitional attributes

<i>Data item name</i>	Number of days since last screening test
<i>Definition</i>	The number of days that have passed since the last recorded screening test for a person.
<i>Collection status</i>	Essential

Value domain attributes

<i>Representation class</i>	Code
<i>Data type</i>	Number
<i>Format</i>	N[NNNNN]
<i>Maximum character length</i>	6

Data item attributes

Collection and usage attributes

<i>Guide for use</i>	This is the number of days since a person's last screening test, calculated by subtracting the date of test/collection of the last screening test from the current date. When a new screening test occurs, this should be set to 0. The number of days will increase by one day every day. Number of days should be set to 999999 if no previous screening test is recorded (when P2 'Date of last screening test' is NULL).
<i>Collection methods</i>	Derived from P2 'Date of last screening test' and current date.
<i>Comments</i>	This is used to determine the screening history of a person, as never-screener, lapsed screeners, regular screeners etcetera, based on time since a person's last screening test.

Relational attributes

<i>Related metadata reference</i>	Supersedes <i>National Cervical Screening Program data dictionary version 1.0</i> P4 Number of days since last screening test
-----------------------------------	---

4 Classification schemes

The following pages contain classification schemes developed for the renewed National Cervical Screening Program, based on permissible values from key data items included in Section 3. There is a classification scheme for each of the following:

- HPV Test Group;
- Cytology Test Group;
- Clinical Management Recommendation Group;
- Histology Test Group; and
- Colposcopy Group;

with additional tables developed to assist with the classification of:

- Screening Episodes; and
- Follow-up Episodes.

HPV Test Group

HPV test collection method	1 Practitioner-collected sample		2 Self-collected sample	
HPV test specimen site	0 Not stated	1 Cervical	2 Vaginal	3 Other gynaecological site
Reason for HPV test	1 Primary screening HPV test	2 Follow-up HPV test (Repeat HPV test after intermediate risk result) ¹	3 Co-test i. Test of cure ii. Investigation of signs or symptoms iii. Other, as recommended in guidelines	4 Other
HPV test result – oncogenic HPV ²	U Unsatisfactory	0 Oncogenic HPV not detected	1 HPV 16/18 detected ³ i. Type 16 detected ii. Type 18 detected iii. Type 18/45 detected	2 Oncogenic HPV (not 16/18) detected ⁴ i. One or more of the following types detected: 31, 33, 45, 52, or 58 ii. One or more of the following types detected: 35, 39, 51, 56, 59, 66, or 68
HPV test type ⁵	1 Qiagen i. Hybrid Capture II	2 Roche i. cobas 4800 ii. cobas 6800 iii. cobas 8800	3 Abbott i. m2000 ii. Alinity m	4 Becton Dickinson i. Onclarity
	6 Hologic i. Cervista ii. Aptima	7 Seegene i. Anyplex	8 Genera i. PapType	5 Cepheid i. Xpert
			9 Euroimmun i. Euroarray	999 Other

¹ For the purpose of this coding sheet, a repeat test after prior unsatisfactory screening test should be coded according to the circumstances of the original (unsatisfactory test). While this will most commonly be a primary screening HPV test, it may also be a follow-up test or a test of cure.

² All oncogenic HPV types detected are required to be reported, if more than one type is detected, the codes for each detected type must be reported, comma separated. Reporting at the level of 'Not detected', 'HPV type 16/18 detected' and 'Oncogenic HPV (not 16/18) detected' is mandatory. Laboratories should report more detailed information if their test outputs allow, using the more detailed codes as suffixes.

³ One or more oncogenic HPV types 16 or 18 detected

⁴ One or more oncogenic HPV types other than 16 and 18 detected— HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

⁵ The HPV test types listed here will be tests that are registered on the ARTG for HPV testing of cervical samples. It is not an indication of which tests are suitable for use in the NCSP. Only those HPV tests that meet the requirements set out in the NPAAC Standards and Performance Measures for cervical screening should be used in the NCSP. Tests that do not meet the requirements now may meet them in future and therefore all tests listed on the ARTG will be coded. The HPV tests currently listed are tests which were known to be registered on the ARTG at the time of development; there may be others that are on the ARTG and were not identified at the time of development or will be added in future. Any tests that are listed on the ARTG will be added if the NCSP is informed.

HPV test sample	0 Not stated		1 PreservCyt Solution		2 SurePath medium	
	97 Other commercial self-collection device		98 Specimen transport medium		99 Flocked or cotton swab ⁶	
HPV test batch information ⁷						
Control kit	Lot number	Expiry date	Amplification kit	Lot number	Expiry date	
Cellular (LBC) extraction kit	Lot number	Expiry date	Detection kit	Lot number	Expiry date	
Nucleic acid extraction kit	Lot number	Expiry date	Wash buffer	Lot number	Expiry date	

⁶ If a swab is received by the laboratory in sampling media such as PreservCyt or SurePath, then it must be coded as '99 Flocked or cotton swab'.

⁷ For each of these codes one or more Lot numbers and associated expiry dates need to be reported. The fields need to be able to accept both letters and numbers as well as N/A (in the case of LBC extraction on a self-collected sample). Where a 'kit' includes reagents for multiple testing steps the Lot numbers and expiry dates should be repeated for each of the codes.

Cytology Test Group

Cytology specimen type	A0 Not stated		A1 Conventional smear		A2 Liquid based specimen		A3 Conventional and liquid-based	
Cytology specimen site	B0 Not stated		B1 Cervical		B2 Vaginal		B3 Other gynaecological site	
Reason for cytology test	1 Reflex LBC cytology after detection of oncogenic HPV in primary screening HPV test			2 Cytology after detection of oncogenic HPV in self-collected sample			3 Reflex LBC after detection of oncogenic HPV in follow-up HPV test	
	4 Cytology at colposcopy		5 Co-test i. Test of cure ii. Investigation of signs or symptoms iii. Other, as recommended in guidelines			6 Other		P Conventional Pap test to screen for cervical cancer precursors
Result	Squamous			Endocervical			Other/non-cervical	
Unsatisfactory	SU	Unsatisfactory for evaluation		EU	Due to unsatisfactory nature of the specimen, no assessment has been made		OU	Due to the unsatisfactory nature of the specimen, no assessment has been made
Negative	S1	Cell numbers and preservation satisfactory. No abnormality or only reactive changes		E- E0 E1	Not applicable: vault smear/previous hysterectomy No endocervical component Endocervical component present. No abnormality or only reactive changes		O1	No other abnormal cells
Low-grade	S2	Possible low-grade squamous intraepithelial lesion (LSIL)		E2	Atypical endocervical cells of uncertain significance		O2	Atypical endometrial cells of uncertain significance
	S3	Low-grade squamous intraepithelial lesion (LSIL) (HPV and/or CIN I)					O3	Atypical glandular cells of uncertain significance – site unknown
Possible high-grade	S4	Possible high-grade squamous intraepithelial lesion (HSIL)		E3	Possible high-grade endocervical glandular lesion		O4 O5	Possible endometrial adenocarcinoma Possible high-grade lesion – non-cervical
	S5 S6	High-grade squamous intraepithelial lesion (HSIL) (CIN 2/CIN 3) HSIL with possible microinvasion/invasion		E4 E5	Adenocarcinoma-in-situ Adenocarcinoma-in-situ with possible microinvasion/invasion			
Carcinoma	S7	Squamous carcinoma		E6	Adenocarcinoma		O6	Malignant cells – uterine body
							O7	Malignant cells – vagina
							O8	Malignant cells – ovary
							O9	Malignant cells – other

Clinical Management Recommendation Group

Recommendation
0 No recommendation
1 Rescreen in 5 years
2 Rescreen in 3 years
3 Repeat HPV test in 12 months
4 Co-test in 12 months
5 Retest in 6 weeks
6 Refer for colposcopic assessment
7 Test taken at time of colposcopy, no recommendation
8 Discharge from program
9 Other management recommendation
S Symptomatic – clinical management required
P Rescreen in 2 years

Histology Test Group

Specimen site	0 Not stated		1 Cervical		2 Vaginal		3 Other gynaecological site					
Procedure	1 Punch biopsy		2 Endocervical curettage		3 LLETZ/LEEP loop biopsy		4 Cone biopsy		5 Polypectomy			
	6 Subtotal hysterectomy			7 Hysterectomy			8 Amputated cervix			9 other gynaecological sites		
Result	Squamous histology cell analysis				Endocervical (glandular) histology cell analysis				Other/non-cervical histology cell analysis			
Unsatisfactory	SU	Unsatisfactory			EU	Unsatisfactory						
Not applicable	SN	Not applicable			EN	Not applicable			ON	Not applicable		
Negative	S1	Negative			E1	Negative			O1	Negative/no abnormalities reported or benign changes only		
Low-grade	S2	Low-grade intraepithelial lesion (LSIL)			E2	Endocervical atypia			O2	Low-grade neoplasia/hyperplasia NOS		
High-grade	S3.1	High-grade intraepithelial lesion (HSIL) (CIN NOS)			E3.1	Endocervical dysplasia			O3.1	High-grade neoplasia/hyperplasia		
	S3.2	HSIL (CIN 2)			E3.2	Adenocarcinoma-in-situ			O3.2	Carcinoma-in-situ		
	S3.3	HSIL (CIN 3)			E3.3	Mixed carcinoma-in-situ/adenocarcinoma-in-situ						
Carcinoma	S4.1	Superficially invasive squamous cell carcinoma (SISCCA)			E4.1	Endocervical adenocarcinoma, microinvasive			O4.1	Carcinoma, microinvasive		
					E4.2	Invasive adenocarcinoma of cervix			O4.2	Invasive carcinoma		
	S4.2	Squamous cell carcinoma (SCC)			E4.3	Adenosquamous carcinoma						
					E4.4	Carcinoma of the cervix (other)						

Colposcopy Group

Indication for colposcopy	0 Not performed		1 New patient with abnormal cervical screening result		2 Follow-up of patient with previous abnormal cervical screening result	
	3 Symptomatic		4 Abnormal appearance of cervix		5 At time of treatment	6 Other
	0 Inadequate				1 Adequate	
	1 Type 1 Transformation zone		2 Type 2 Transformation zone		3 Type 3 Transformation zone	
Adequacy ¹						
Transformation zone visibility						
Colposcopic impression	1	Normal				
	2	No visible lesion				
	3	LSIL				
	4	HSIL				
	5	Glandular abnormality (adenocarcinoma-in-situ)				
	6	Cancer				
	7	Other				
Biopsy this episode	0 No – biopsy not performed			1 Yes – biopsy performed		
Pregnancy flag	1 Pregnant at time of colposcopic episode					
Treatment this episode	0 No – treatment not performed			1 Yes – treatment performed		
Excision performed this episode	0 No	1a Yes – Type 1 excision (≤10 mm)		1b Yes – Type 2 excision (>10 and ≤15 mm)		1c Yes – Type 3 excision (>15 mm)
Modality/method used for excision	0 Excision not performed	1a Loop Diathermy	1b Scalpel (Cold Knife)		1c Laser	1d Other
Ablation performed this episode	0 No	1a Yes – Laser		1b Yes – Thermal Coagulation (Semm)		1c Yes – Diathermy
Hysterectomy	0 No			1 Yes		
Treatment anaesthetic type	1 Local		2 Regional		3 General	
Location of service	1 Public hospital		2 Private Hospital		3 Private rooms	
					9 Unknown/Other	

¹ Adequacy of colposcopy refers to the visibility of the cervix; 'Adequate' indicates that the view of the cervix is not obscured; 'Inadequate' indicates that the cervix cannot be adequately visualised, for example due to inflammation, bleeding, atrophy, or scar tissue.

Screening HPV test result	Cytology test result	Screening episode risk	
Unsatisfactory Oncogenic HPV types not detected Oncogenic HPV (not 16/18) HPV 16/18	..	Unsatisfactory	
	..	Low risk	
	None (applies to self-collected samples only)		
	Unsatisfactory	Unsatisfactory	
	Negative	Intermediate risk	→ Follow-up (repeat HPV test in 12 months)
	Possible or definite low-grade intraepithelial lesion (LSIL)	Intermediate risk	
	Possible or definite high-grade intraepithelial lesion (HSIL) or cervical cancer	Higher risk	
	Any glandular abnormality	Higher risk	
	None (applies to self-collected samples only)	Higher risk	
	Unsatisfactory	Higher risk	
	Negative	Higher risk	
	Possible or definite low-grade intraepithelial lesion (LSIL)	Higher risk	
	Possible or definite high-grade intraepithelial lesion (HSIL) or cervical cancer	Higher risk	
	Any glandular abnormality	Higher risk	

Risk	Follow-up HPV test result	Cytology test result	Follow-up episode risk	
Intermediate risk	Unsatisfactory	. .	Unsatisfactory	
	Oncogenic HPV types not detected	. .	Low risk	
	Oncogenic HPV (not 16/18)	None (applies to self-collected samples only)		
		Unsatisfactory	Unsatisfactory	
		Negative	Intermediate risk	→ Follow-up (repeat HPV test in 12 months)
		Possible or definite low-grade intraepithelial lesion (LSIL)	Intermediate risk	
		Possible or definite high-grade intraepithelial lesion (HSIL) or cervical cancer	Higher risk	
		Any glandular abnormality	Higher risk	
	HPV 16/18	None (applies to self-collected samples only)	Higher risk	
		Unsatisfactory	Higher risk	
		Negative	Higher risk	
		Possible or definite low-grade intraepithelial lesion (LSIL)	Higher risk	
		Possible or definite high-grade intraepithelial lesion (HSIL) or cervical cancer	Higher risk	
		Any glandular abnormality	Higher risk	

Exceptions to this are participants who are 2 or more years overdue for screening at the time of the initial screen, participants who identify as being Aboriginal and/or Torres Strait Islander, and participants aged 50 years or older, who should instead be referred to colposcopy if any HPV is detected at 12 months.

5 Performance indicators

With the major changes that the renewed NCSP has brought, including an HPV test every five years and a commencement age of 25 years, there was both a need and an opportunity to develop new performance indicators for the renewed NCSP that would continue to meet the need for national monitoring of this important screening program.

These new performance indicators were developed concurrently with the development of new quality measures, safety monitoring measures, as well as standards and measures that are external to the NCSP (such as performance measures for pathology laboratories reporting on cervical screening tests). The new performance indicators are listed in Table 5.1.

These new performance indicators were developed by the AIHW in consultation with the Australian Government Department of Health and state and territory cervical screening programs, as well as the NCSP Quality and Safety Monitoring Committee, the Colposcopy Working Group convened to progress the collection and reporting of colposcopy data in the renewed NCSP, and cervical screening experts Professor Ian Hammond, Associate Professor Marion Saville, Dr Julia Brotherton, Professor David Roder and Professor Dorota Gertig.

Table 5.1: Performance indicators for the renewed National Cervical Screening Program

Screening pathway	Performance indicator
Recruitment	1 Participation
	2 Response to invitation
	3 Rescreening
Screening	4 Screening results
	5 Correlation of screening results
Screening HPV test performance	6 Screening HPV test positivity
	7 Cervical cancer diagnosed after a low risk screening test result
Self-collection	8 Self-collection people positive for oncogenic HPV (not 16/18) who have an LBC test within 6 months
	9 Self-collection people positive for oncogenic HPV 16/18 who have a colposcopy within 6 months
Follow-up	10 Adherence to recommendation for follow-up
	11 Follow-up results
Assessment	12 Colposcopy rate
	13 Time to colposcopy
	14 Biopsy rate
	15 Yield of high-grade abnormalities on biopsy among people who attend colposcopy with higher risk screening results
Diagnosis	16 Positive predictive value of colposcopy
	17a High-grade cervical abnormality detection rate
	17b Cervical cancer detection rate
Outcomes	18 Cervical cancers diagnosed by time since last screen
	19 Incidence of cervical cancer
	20 Mortality from cervical cancer

Disaggregation of performance indicators

Age groups

Most performance indicators are defined for the target age group 25–74, but are also reported for 5-year age groups within this range, and for ages under 25, and 75 and over.

Where appropriate, performance indicators will also be reported separately for birth cohorts that represent whether or not a person was offered HPV vaccination. People not offered HPV vaccination are defined as those born on or before 30 June 1980; people offered HPV vaccination are defined as those born after 30 June 1980 (1 July 1980 onwards).

Population groups

Performance indicators will be disaggregated, where numbers allow, by state and territory of residence, remoteness area of residence, socioeconomic area of residence, Indigenous status, CALD status and HPV vaccination status, as appropriate.

Remoteness area of residence, socioeconomic area of residence, and other areas of interest such as Primary Health Networks will be assigned using the most accurate geographic area available.

Clinical or program relevance

Performance indicators will also be disaggregated into different categories, where this is clinically relevant and/or provides important program information. These categories include reason for HPV test, HPV test collection method, and test results.

Notes for performance indicators

Cervical screening tests

All screening and histology tests are limited to those associated with cervical screening.

For **screening tests**, cervical screening tests are defined as:

- practitioner-collected samples where HPV test specimen site is NOT *Vaginal* or *Other gynaecological site* (allows *Not stated*, *Cervical* and NULL); and
- self-collected samples where HPV test specimen site is NOT *Other gynaecological site* (allows *Not stated*, *Cervical*, *Vaginal* and NULL).

Requires *H2 HPV test collection method*; *H3 HPV test specimen site*.

For **histology tests**, cervical screening tests are defined as:

- samples where site is NOT *Vaginal* or *Other gynaecological site* (allows *Not stated*, *Cervical* and NULL).

Further, as a histology result is required for performance indicators that use histology, only histology data where the source is a pathology laboratory are included.

Requires *L2 Histology test specimen site*; *L11 Histology data source*.

Data quality and completeness

Specifications for performance indicators assume a level of data quality and completeness that is sufficient to allow robust and meaningful data to be reported. Where there are concerns about data quality and completeness, and/or where data items required are not available, aspects of performance indicators that have been specified in this document will not be reported.

Indicator 1 Participation

Definition:

Number of people aged 25–74 screened in a 5-year period as a percentage of females in the population.

Rationale:

Higher participation in cervical screening means that more people with precancerous abnormalities can be detected and treated, which is necessary for achieving the overall aim of reducing incidence and mortality from cervical cancer.

Calculation:

Participation

$$\frac{\text{Number of people aged 25–74 who had at least one screening HPV test in a 5-year period} \times 100}{\text{Estimated resident population for females aged 25–74 averaged over the 5 years of the reporting period, adjusted for the estimated proportion of females who have had a hysterectomy}}$$

Coverage

$$\frac{\text{Number of people aged 25–74 who had at least one HPV test or cytology test for any reason in a 5-year period} \times 100}{\text{Estimated resident population for females aged 25–74 averaged over the 5 years of the reporting period, adjusted for the estimated proportion of females who have had a hysterectomy}}$$

Count is of people

Specifications:

Numerator specifications

<i>Definition</i>	Number of people aged 25–74 who had at least one screening HPV test (reason for HPV test of Primary screening HPV test or Follow-up HPV test) in a 5-year period
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	B4 Date of birth
	G1 Type of test
	H1 HPV test date
	H4 Reason for HPV test

Denominator specifications

<i>Definition</i>	Estimated resident population for females aged 25–74 averaged over the 5 years of the reporting period, adjusted for the estimated proportion of females who have had a hysterectomy
<i>Source</i>	Australian Bureau of Statistics; AIHW National Hysterectomy Fractions

Indicator 2 Response to invitation

Definition:

The percentage of people aged 25–74 invited to screen or rescreen in a calendar year and who screened within 6 months.

Rationale:

How many people screen in response to an invitation provides a measure of the effectiveness of sending invitations. Measuring this by mode of invitation will also provide useful information as to the most effective method of inviting people (which may differ by age or other factors).

Calculation:

$$\frac{\text{Number of people aged 25–74 invited to screen or rescreen in a calendar year who had an HPV test within 6 months of the invitation being sent}}{\text{Number of people aged 25–74 invited to screen or rescreen in a calendar year}} \times 100$$

Numerator is a subset of the denominator

Count is of people

Specifications:

Numerator specifications

<i>Definition</i>	Number of people aged 25–74 invited to screen or rescreen in a calendar year who had an HPV test within 6 months
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	F2 Correspondence date
	G1 Type of test
	H1 HPV test date

Denominator specifications

<i>Definition</i>	Number of people aged 25–74 who are invited to screen or rescreen through the NCSP in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	B4 Date of birth
	F1 Correspondence type
	F2 Correspondence date

Indicator 3 Rescreening

Definition:

The percentage of people aged 25–69 whose screening HPV test in the index calendar year did not detect oncogenic HPV who rescreened within a specified period of time.

Rationale:

The proportion of the target population screened within the recommended screening interval is a key determinant of the success of a screening program; screening more frequently increases costs with minimal or no gain in a reduction in incidence and mortality; screening less frequently results in a decrease in overall participation in screening and means that fewer people with precancerous abnormalities can be detected and treated, necessary for achieving the overall aim of reducing incidence and mortality from cervical cancer. This indicator measures the proportion of people who rescreened early, appropriately, or late.

Note that although the National Cervical Screening Program target age group is 25–74, only people aged 25–69 are reported for rescreening because people aged 70–74 at the time of their screen would be outside the target age group of 25–74 when they are due for their 5-year rescreen.

Calculation:

Early rescreening

$$\frac{\text{Number of people aged 25–69 whose screening HPV test in the index calendar year did not detect oncogenic HPV who had a screening HPV test before 4.5 years} \times 100}{\text{Number of people aged 25–69 whose screening HPV test in the index calendar year did not detect oncogenic HPV}}$$

Adequate rescreening

$$\frac{\text{Number of people aged 25–69 whose screening HPV test in the index calendar year did not detect oncogenic HPV who had a screening HPV test between 4.5 years and 5.5 years} \times 100}{\text{Number of people aged 25–69 whose screening HPV test in the index calendar year did not detect oncogenic HPV}}$$

Late rescreening

$$\frac{\text{Number of people aged 25–69 whose screening HPV test in the index calendar year did not detect oncogenic HPV who had a screening HPV test after 5.5 years} \times 100}{\text{Number of people aged 25–69 whose screening HPV test in the index calendar year did not detect oncogenic HPV}}$$

Numerator is a subset of the denominator

Count is of people

Specifications:

Numerator specifications

<i>Definition</i>	Number of people aged 25–69 whose screening HPV test in the index calendar year did not detect oncogenic HPV who had a screening HPV test within 4.5 years, between 4.5 years and 5.5 years, or after 5.5 years
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier G1 Type of test H1 HPV test date

Denominator specifications

<i>Definition</i>	Number of people aged 25–69 whose screening HPV test in the index calendar year did not detect oncogenic HPV
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier B4 Date of birth G1 Type of test H1 HPV test date H4 Reason for HPV test H5 HPV test result – oncogenic HPV

Indicator 4 Screening results

Definition:

The percentage of screening episodes in each risk category in a calendar year in people aged 25–74.

Rationale:

Distribution of screening episode results is a key measure for the screening program and any changes in these distributions over time will require investigation within the broader context of the screening program.

Calculation:

Unsatisfactory

$$\frac{\text{Number of screening episodes that were unsatisfactory in people aged 25– 74 in a calendar year} \times 100}{\text{Number of screening episodes in people aged 25– 74 in a calendar year}}$$

Low risk

$$\frac{\text{Number of screening episodes that were low risk in people aged 25– 74 in a calendar year} \times 100}{\text{Number of screening episodes in people aged 25– 74}}$$

Intermediate risk

$$\frac{\text{Number of screening episodes that were intermediate risk in people aged 25– 74 in a calendar year} \times 100}{\text{Number of screening episodes in people aged 25– 74 in a calendar year}}$$

Higher risk

$$\frac{\text{Number of screening episodes that were higher risk in people aged 25– 74 in a calendar year} \times 100}{\text{Number of screening episodes in people aged 25– 74 in a calendar year}}$$

Count is of screening episodes

Specifications:

Numerator specifications

<i>Definition</i>	Number of screening episodes in people aged 25–74 in a calendar year that had a risk of significant cervical abnormality of: unsatisfactory low risk intermediate risk higher risk
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier B4 Date of birth J1 Primary screening episode commencement date J4 Primary screening episode risk of significant cervical abnormality

Denominator specifications

<i>Definition</i>	Number of screening episodes in people aged 25–74 in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier B4 Date of birth J1 Primary screening episode commencement date J4 Primary screening episode risk of significant cervical abnormality

Indicator 5 Correlation of screening results

Definition:

The level of agreement between screening results in a calendar year and subsequent histology test results within 6 months in people aged 25–74.

Rationale:

The correlation between a positive screening test result and the histology test or 'truth' (where this is performed) is a key measure of the accuracy of the HPV test, LBC test, and overall risk assigned to a screening episode.

Calculation:

$$\frac{\text{Histology test results within 6 months}}{\text{Number of screening episodes in people aged 25–74 in a calendar year that are followed by a histology test within 6 months}}$$

Numerator is a subset of the denominator

Count is of tests

Specifications:

Numerator specifications

<i>Definition</i>	Histology test results within 6 months
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	G1 Type of test
	J2 Primary screening episode completion date
	L1 Histology test date
	L7 Histology test result

Denominator specifications

<i>Definition</i>	Number of screening episodes followed by histology within 6 months in people aged 25–74 in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	B4 Date of birth
	H4 Reason for HPV test
	H5 HPV test result – oncogenic HPV
	J1 Primary screening episode commencement date
	J2 Primary screening episode completion date

SCREENING HPV TEST PERFORMANCE

Indicator 6 Screening HPV test positivity

Definition:

The percentage of screening HPV tests that are positive for HPV in a calendar year in people aged 25–74.

Rationale:

Monitoring the positivity rate provides important information about a screening test. There are three measures of positivity relevant to the NCSP; any oncogenic HPV positivity is the proportion of HPV test that are positive for any oncogenic HPV type, oncogenic HPV 16/18 positivity is the proportion of HPV tests that are positive for oncogenic HPV 16/18, and oncogenic HPV (not 16/18) positivity is the proportion of HPV tests that are positive for oncogenic HPV (not 16/18).

Calculation:

Any oncogenic HPV positivity rate

$$\frac{\text{Number of screening HPV tests in which any oncogenic HPV type is detected in people aged 25– 74 in a calendar year} \times 100}{\text{Number of screening HPV tests in people aged 25– 74 in a calendar year}}$$

Oncogenic HPV 16/18 positivity rate

$$\frac{\text{Number of screening HPV tests in which oncogenic HPV 16/18 is detected in people aged 25– 74 in a calendar year} \times 100}{\text{Number of screening HPV tests in people aged 25– 74 in a calendar year}}$$

Oncogenic HPV (not 16/18) positivity rate

$$\frac{\text{Number of screening HPV tests in which oncogenic HPV (not 16/18) is detected in people aged 25– 74 in a calendar year} \times 100}{\text{Number of screening HPV tests in people aged 25– 74 in a calendar year}}$$

Count is of tests

Specifications:

Numerator specifications

<i>Definition</i>	Number of screening HPV tests in people aged 25–74 in a calendar year in which: any oncogenic HPV detected oncogenic HPV 16/18 detected oncogenic HPV (not 16/18) detected
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier B4 Date of birth G1 Type of test H1 HPV test date H4 Reason for HPV test H5 HPV test result – oncogenic HPV

Denominator specifications

<i>Definition</i>	Number of screening HPV tests in people aged 25–74 in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier B4 Date of birth G1 Type of test H1 HPV test date H4 Reason for HPV test

Indicator 7 Cervical cancer diagnosed after a low risk screening test result

Definition:

The percentage of people aged 25–74 who are diagnosed with cervical carcinoma within 5 years of a screening HPV test that did not detect oncogenic HPV.

Rationale:

This measures the false negative rate of the screening HPV test.

Calculation:

$$\frac{\text{Number of people with cervical carcinoma diagnosed within 5 years of a screening HPV test that did not detect oncogenic HPV}}{\text{Number of people aged 25–74 who had a screening HPV test that did not detect oncogenic HPV in a calendar year}} \times 100$$

Numerator is a subset of the denominator

Count is of people

Specifications:

Numerator specifications

<i>Definition</i>	Number of people with cervical carcinoma diagnosed within 5 years of a screening HPV test that did not detect oncogenic HPV
<i>Source</i>	AIHW Australian Cancer Database

Denominator specifications

<i>Definition</i>	Number of people aged 25–74 who had a screening HPV test that did not detect oncogenic HPV in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier B4 Date of birth G1 Type of test H1 HPV test date H4 Reason for HPV test H5 HPV test result – oncogenic HPV

Indicator 8 Self-collection people positive for oncogenic HPV (not 16/18) who have an LBC test within 6 months

Definition:

The percentage of people aged 30–74 who self-collect and test positive for oncogenic HPV (not 16/18) in a calendar year who have an LBC test within 6 months.

Rationale:

People who self-collect and who test positive for oncogenic HPV (not 16/18) are recommended to have a practitioner-collected sample taken within 6 weeks. This indicator monitors compliance with this recommendation within 6 months, by which time it is considered that most people would have been able to attend an appointment with a practitioner.

Note that only people aged 30–74 are currently eligible for self-collection.

Calculation:

$$\frac{\text{Number of people aged 30–74 who self-collect and test positive for oncogenic HPV (not 16/18) in a calendar year who have an LBC test within 6 months} \times 100}{\text{Number of people aged 30–74 who self-collect and test positive for oncogenic HPV (not 16/18) in a calendar year}}$$

Numerator is a subset of the denominator

Count is of people

Specifications:

Numerator specifications

<i>Definition</i>	Number of people aged 30–74 who self-collect and test positive for oncogenic HPV (not 16/18) in a calendar year who have an LBC test within 6 months
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	G1 Type of test
	H1 HPV test date
	I1 Cytology test date

Denominator specifications

<i>Definition</i>	Number of people aged 30–74 who self-collect and test positive for oncogenic HPV (not 16/18) in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	B4 Date of birth
	G1 Type of test
	H1 HPV test date
	H2 HPV test collection method
	H4 Reason for HPV test
	H5 HPV test result – oncogenic HPV

Indicator 9 Self-collection people positive for oncogenic HPV 16/18 who have a colposcopy within 6 months

Definition:

The percentage of people aged 30–74 who self-collect and test positive for oncogenic HPV 16/18 in a calendar year who have a colposcopy within 6 months.

Rationale:

People who self-collect and who test positive for oncogenic HPV 16/18 are recommended to have a colposcopy within 8 weeks. This indicator monitors compliance with this recommendation within 6 months, by which time it is considered that most people would have been able to attend an appointment with a colposcopist. Note that only people aged 30–74 are currently eligible for self-collection.

Calculation:

$$\frac{\text{Number of people aged 30–74 who self-collect and test positive for oncogenic HPV 16/18 in a calendar year who have a colposcopy within 6 months}}{\text{Number of people aged 30–74 who self-collect and test positive for oncogenic HPV 16/18 in a calendar year}} \times 100$$

Numerator is a subset of the denominator

Count is of people

Specifications:

Numerator specifications

<i>Definition</i>	Number of people aged 30–74 who self-collect and test positive for oncogenic HPV 16/18 in a calendar year who have a colposcopy within 6 months
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	G1 Type of test
	H1 HPV test date
	K1 Date of colposcopy episode

Denominator specifications

<i>Definition</i>	Number of people aged 30–74 who self-collect and test positive for oncogenic HPV 16/18 in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	B4 Date of birth
	G1 Type of test
	H1 HPV test date
	H2 HPV test collection method
	H4 Reason for HPV test
	H5 HPV test result – oncogenic HPV

Indicator 10 Adherence to recommendation for follow-up

Definition:

The percentage of people aged 25–74 who are determined to be of intermediate risk as the result of a screening episode in a calendar year who have a follow-up HPV test between 9 and 15 months.

Rationale:

People who test positive for oncogenic HPV (not 16/18) and have a negative or pLSIL/ LSIL reflex LBC test result are considered to be of intermediate risk, and are recommended to have a follow-up HPV test in 12 months. This indicator monitors compliance with this recommendation (allowing 3 months either side of the recommended 12 months).

Calculation:

$$\frac{\text{Number of people aged 25– 74 who are determined to be of intermediate risk as the result of a screening episode in a calendar year who have a follow- up HPV test between 9 and 15 months} \times 100}{\text{Number of people aged 25– 74 who are determined to be of intermediate risk as the result of a screening episode in a calendar year}}$$

The numerator will be additionally disaggregated into the following two groups:

Percentage of people whose follow-up HPV test did not detect any oncogenic HPV

$$\frac{\text{Number of people with a follow- up HPV test that did not detect any oncogenic HPV} \times 100}{\text{Number of people aged 25– 74 who are determined to be of intermediate risk as the result of a screening episode in a calendar year who have a follow- up HPV test between 9 and 15 months}}$$

Percentage of people whose follow-up HPV test detected oncogenic HPV (any)

$$\frac{\text{Number of people with a follow – up HPV test that detected oncogenic HPV (any)} \times 100}{\text{Number of people aged 25– 74 who are determined to be of intermediate risk as the result of a screening episode in a calendar year who have a follow- up HPV test between 9 and 15 months}}$$

Numerator is a subset of the denominator

Count is of people

Specifications:

Numerator specifications

<i>Definition</i>	Number of people aged 25–74 who are determined to be of intermediate risk as the result of a screening episode in a calendar year who have a follow-up HPV test between 9 and 15 months
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier G1 Type of test H1 HPV test date J2 Primary screening episode completion date

Denominator specifications

<i>Definition</i>	Number of people aged 25–74 who are determined to be of intermediate risk as the result of a screening episode in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier B4 Date of birth J1 Primary screening episode commencement date J4 Primary screening episode risk of significant cervical abnormality J5 Primary screening episode recommendation

Indicator 11 Follow-up results

Definition:

The percentage of follow-up episodes in each risk category in a calendar year in people aged 25–74

Rationale:

Follow-up results are the follow-up HPV test result and reflex LBC (where indicated) that occur 12 months after an intermediate risk screening episode result. Distribution of follow-up episode results is a key measure for the screening program and any changes in these distributions over time will require investigation within the broader context of the screening program.

Calculation:

Unsatisfactory

$$\frac{\text{Number of follow – up episodes that were unsatisfactory in people aged 25– 74 in a calendar year} \times 100}{\text{Number of follow – up episodes in people aged 25– 74 in a calendar year}}$$

Low risk

$$\frac{\text{Number of follow- up episodes that were low risk in people aged 25– 74 in a calendar year} \times 100}{\text{Number of follow – up episodes in people aged 25– 74}}$$

Intermediate risk

$$\frac{\text{Number of follow- up episodes that were intermediate risk in people aged 25– 74 in a calendar year} \times 100}{\text{Number of follow- up episodes in people aged 25– 74 in a calendar year}}$$

Higher risk

$$\frac{\text{Number of follow- up episodes that were higher risk in people aged 25– 74 in a calendar year} \times 100}{\text{Number of follow- up episodes in people aged 25– 74 in a calendar year}}$$

Count is of follow-up episodes

Specifications:

Numerator specifications

<i>Definition</i>	Number of follow-up episodes in people aged 25–74 in a calendar year that had a risk of significant cervical abnormality of: – unsatisfactory – low risk – higher risk
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier B4 Date of birth J6 Follow-up episode commencement date J9 Follow-up episode risk of significant cervical abnormality

Denominator specifications

<i>Definition</i>	Number of follow-up episodes in people aged 25–74 in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier B4 Date of birth J6 Follow-up episode commencement date

Indicator 12 Colposcopy rate

Definition:

The percentage of people aged 25–74 who are referred for colposcopy who attend colposcopy within 3 months.

Rationale:

The success of a screening program is reliant on assessment being performed when required. This measures compliance with referral for colposcopy based on a screening episode result that places them at higher risk of significant cervical abnormality, and should be calculated for each screening episode result.

Calculation:

Oncogenic HPV 16/18 detected + any reflex LBC result

$$\frac{\text{Number of people aged 25– 74 with an HPV test in which oncogenic HPV 16/18 is detected in a calendar year who had a colposcopy within 3 months} \times 100}{\text{Number of people aged 25– 74 with an HPV test in which oncogenic HPV 16/18 is detected in a calendar year}}$$

Oncogenic HPV (not 16/18) detected + reflex LBC result of pHSIL/HSIL/cervical cancer/any glandular abnormality

$$\frac{\text{Number of people aged 25– 74 with an HPV test in which oncogenic HPV (not 16 or 18) is detected and who had an LBC result of pHSIL/HSIL/cervical cancer/any glandular abnormality in a calendar year who had a colposcopy within 3 months} \times 100}{\text{Number of people aged 25– 74 with an HPV test in which oncogenic HPV (not 16 or 18) is detected and who had an LBC result of pHSIL/HSIL/cervical cancer/any glandular abnormality in a calendar year}}$$

Follow-up HPV test result that indicates higher risk

$$\frac{\text{Number of people aged 25– 74 with a follow- up HPV test result that indicates they are higher risk in a calendar year who had a colposcopy within 3 months} \times 100}{\text{Number of people aged 25– 74 with a follow- up HPV test in which any oncogenic HPV is detected in a calendar year}}$$

The numerator is a subset of the denominator

Count is of people

Specifications:

Numerator specifications

<i>Definition</i>	Number of people who had a colposcopy after each specified screening episode result within 3 months
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier B4 Date of birth G1 Type of test K1 Date of colposcopy episode

Denominator specifications

<i>Definition</i>	Number of people aged 25–74 who have a screening episode result that places them at higher risk of significant cervical abnormality in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier B4 Date of birth G1 Type of test J2 Primary screening episode completion date J3 Primary screening episode result J7 Follow-up episode completion date J8 Follow-up episode result

Comments:

This performance indicator is affected by the change in the screening policy for people at *Intermediate risk*.

From 1 February 2021

For people with a cervical screening result of *Intermediate risk* recommended to have a follow-up HPV test at 12 months, if HPV (not 16/18) is detected and LBC prediction is negative, pLSIL or LSIL in the follow-up HPV test at 12 months, they will continue to be managed as *Intermediate risk* and recommended to undertake a second HPV follow-up test at 12 months (unless the participant is 2 or more years overdue for screening at the time of the initial screen, identifies as Aboriginal and/or Torres Strait Islander, or is aged 50 years or older, in which case any HPV detected in the follow-up HPV test at 12 months indicates they are *Higher risk* and should be referred to colposcopy).

Indicator 13 Time to colposcopy

Definition:

For people aged 25–74 who have a screening episode result that places them at higher risk of significant cervical abnormality, the time between the screening result and colposcopy, measured as median and 90th percentile values, as well as within specified timeframes.

Rationale:

People who receive a screening episode result that places them at higher risk of significant cervical abnormality will be referred to colposcopy. The recommended timeframe in which they should undergo colposcopic assessment is as per the NCSP 2016 Guidelines (Cancer Council Australia and Cervical Cancer Screening Guidelines Working Party 2016). Monitoring actual time between screening result and colposcopy provides important information as to whether people are receiving timely assessment, as delay in assessment may lead to poorer outcomes.

Calculation:

Oncogenic HPV 16/18 detected + any reflex LBC result

For people aged 25–74 with a screening HPV test in which oncogenic HPV 16/18 is detected in a calendar year who had a colposcopy within 365 days, time to colposcopy in number of days

Oncogenic HPV detected (not 16/18) + reflex LBC result of pHSIL/HSIL/cervical cancer/any glandular abnormality

For people aged 25–74 with a screening HPV test in which oncogenic HPV (not 16/18) is detected and who had an LBC result of pHSIL/HSIL/cervical cancer/any glandular abnormality in a calendar year who had a colposcopy within 365 days, time to colposcopy in number of days

Follow-up HPV test result that indicates higher risk

For people aged 25–74 with a follow-up HPV test that indicates they are higher risk in a calendar year who had a colposcopy within 365 days, time to colposcopy in number of days

Count is of days

Specifications:

Specifications

<i>Definition</i>	For people who had a colposcopy within 365 days of a screening episode result that places them at higher risk of significant cervical abnormality, the number of days to colposcopy
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier B4 Date of birth G1 Type of test J2 Primary screening episode completion date J3 Primary screening episode result J7 Follow-up episode completion date J8 Follow-up episode result K1 Date of colposcopy episode

Comments:

This performance indicator is affected by the change in the screening policy for people at *Intermediate risk*.

From 1 February 2021

For people with a cervical screening result of *Intermediate risk* recommended to have a follow-up HPV test at 12 months, if HPV (not 16/18) is detected and LBC *prediction is negative, pLSIL or LSIL in the follow-up HPV test at 12 months, they will continue to be managed as Intermediate risk* and recommended to undertake a second HPV follow-up test at 12 months (unless the participant is 2 or more years overdue for screening at the time of the initial screen, identifies as Aboriginal and/or Torres Strait Islander, or is aged 50 years or older, in which case any HPV detected in the follow-up HPV test at 12 months indicates they are *Higher risk* and should be referred to colposcopy).

Indicator 14 Biopsy rate

Definition:

The percentage of colposcopies in people aged 25–74 in which a biopsy was performed.

Rationale:

Although there are reasons why a biopsy would not be performed at colposcopy, a lower than expected biopsy rate would require further investigation.

Calculation:

$$\frac{\text{Number of colposcopy episodes at which a biopsy was performed in people aged 25–74 in a calendar year}}{\text{Number of colposcopy episodes in people aged 25–74 in a calendar year}} \times 100$$

Numerator is a subset of the denominator

Count is of colposcopy episodes

Specifications:

Numerator specifications

<i>Definition</i>	Number of colposcopy episodes at which a biopsy was performed in people aged 25–74 in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	B4 Date of birth
	G1 Type of test
	K1 Date of colposcopy episode
	K8 Biopsy this episode

Denominator specifications

<i>Definition</i>	Number of colposcopy episodes in people aged 25–74 in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	B4 Date of birth
	G1 Type of test
	J2 Primary screening episode completion date
	J7 Follow-up episode completion date
	K1 Date of colposcopy episode

Indicator 15 Yield of high-grade abnormalities on biopsy among people who attend colposcopy after higher risk screening results

Definition:

Percentage of people aged 25–74 with a higher risk screening result who had a colposcopy in a calendar year who were diagnosed with a high-grade abnormality or cervical cancer on histology within 6 months of colposcopy.

Rationale:

As people who are referred to colposcopy are at higher risk of significant cervical abnormality, it is expected that a proportion of these will be diagnosed with a high-grade abnormality or cervical cancer. This indicator can be used as a measure of the accuracy of colposcopy in identifying and sampling a high-grade abnormality or cervical cancer that is present.

Calculation:

$$\frac{\text{Number of people aged 25–74 with a higher risk screening episode result who had a colposcopy in a calendar year who were diagnosed with a high-grade abnormality or cervical cancer on histology within 6 months of colposcopy} \times 100}{\text{Number of people aged 25–74 with a higher risk screening episode result who had a colposcopy in a calendar year}}$$

The numerator is a subset of the denominator

Count is of people

Specifications:

Numerator specifications

<i>Definition</i>	Number of people aged 25–74 with a higher risk screening episode result who had a colposcopy in a calendar year who were diagnosed with a high-grade abnormality or cervical cancer on histology within 6 months of colposcopy
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	B4 Date of birth
	K1 Date of colposcopy episode
	L1 Histology test date
	L7 Histology test result

Denominator specifications

<i>Definition</i>	Number of people aged 25–74 with a higher risk screening episode result who had a colposcopy in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	B4 Date of birth
	J4 Primary screening episode risk of significant cervical abnormality
	K1 Date of colposcopy episode

Indicator 16 Positive predictive value of colposcopy

Definition:

Percentage of people aged 25–74 with a higher risk screening result who had a colposcopic impression of HSIL, glandular abnormality (adenocarcinoma-in-situ) or cancer in a calendar year who were diagnosed with a high-grade abnormality or cervical cancer on histology within 6 months of colposcopy.

Rationale:

This indicator correlates the colposcopic impression with histological findings to determine the predictive value of colposcopy for high-grade cervical abnormalities. This is an important measure of the quality of colposcopy.

Calculation:

$$\frac{\text{Number of people aged 25–74 with a higher risk screening result who had a colposcopic impression of HSIL, glandular abnormality (adenocarcinoma – in – situ) or cancer in a calendar year who were diagnosed with a high-grade abnormality or cervical cancer on histology within 6 months of colposcopy}}{\text{Number of people aged 25–74 with a higher risk screening result who had a colposcopic impression of HSIL, glandular abnormality (adenocarcinoma – in – situ) or cancer in a calendar year}} \times 100$$

The numerator is a subset of the denominator

Count is of people

Specifications:

Numerator specifications

<i>Definition</i>	Number of people aged 25–74 with a higher risk screening result who had a colposcopic impression of HSIL, glandular abnormality (adenocarcinoma-in-situ) or cancer in a calendar year who were diagnosed with a high-grade abnormality or cervical cancer on histology within 6 months of colposcopy
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier K1 Date of colposcopy episode L1 Histology test date L7 Histology test result

Denominator specifications

<i>Definition</i>	Number of people aged 25–74 with a higher risk screening result who had a colposcopic impression of high-grade or higher in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier B4 Date of birth J4 Primary screening episode risk of significant cervical abnormality K1 Date of colposcopy episode K6 Colposcopic impression – primary diagnosis

Indicator 17a High-grade cervical abnormality detection rate

Definition:

Number of people aged 25–74 with a high-grade abnormality detected on histology in a calendar year per 1,000 people screened.

Rationale:

The detection of high-grade abnormalities is an indicator of program performance. High-grade abnormalities have a greater probability of progressing to invasive cancer than do low-grade lesions. Detection of high-grade abnormalities provides an opportunity for treatment before cancer can develop, thus the NCSP aims to detect high-grade abnormalities in line with its broader aim to reduce the incidence of cervical cancer.

Calculation:

$$\frac{\text{Number of people aged 25–74 with a high-grade abnormality detected on histology in a calendar year} \times 1,000}{\text{Number of people aged 25–74 screened in a calendar year}}$$

Count is of people

Specifications:**Numerator specifications**

<i>Definition</i>	Number of people aged 25–74 with a high-grade abnormality detected on histology in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	B4 Date of birth
	G1 Type of test
	L1 Histology test date
	L4 Squamous histology cell analysis
	L5 Endocervical (glandular) histology cell analysis

Denominator specifications

<i>Definition</i>	Number of people aged 25–74 screened in a calendar year.
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	B4 Date of birth
	G1 Type of test
	H1 HPV test date

Indicator 17b Cervical cancer detection rate

Definition:

Number of people aged 25–74 with cervical carcinoma on histology per 1,000 people screened.

Rationale:

The cancer detection rate will be measured alongside the high-grade detection rate.

Calculation:

$$\frac{\text{Number of people aged 25–74 with a cervical carcinoma detected on histology in a calendar year} \times 1,000}{\text{Number of people aged 25–74 screened in a calendar year}}$$

Count is of people

Specifications:

Numerator specifications

<i>Definition</i>	Number of people aged 25–74 with a cervical cancer detected on histology in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	B4 Date of birth
	G1 Type of test
	L1 Histology test date
	L4 Squamous histology cell analysis
	L5 Endocervical (glandular) histology cell analysis

Denominator specifications

<i>Definition</i>	Number of people aged 25–74 screened in a calendar year
<i>Source</i>	National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier
	B4 Date of birth
	G1 Type of test
	H1 HPV test date

Indicator 18 Cervical cancers diagnosed by time since last screen

Definition:

Number of females aged 25–74 diagnosed with cervical carcinoma categorised into never screened, lapsed screening, and recently screened based on time since last screen.

Rationale:

A measure of the burden of disease from a lack of participation in the screening program. Time since last screen is used to categorise all females diagnosed with cervical carcinoma as never screened, lapsed screening, or recently screened. Most cervical carcinomas have historically been diagnosed in never screened, which is evidence of the benefit of participation in cervical screening.

Only cervical carcinomas (cervical cancers of epithelial origin) are included, as cervical cancers not of epithelial origin are not expected to be detected through cervical screening.

Never screened is defined as no record of having had a screening test in Australia prior to cancer diagnosis.

Lapsed screening is defined as last screening test >5.5 and ≤7.5 years, >7.5 and ≤10 years or >10 years prior to cancer diagnosis.

Recently screened is defined as last screening test ≤5.5 years prior to cancer diagnosis.

Calculation:

Never screened

Females aged 25–74 diagnosed with cervical carcinoma in a calendar year who are either on a register with no record of a screening test or not on a register

Lapsed screening

Females aged 25–74 diagnosed with cervical carcinoma in a calendar year whose last screening test was >5.5 years and ≤7.5 years before the cervical cancer diagnosis date

Females aged 25–74 diagnosed with cervical carcinoma in a calendar year whose last screening test was >7.5 years and ≤10 years before the cervical cancer diagnosis date

Females aged 25–74 diagnosed with cervical carcinoma in a calendar year whose last screening test was >10 years before the cervical cancer diagnosis date

Recently screened

Females aged 25–74 diagnosed with cervical carcinoma in a calendar year whose last screening test was ≤5.5 years before the cervical cancer diagnosis date

Specifications:

Specifications

<i>Definition</i>	Females aged 25–74 diagnosed with cervical carcinoma in a calendar year categorised into never screened, lapsed screening, and recently screened
<i>Source</i>	AIHW Australian Cancer Database; National Cancer Screening Register
<i>Data items</i>	A1 Participant identifier B4 Date of birth P2 Date of last screening test P3 Last screening test type

Indicator 19 Incidence of cervical cancer

Definition:

Number of new cases of cervical cancer in females aged 25–74 per 100,000 estimated resident population in a calendar year.

Rationale:

Incidence data provide contextual information about the number of new cases of cervical cancer in the population that is an indicator of program performance against its aim to reduce cervical cancer through organised screening.

Calculation:

$$\frac{\text{Number of new cases of cervical cancer diagnosed in females aged 25–74 in a calendar year} \times 100,000}{\text{Estimated resident population for females aged 25–74 in a calendar year}}$$

Count is of new cases

Specifications:

Numerator specifications

<i>Definition</i>	Number of new cases of cervical cancer diagnosed in females aged 25–74 in a calendar year
<i>Source</i>	AIHW Australian Cancer Database

Denominator specifications

<i>Definition</i>	Estimated resident population for females aged 25–74 in a calendar year
<i>Source</i>	Australian Bureau of Statistics

Indicator 20 Mortality from cervical cancer

Definition:

Number of deaths from cervical cancer in females aged 25–74 per 100,000 estimated resident population in a calendar year.

Rationale:

Mortality data provide contextual information about the number of deaths from cervical cancer in the population that is an indicator of program performance against its aim to reduce mortality from cervical cancer through organised screening.

Calculation:

$$\frac{\text{Number of deaths from cervical cancer in females aged 25–74 in a calendar year} \times 100,000}{\text{Estimated resident population for females aged 25–74 in a calendar year}}$$

Count is of deaths

Specifications:

Numerator specifications

<i>Definition</i>	Number of deaths from cervical cancer in females aged 25–74 in a calendar year
<i>Source</i>	AIHW National Morbidity Database

Denominator specifications

<i>Definition</i>	Estimated resident population for females aged 25–74 in a calendar year
<i>Source</i>	Australian Bureau of Statistics

References

Australian Institute of Health and Welfare (AIHW) 2014. National Cervical Cancer Prevention Data Dictionary version 1: working paper. Cancer series no. 88. Cat. No. CAN85. Canberra: AIHW.

AIHW 2017. National Cervical Screening Program data dictionary: Version 1.1. Cancer series no. 103. Cat. no. CAN 102. Canberra: AIHW.

Cancer Council Australia and Cervical Cancer Screening Guidelines Working Party 2016. National Cervical Screening Program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Cancer Council Australia: Sydney.

International Agency for Research on Cancer 2012. Pharmaceuticals. Volume 100 A: A review of human carcinogens. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon France: World Health Organization; 2012 Available from: <http://monographs.iarc.fr/ENG/Monographs/vol100A/mono100A.pdf>.

Medical Services Advisory Committee (MSAC) 2014. Outcomes from Application No. 1276 – Renewal of the National Cervical Screening Program. Canberra, Australia.

Abbreviations

ABS	Australian Bureau of Statistics
ACD	Australian Cancer Database
AIHW	Australian Institute of Health and Welfare
AIS	adenocarcinoma-in-situ
HPV	human papillomavirus
LSIL	low-grade squamous intraepithelial lesion
HSIL	high-grade squamous intraepithelial lesion
NCSP	National Cervical Screening Program
NCSR	National Cancer Screening Register
NHMRC	National Health and Medical Research Council

Symbols

<	less than
≤	less than or equal to
>	greater than

List of tables

Table 2.1: New terminology.....	3
Table 2.2: Revised screening pathway	4
Table 2.3: New data items.....	5
Table 2.4: Deleted data items	6
Table 2.5: Revised data items.....	7
Table 2.6: Revised performance indicators.....	10
Table 2.7: Revised coding sheets	10
Table 3.1: Data item format – codes	12
Table 3.2: Data item format – use of brackets	12
Table 3.3: Data item structure	13
Table 3.4: Summary of data items	14
Table 5.1: Performance indicators for the renewed National Cervical Screening Program.....	226

Acknowledgments

The *National Cervical Screening Program Data Dictionary version 1.1* was prepared by the Screening Analysis and Monitoring Unit of the Australian Institute of Health and Welfare (AIHW), with assistance from state and territory cervical screening programs, the National Cervical Screening Program (NCSP) data dictionary working group, and from cervical screening experts on behalf of the NCSP.

The NCSP data dictionary working group was comprised of the following state and territory cervical screening program representatives.

National Cervical Screening Program data dictionary working group contributing members	
New South Wales Victor Kapruziak Flora Ding	Victoria Professor Marion Saville Genevieve Chappell Karen Peasley
Queensland Nick Ormiston-Smith	Western Australia Nerida Steel Robert Henderson Duane Pearce
Tasmania Sophia Avery Scott Marshall	Australia Institute of Health and Welfare Alison Budd

Thanks are extended to all these individuals for their assistance.

Additional input into specific elements of the data dictionary was provided by the NCSP Quality and Safety Monitoring Committee, the Colposcopy Working Group convened to progress the collection and reporting of colposcopy data in the new NCSP, and cervical screening experts Professor Ian Hammond, Professor Marion Saville, Professor Julia Brotherton, Professor David Roder and Professor Dorota Gertig.

Thanks are extended to all these individuals for their assistance.

The financial support and professional assistance of the Cervical Screening Section, Cancer Policy and Services Branch of the Cancer, Hearing and Program Support Division of the Australian Government Department of Health is also gratefully acknowledged.



The National Cervical Screening Program aims to reduce incidence, morbidity and mortality from cervical cancer in Australia. The National Cervical Screening Program data dictionary is a key document that has been developed by the Australian Institute of Health and Welfare with the assistance of state and territory cervical screening programs and other cervical screening experts, to support monitoring and reporting by the Australian Institute of Health and Welfare for the renewed National Cervical Screening Program.

aihw.gov.au



Stronger evidence,
better decisions,
improved health and welfare

